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Abstract	
Cardiometabolic diseases continue to be a major cause of mortality and morbidity, despite the 
progress in risk prediction and stratification. Besides the traditional risk factors, sphingolipids 
are emerging as novel players in the pathogenesis of atherosclerosis and metabolic diseases. 
Sphingolipid de novo synthesis is typically initiated by the conjugation of L-serine and 
palmitoyl-CoA, a reaction catalysed by the serine-palmitoyltransferase (SPT). SPT can also 
metabolise other acyl-CoAs (C12 to C18) and other amino acids such as L-alanine and glycine, 
giving rise to a spectrum of atypical sphingolipids. In a special class of atypical sphingolipids, 
alanine is conjugated with palmitoyl-CoA, generating 1-deoxysphingolipids (1-deoxySLs) 
that lack the C1 hydroxyl group. 
In cross-sectional and prospective clinical studies, we explored the potential of these atypical 
sphingolipids as predictive biomarkers in metabolic syndrome (MetS), type 2 diabetes 
mellitus (T2DM) and cardiovascular disease. Plasma sphingolipids were extracted, 
hydrolyzed and the sphingoid base backbones were measured by LC/MS. 1-Deoxy-
sphingolipids (1-deoxySLs) were significantly elevated in patients with the metabolic 
syndrome (MetS) and T2DM compared with controls. In the prospective analysis, baseline 
plasma 1-deoxySLs were identified as independent predictors for the development of T2DM 
even after adjustment for HbA1c and the presence of metabolic syndrome. Furthermore, 
baseline C20SO levels were identified as independent risk predictors for cardiovascular-related 
events after the adjustment for the traditional risk factors including the degree of coronary 
artery stenosis.  
Pathologically elevated 1-deoxySL levels were found to be associated with hereditary sensory 
and autonomic neuropathy type 1 HSANI - which is caused by several missense mutations in 
SPT. The pathological formation of 1-deoxySLs in HSAN1 is significantly suppressed in 
response to an oral L-serine supplementation in patients and mice models. Given the 
similarity in the clinical picture of HSAN1 and diabetic sensory neuropathy and the increased 
plasma levels of 1-deoxySLs in both conditions, we investigated whether a serine 
supplementation could also be beneficial in the context of the diabetic neuropathy in 
streptozotocin-treated rats. The effect of serine was tested in preventive and therapeutic 
schemes. Plasma and tissue sphingolipids were quantified using LC/MS after lipid extraction 
and hydrolysis. Thermal, mechanical nociception and nerve conduction velocity (NCV) were 
measured. In both schemes (therapeutic and preventive), plasma 1-deoxySLs were 
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significantly lowered in the serine-supplemented diabetic rats. Neurologically, the serine 
supplemented animals showed significantly improved mechanical sensitivity in both the 
preventive and therapeutic groups, while NCV was significantly better in the preventive but 
not in the therapeutic group. 
We observed consistently a strong positive correlation between plasma 1-deoxySLs and 
triglycerides (TG). We, therefore, investigated the effect of the triglyceride-lowering drugs, 
fenofibrate and niacin, on the sphingoid base profile in the plasma of dyslipidemic patients in 
a multi-center, open label, cross-over study. While fenofibrate and niacin had comparable 
effects on plasma triglycerides, only fenofibrate lowered significantly the atypical sphingoid 
bases including 1-deoxySLs. Interestingly, neither fenofibrate nor niacin had any significant 
effect on the typical sphingolipids (C18-based sphingolipids). 
In summary, we showed that 1-deoxySLs are significantly elevated in patients with T2DM 
and MetS where they could serve as predictive biomarkers for the development of T2DM .We 
also showed that plasma C20SO is a predictive biomarker for cardiovascular events. We 
demonstrated that fenofibrate but not niacin was effective in lowering the atypical plasma 
sphingolipids in dyslipidemic patients. Moreover, an oral L-serine supplementation 
effectively lowered the plasma 1-deoxySLs in a diabetic STZ rat model and significantly 
improved the mechanical sensitivity and nerve conduction velocity in these animals. This 
suggests that oral serine supplementation could be a potential therapeutic strategy in diabetic 
neuropathy.  
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Zusammenfassung1	
Trotz grosser Fortschritte in der Risikovorhersage und der Einteilung der Patienten in 
entsprechende Risikogruppen, sind Herz und Stoffwechselerkrankungen weiterhin unter den 
Hauptursachen von Invalidität und erhöhter Sterblichkeit zu finden. Neben den klassischen 
Risikofaktoren, spielen auch Sphingolipide bei der Pathogenese von Arthrosklerose und 
anderen Stoffwechselerkrankungen eine immer grössere Rolle. 
Die De-novo-Synthese der Sphingolipide wird normalerweise durch die Kondensation von L-
Serin und Palmitoyl-CoA, welche durch das Enzym Serin-Palmitoyltransferase (SPT) 
katalysiert wird, eingeleitet. Die SPT kann jedoch auch andere Acyl-CoA’s (C12 bis C18) und 
Aminosäuren, wie etwa L-Alanin und Glycin, als Substrate für dieses Reaktion 
verstoffwechseln. Diese Substratpromiscuität führt zur Bildung einer ganzen Reihe atypischer 
Sphingolipide. Die 1-deoxysphingolipide (1-deoxySL), bei denen Alanin mit palmitoyl-CoA 
konjugiert ist, wodurch es zum Verlust der C1 Hydroxylgruppe kommt, stellen dabei eine 
besondere Klasse der atypischen Sphingolipide dar. 
In mehrere klinischen Studien untersuchten wir die Verwendungsmöglichkeit dieser 
atypischen Sphingolipide als prädiktive Biomarker für das Metabolische Syndrom (MetS), 
den Typ-2-Diabetes mellitus (T2DM) und Herz-Kreislauferkrankungen. Die gesammten 
Sphingolipide wurden aus dem Plasma extrahiert und hydrolysiert. Letztendlich wurden die 
freien Sphingoid Basen mittels LC/MS identifiziert und quantifiziert. In Patienten mit MetS 
und T2DM waren die 1-deoxySL im Vergleich zu den Kontrollen signifikant erhöht. Bei der 
prospektiven Analyse wurden die Ausgangskonzentrationen der 1-deoxySL im Plasma als 
unabhängige Prädiktoren für die Entstehung von T2DM identifiziert. Diese Assoziation hielt 
selbst der Adaptierung der Werte an die HbA1c-Werte und das mitunter bereits vorhandene 
Metabolische Syndrom stand. Des Weiteren konnten wir die gemessenen C20SO-
Ausgangswerte selbst nach der Anpassung an an die klassischen Risikofaktoren, sowie den 
Schweregrad der Herzkranzgefässverengung als unabhängige Risikoprädiktoren für das 
Auftreten von kardiovaskulären Vorfällen identifizieren. 
Es hatte sich herausgestellt, dass pathologisch erhöhte 1-deoxySL-Werte eng mit der 
hereditären sensorischen und autonomen Neuropathie Typ1 (HSAN1) verbunden sind. 
HSAN1 wird durch mehrere Fehlsinnmutationen in der Sequenz der SPT verursacht. Die 
                                                            
1
 Translated from the English version of the abstract by Heiko Bode 
vii 
 
krankhaft gesteigerte Bildung von 1-deoxySL wird sowohl im HSAN1-Mausmodel, als auch 
in HSAN1-Patienten durch die orale Verabreichung von L-Serin wirkungsvoll unterdrückt. In 
Anbetracht der Ähnlichkeit der klinischen Symptome von HSAN1 und der diabetisch 
sensorischen Neuropathie untersuchten wir weiterhin, ob die Nahrungsergänzung mit L-Serin 
auch in diesem Kontext hilfreich sein könnte. Diese Untersuchungen wurden mit Ratten 
durchgeführt, welche durch Behandlung mit Streptozotocin (STZ) zu Diabetikern wurden. 
Die Wirkung von L-Serin wurde sowohl in einem präventiven, als auch therapeutischen 
Behandlungsansatz untersucht. Die Sphingolipidzusammensetzung wurde sowohl im Plasma, 
als auch in den verschiedenen Geweben untersucht und mittels LC/MS nach vorheriger 
Extraktion und Hydrolyse quantifiziert. Die Schmerzempfindlichkeiten für thermische, und 
mechanische Reize sowie die Nervenleitgeschwindigkeit wurden ebenfalls gemessen. In 
beiden Behandlungsansätzen (sowohl präventiv, als auch therapeutisch) führte die 
Verabreichung von L-Serin zu einer signifikanten Senkung der 1-deoxySL-Konzentrationen 
im Plasma der diabetischen Ratten. Die mit Serin behandelten Tiere zeigten sowohl in der 
Präventiv- als auch in der Therapiegruppe eine signifikante Steigerung der mechanischen 
Empfindlichkeit. Die Nerveneitgeschwindigkeit hingegen konnte nur durch die präventive 
Gabe von Serin verbessert werden. 
Wir beobachteten eine konstante, stark positive Korrelation zwischen den Konzentrationen 
der 1-deoxySL und den Triglyceridwerten im Plasma. Daher untersuchten wir die 
Auswirkungen der beiden lipidmodifizierenden Medikamente Fenofibrat und Niacin auf das 
Profil der Sphingolipide im Plasma von dyslipidämischen Patienten. Die Studie wurde als 
ofene cross-over Studie in mehrere Zentren durchgeführt. Fenofibrat und Niacin zeigten 
ähnliche Auswirkungen auf Lipoproteine und Apolipoprotein. Lediglich Fenofibrat hingegen 
konnte die Konzentrationen aller atypischer Sphingolipide inclusive der 1-deoxySL 
signifikant senken, dabei wurden die gemessenen Konzentration der typischen Sphingolipide 
(aus C18-Sphingoidbasen aufgebaut) weder durch Fenofibrat, noch Niacin signifikant 
verändert.  
Zusammenfassend konnten wir zeigen, dass 1-deoxySL sowohl in T2DM- als auch in MetS-
patienten in signifikant erhöhten Konzentrationen gemessen werden können. Im Falle des 
metabolischen Syndroms können sie daher als prädiktive Biomarker für die Entstehung von 
T2DM herangezogen werden. Des Weiteren zeigten wir, dass die Konzentration von C20SO 
im Plasma ein prädiktiver Biomarker für das Auftreten kardiovaskulärer Ereignisse ist. Wir 
demonstrierten, dass Fenofibrat, jedoch nicht Niacin, die Konzentrationen der atypischen 
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Sphingolipide im Plasma von dyslipidämischen Patienten wirkungsvoll senken kann. Darüber 
hinaus senkte die orale Verabreichung von L-Serin die 1-deoxySL-Konzentrationen im 
Plasma von diabetischen STZ-Ratten und verbesserte zeitgleich sowohl deren 
Empfindlichkeit für mechanische Reize als auch die Nervenleitgeschwindigkeit. Dies lässt 
darauf schließen, dass die orale Verabreichung von L-Serin eine potentielle 
Therapiemöglichkeit für die Behandlung der diabetischen Neuropathie sein könnte. 
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Introduction:	
Sphingolipids: More than a century of biochemical pathways and not yet totally deciphered 
“Enigmatic by nature” is the best fitting and most frequently used description of 
sphingolipids. The term “sphingosine” was first used by J.L.W. Thudichum (1829 – 1901) in 
his book “A treatise on the chemical constitution of the brain"[1], after being inspired by the 
Greek myth about the Sphinx, and in his words “in commemoration of the many enigmas 
which it presented to the inquirer”.  
De novo sphingolipid biosynthesis (Fig. 1) usually starts in the ER with the condensation of 
serine and palmitoyl-CoA generating 3-ketosphingaine. This, first and rate limiting, reaction 
is catalyzed by the enzyme serine palmitoyltransferase (SPT) [2-5], a pyridoxal 5′-phosphate 
(PLP)-dependent enzyme which belongs to the subfamily α-oxoamine synthase. SPT is likely 
a multimeric protein complex with a molecular weight of 460-480kDa [6]. Three subunits, 
SPTLC1, SPTLC2 [2, 3, 5] and SPTLC3 [7], have been identified as part of  this complex. 
Besides serine and palmitoyl-CoA, SPT can also use other acyl CoAs (C12-C18) [8] and other 
amino acids such as alanine and glycine as alternative substrates [9, 10]. The canonical 
(typical) reaction with serine and palmitoyl CoA forms sphingoid bases with a C18 carbon 
chain length (C18-based sphingolipids) whereas the use of other acyl CoAs results in the 
formation of sphingoid bases with a different carbon chain length. The use of alanine or 
glycine instead of serine generates, in contrast, an atypical category of 1-deoxysphinoglipids 
(1-deoxySL) which lack the C1 hydroxyl group.   
The direct SPT product, 3-keto-sphinganine, is rapidly reduced to sphinganine (SA) by the 
NADPH-dependent enzyme, 3-keto-sphinganine reductase (KSR) [11]. Typically, SA is N-
acylated by the enzyme ceramide synthase (CerS) to form dihydroceramides [12]. CerS 
comprises a family of related enzymes (CerS1-6), each of which has a different tissue 
distribution and a distinct specificity for certain fatty acid substrates [12]. This generates a 
combinatorial diversity since distinct fatty acids, differing in the carbon chain length (C12-
C26), hydroxylation and the number of double bonds, can be attached to the sphinganine 
backbone. In a minor pathway, SA can also be phosphorylated at C1 by the enzyme 
sphingosine kinase (SphK) [13] to form sphinganine 1-phosphate (SA1P). 
Ceramides [14, 15] are formed subsequently by introducing a trans-double bond into the SA 
backbone of the dihydroceramide at the C4-C5 position. This desaturation step is catalyzed by 
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the enzyme ∆4-dihydroceramide desaturase (DES) which uses NADH or NADPH as an 
electron donor and oxygen as an electron acceptor in  a series of NADH-FADH-cytochrome 
b5 electron transfer reactions [14]. Two isoforms of the mammalian dihydroceramide 
desaturases are characterized which appear to have different functions. While DES1 is 
primarily responsible for introducing the double bond, DES2 can hydroxylate the  C4 of the 
sphinganine backbone which then forms phytoceramide [16]. 
Ceramides are the central branching points in sphingolipid de-novo synthesis and represent a 
crossing point for the degradation and salvage pathways. Ceramides are one of the major 
bioactive sphingolipids with diverse roles in intracellular and extracellular signaling [17]. 
Notably, all the enzymes involved  in the de-novo synthesis of ceramides are located at the 
cytosolic surface of the ER [18] [14]. For further metabolism, ceramides have to be 
transported from the ER to the Golgi either through vesicular or non-vesicular transport. 
Ceramide transfer protein (CERT) is responsible for the non-vesicular transport of ceramides 
from the ER to the Golgi compartment [19]. In the Golgi, ceramides can be converted to 
sphingomyelins by sphingomyelin synthase (SMS) [20, 21]. Sphingomyelin synthase 
catalyzes the exchange of a phosphocholine group from phosphatidyl choline to the C1 
hydroxyl group of ceramides thereby forming sphingomyelin and diacylglyerol in the same 
reaction. There are three sphingomyelin synthases - SMS1, SMS2 and SMSr. While SMS1 is 
present on the lumenal surface of the Golgi, SMS2 is located within the plasma membrane 
[22]. Additionally, the sphingomyelin synthase-related enzyme (SMSr) is present in the ER 
where it exchanges a phosphoethanolamine group from phosphatidyl ethanolamine to 
ceramides generating ceramide phosphoethanolamine [22, 23]. SMSr has been suggested to 
play a role in ceramide homeostasis in the ER [23].  
Ceramides can be glucosylated in the Golgi by GlcCer synthase (UDP-Glc:ceramide 
glucosyltransferese) to form glucoceramide (GlcCer). GlcCer synthase attaches one glucose 
moiety to the C1 hydroxyl group of ceramides forming a β glycosidic bond to the C4 hydroxyl 
group of glucose (4Glcβ1-Cer) [24]. In contrast to  SMS1, GlcCer synthase is located at the 
cytosolic side of the Golgi [25]. For GlcCer to be further metabolized, the recently discovered 
transport protein FAPP2 (four-phosphate adaptor protein) [26] is essential to transfer the 
GlcCer from the cytosolic surface of the Golgi to the luminal side. 
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Figure 1. Sphingolipid metabolism pathways. Overview of the major enzymes and reactions in 
typical sphingolipid metabolism using the canonical substrates (serine and palmitoyl-CoA and in 
atypical sphingolipid metabolism using alternative acyl-CoAs and amino acids (alanine). green color 
represent the biosynthetic pathway while red color represents the degradation pathway  
 SPT, serine palmitoyltransferase, CerS, ceramide synthase, SPHK, sphingosine kinase, S1P, 
sphingosine 1-phosphate,KSR, ketosphinganine reductase, DES, dihydroceramide desaturase,1-
deoxySA,1-deoxysphinganine,1-deoxySO,1deoxysphingosine, R, an alkyl chain with the length (C10 
to C20) 
 
Complex gylcosphingolipids are then formed on the luminal side of the Golgi by the 
sequential addition of different sugar moieties (glucose or galactose), sialic acid and 
hexosamine (glucosamine or galactosamine).  
Besides glucose, ceramides are also conjugated to galactose by the enzyme GalCer synthase 
(UDP-Gal:ceramide galactosyltransferese) to form galactosyl-ceramide (GalCer) [27-29]. 
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GalCer are mainly present in the nervous systems of mammals. Interestingly, GalCer synthase 
is an integral membrane protein of the ER [30], where the active site is located on the lumenal 
side of ER. This indicates that ceramides produced in the ER by the de novo pathway have to 
flip to the lumenal side to form GalCer. GalCer are transported to the Golgi and then to the 
plasma membrane. Along the way they can be sulfated forming sulfatides [31]. 
Gylcosphingolipids and sphingomyelin are transported from the Golgi to the plasma 
membrane mostly by vesicular transport along the exocytic or endocytic recycling pathways 
[32]. It is noteworthy, that the pathway for the de novo synthesis of sphingolipid is well 
aligned with the secretory pathway (ER-Golgi-plasma membrane).  
Ceramides can also be phosphorylated in a reaction catalyzed by the ceramide kinase to form 
ceramide1-phosphate (Cer1-P) [33, 34].  Cer1-P has been suggested to promote proliferation 
and to play a role in inflammation [35]. 
Sphingomyelinase (SMase) is responsible for the degradation of sphingomyelin into 
ceramide. Three SMases have been identified; acid, alkaline and neutral sphingomyelinase 
[36-38], depending on the optimum pH for their activity. Acid SMase exists as both a 
lysosomal and a secreted enzyme while alkaline SMase is secreted in the gut. Neutral 
sphingomyelinase represents a family of enzymes which reside in the ER, Golgi, plasma 
membrane or nucleus where they are suggested to play different biological functions in the 
local sphingolipid homeostasis within these compartments [39]. 
The degradation of gylcosphingolipids happens in the lysosome in a stepwise fashion by 
releasing one carbohydrate moiety at a time until gulcosylceramidase hydrolyses GlcCer into 
ceramides in the last step [40]. Non-lysosomal degradation of gylcosphingolipids (e.g. on the 
plasma membrane) is also reported [41]. Ceramides formed from gylcosphingolipids or 
sphingomyelin are finally hydrolyzed by ceramidase to form sphingosine and a free fatty acid, 
both of which can leave the lysosome in contrast to ceramides [42]. Five different 
ceramidases have been identified: acid ceramidase, neutral ceramidase and alkaline 
ceramidase 1, 2 and 3. They reside in the lysosome, plasma membrane and ER probably 
playing distinct roles in maintaining an appropriate sphingosine to ceramide balance within 
these compartments [42]. The sphingosine (SO) released from ceramides differs from 
sphinganine (SA) by the presence of a C4-C5 trans double bond. SO is mainly released from 
the lysosome but can also be generated in the ER, Golgi or plasma membrane depending on 
the action and tissue distribution of the various ceramidases [42]. SO can be reacylated by 
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CerS to reform ceramides [43]. Alternatively, SO can be phosphorylated by sphingosine 
kinases (SphK) to form sphingosine 1-phosphate (S1P). There are two known isoforms of 
sphingosine kinases, SphK1 [44] and SphK2 [45] which are mostly located in the cytosol and 
differ in tissue distribution and biochemical properties [46].  S1P is a highly bioactive lipid 
which acts as an intracellular and extracellular ligand for five G-coupled receptors (S1PR1-5). 
S1P can be de-phosphorylated by S1P phosphatase to form SO again or irreversibly degraded 
by S1P lyase [47] to hexadecenal and ethanolamine phosphate. This final degradation step 
occurs at the cytosolic surface of the ER [48]. Thus, the entry and the exit points of the 
sphingolipid metabolism are both located at the ER. 
Three major observations can be made by studying sphingolipid metabolism. First, the vast 
combinatorial diversity in sphingolipid molecules which arise by the combination of different 
sphingoid bases with different N-acyl chains and various headgroups. In theory, these 
permutations can form thousands of  individual sphingolipid subspecies [49], although it is 
not clear whether all these species are really present in biological systems. However, already 
in human plasma > 200 distinct sphingolipid species have been identified [50].  Second, the 
subcellular localization and compartmentalization of the metabolizing enzymes point at 
distinct local pools for each compartment and the need for an intricate balance between 
synthesis and degradation within each compartment and within the whole cell. Third, most of 
the above mentioned pathways, if not all, were studied by focusing on the canonical pathway, 
i.e. on C18-based sphingolipids. Little is known about the metabolism, regulation and transport 
of sphingolipids with different backbones. It is therefore largely unknown whether these 
metabolites follow the same metabolic pathways or whether they have their own specific 
enzyme machinery. 
Sphingolipids and disease: 
We will focus here on the mutations affecting different enzymes of sphingolipid metabolism 
leading to monogenic disease, and the role of different sphingolipids metabolites in 
cardiometabolic diseases  
Monogenic inborn errors of sphingolipid metabolism 
Most disease causing mutations in the sphingolipid metabolism affect enzymes involved in 
the degradation  of complex sphingolipids (gylcosphingolipids and sphingomyelins), 
ceramides or essential co-factors such as sphingolipid-activator proteins (SAPs) which are 
required for the hydrolysis of certain gylcosphingolipids (Fig. 2) [51]. Since the breakdown of 
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sphingolipids occurs mainly in the lysosomes, these defects in sphingolipid catabolism are 
typically associated with lysosomal storage disorders - collectively termed as 
sphingolipidoses. Sphingolipidoses are inherited as autosomal recessive disorders with the 
exception of Fabry`s disease which is X-linked [52]. The clinical presentation is 
heterogeneous and depends mainly on the metabolic flux through the defective enzymes and 
their tissue distribution. GM1 gangliosidosis, Tay-Sachs and Sandhoff disease are 
characterized by the accumulation of gangliosides [53, 54] leading primarily to neurological 
manifestations as well as to an enlargement of spleen and liver. Fabry`s disease is caused by 
defective action of the α-galactosidase enzyme leading to accumulation of neutral 
glycosphingolipids in the vascular endothelium of the heart, kidney and nervous system [55]. 
This in turn leads to cardiac, renal and neurological impairment in these patients [55].  
 
Figure 2. Enzymatic defects in sphingolipid lysosomal storage diseases (sphingolipidoses). Each 
disease is mapped to the enzyme defect responsible for the accumulation of its substrate. Reproduced 
from [51] 
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In Gaucher disease, which is the most common sphingolipidoses, the accumulation of 
glucosylceramide happens to a large degree in the macrophages of the reticulo-endothelial 
system leading to hepato-spleenomegaly and blood disorders. In some variants of Gaucher 
disease, the accumulation of glucosyl-sphingosine and not of glucosylceramide is the cause of 
the disease which then leads to primarily neurological manifestations [56, 57].  
In metachromatic leukodystrophy, the accumulation of sulfatides affects mostly the myelin 
sheath [58] in the white matter of the brain and peripheral nerves leading to a progressive 
demyelination and a dysfunction of the central and peripheral neurons [58]. Farber`s disease 
is characterized by acid ceramidase deficiency and an accumulation of ceramides in the 
lysosomes [59, 60] which affects many organs and results in a typical skin phenotype. 
Niemann–Pick disease (NPD) type A and B is caused by defects in acid sphingomyelinase 
which leads to an accumulation of sphingomyelin and sphingosyl-phosphocholine in the 
lysosomes and other organelles [61]. Patients with NPD usually present with hepato-
splenomegaly and impairments in the nervous system. Interestingly, NPD  type C is caused by 
mutations in the two proteins (NPC 1 and 2) that are involved in the lysosomal transport of 
cholesterol [62] but leads also to an accumulation of sphingomyelin which indicates an 
association between sphingolipid and sterol metabolism [63]. 
Interestingly, almost all catabolic enzymes in sphingolipid degradation are associated with a 
genetic disease, while only two diseases have been associated with enzymes in the 
sphingolipid biosynthetic pathway. This is the infantile epileptic syndrome and hereditary 
sensory and autonomic neuropathy type I (HSAN1). Infantile epileptic syndrome has been 
reported recently to be caused by GM3 synthase deficiency which leads to an increase in 
lactosyl-ceramide, the substrate for GM3 synthase [64]. Mutations in the SPT, the first and 
rate limiting enzyme for sphingolipid biosynthesis, have been reported to cause HSAN1 [65-
68]. HSAN1 is an autosomal dominant genetic disease which affects mainly the peripheral 
sensory nerves and to a variable extent the motor and autonomic nerves. HSAN1 mutations in 
SPT were shown to increase the activity of SPT to use alanine and glycine as alternative 
substrates [9, 69], which leads to an increased generation of 1-deoxySLs. 1-deoxySLs are 
toxic to neurons in vitro and were shown to affect neurite length and branching in chicken 
dorsal root ganglia (DRGs) [70]. 
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Sphingolipids and cardiovascular disease: 
Cardiovascular disease comprises a broad spectrum of heterogeneous disorders affecting the 
heart and blood vessels. This includes atherosclerotic cardiovascular disease, congenital heart 
disease, rheumatic heart disease and others. Atherosclerotic cardiovascular disease affects the 
large and medium-sized arteries leading to coronary artery disease (CAD), cerebrovascular 
disease or peripheral artery disease. Atherosclerosis is a chronic process where lipids 
accumulate over decades within plaques in the arterial wall leading to a narrowing of the 
lumen. Severe narrowing or plaque rupture compromises the blood flow to the affected organs 
and presents clinically as acute pain or dysfunction of the affected organ. Limiting the blood 
flow in the coronary arteries leads to chest pain (angina) while a complete occlusion, usually 
by a thrombus of one of the arteries, leads to an ischemic damage of the heart muscle 
(myocardium) and myocardial infarction (MI). A similar situation in the brain leads to 
transient ischemic attacks (TIAs) or stroke. In severe conditions, where the heart or the brain 
function is largely compromised, death can occur. Atherosclerotic cardiovascular disease 
represents one of the major health problems worldwide causing substantial morbidity and 
mortality and affects significantly the quality of life [71-74]. 
Several lipid classes accumulate in the arterial wall and it has been shown in several cohorts 
over decades that an altered plasma lipoprotein profile is one of the major risk factors to 
develop MI or stroke [75]. Of these lipid classes, sphingolipids are increasingly recognized as 
mediators in the pathogenesis of atherosclerotic cardiovascular disease [76-78].  In particular, 
the role of sphingomyelin, ceramides and sphingosine 1-phosphate in atherosclerosis has been 
extensively studied. Conversion of sphingomyelins to ceramides by soluble acid SMase in the 
LDL particles was shown to increase LDL particle aggregation in the arterial wall and to 
promote atherosclerosis [79, 80]. S1P was shown to play a pro- and anti-atherogenic role, thus 
the role of S1P in atherosclerosis remains a matter of debate [81, 82]. It cannot be excluded 
that the pro- and anti-atherogenic effects of S1P depend on the functional context (e.g. source 
and carrier of S1P in plasma, expression of S1P receptor isoforms and other lipids that might 
interfere with its function).  Plasma sphingomyelin (SM) was found to be significantly 
elevated in patients with CAD [83, 84] and to be an independent predictor of MI and 
cardiovascular death in acute coronary syndrome patients [85]. Moreover, oral administration 
of myriocin, a potent inhibitor of SPT, decreased plasma SM, total cholesterol, triglycerides 
and increased HDL cholesterol and resulted in reduced atherosclerotic lesions in ApoE 
knockout mice [86]. Mechanistically, it has been suggested that plasma SM plays a role in 
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regulating the activity of lecithin-cholesterol acyltransferase (LCAT) [87] and it was shown 
that SPTLC2-deficient mice and SM synthase-deficient mice have elevated LCAT activities 
which was suggested to result from the decrease in plasma sphingomyelin. Interestingly, 
patients with mutations in the enzyme acid SMase (Niemann Pick disease type B) were found 
to have significantly lower plasma HDL-C levels and elevated triglycerides. It has been 
suggested that HDL maturation is impaired in these patients due to the inhibitory effect of SM 
on LCAT activity [88]. This suggests that plasma sphingomyelin plays a role in lipoprotein 
metabolism, which might explain its relation to coronary artery disease. 
Sphingolipids, T2DM and the metabolic syndrome: 
Diabetes mellitus (DM, Latin for sweet urine) represents one of the major health problems 
worldwide contributing substantially to mortality and morbidity and affecting the quality of 
life of millions of patients [71-74]. DM is diagnosed by elevated plasma glucose levels 
(hyperglycemia) either after fasting or 2h hours after an oral glucose challenge [89]. There are 
two major distinct clinical and pathological types of diabetes mellitus, DM type 1 (T1DM) 
and DM type 2 (T2DM). In T1DM, hyperglycemia occurs due to the loss of pancreatic β islets 
as a result of an autoimmune reaction leading to a significant drop in plasma insulin levels 
within a few days to weeks which finally results in absolute insulin deficiency. On the 
contrary, T2DM is a multifactorial disease with several genetic and environmental factors 
involved. Insulin resistance is one of the hallmarks of T2DM pathogenesis which leads to 
hyper-insulinemia as a compensatory mechanism. After several years of hyperinsulinemia, β 
cell failure occurs in a group of patients leading to impaired glucose tolerance and overt 
T2DM [90]. T2DM leads to various macrovascular (e.g. MI and stroke) and microvascular 
complications such as diabetic retinopathy and nephropathy as well as peripheral neuropathy. 
Insulin resistance tends to cluster in the same patients together with other risk factors for 
cardiovascular disease such as dyslipidemia and hypertension. This accumulation of these risk 
factors is usually referred to as the “metabolic syndrome (MetS)” [91, 92].  
A unified model for the pathogenesis of insulin resistance is still elusive, despite the 
considerable progress in understanding the different molecular mechanisms [93, 94]. A 
growing body of evidence suggests that sphingolipids contribute to the pathogenesis of insulin 
resistance and diabetes [95-98]. In particular, ceramides have been shown to be involved in 
the development of insulin resistance. Plasma ceramides were found to be elevated in T2DM 
patients [99] and to correlate positively with insulin resistance. Furthermore, ceramides have 
been shown to counteract insulin action on glucose uptake and glycogen synthesis by 
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inhibiting protein kinase B/Akt through different mechanisms [100]. Recently, it was 
demonstrated that many of the beneficial effects of adiponectin on insulin sensitivity could be 
attributed to its lowering effects of intracellular ceramides [101]. Other sphingolipids such as 
glycosphingolipids may also play a role in T2DM [102]. For instance, it was shown that 
plasma gylcosphingolipids are significantly altered in diabetic monkeys. It was also reported 
that mice lacking the ganglioside GM3 had improved insulin sensitivity [103, 104]. 
Moreover, inhibiting SPT with myriocin was shown to improve insulin resistance and to 
preclude the development of T2DM in animal models [105].  
Novel biomarkers: unmet needs in Cardio-metabolic disease 
Cardiometabolic diseases such as T2DM and atherosclerotic CVD are classical examples for 
complex multifactorial diseases where several factors inter-play to produce a heterogeneous 
phenotype. Despite of a variety of risk prediction algorithms and biomarkers, a considerable 
number of patients cannot be assigned to their appropriate risk categories. At least 15-20 % of 
the CAD patients cannot be predicted by any of the traditional risk factors [106]. Similarly, 
impaired fasting glucose and impaired glucose tolerance fail to predict almost 50% of the 
patients who will develop T2DM [107, 108]. These patients cannot be subjected to primary 
prevention as they do not fit into the current risk classification schemes. This underscores the 
need for novel biomarkers that allow the identification of those patients who are at risk 
despite the absence of classical risk factors and biomarkers [109, 110]. Moreover, there is a 
clear need for biomarkers to stratify groups of diabetic patients with an increased risk to 
develop macrovascular or microvascular complications [111, 112]. 
In general, a biomarker is defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (NIH biomarkers definitions working 
group) [110, 113]. According to this definition, biomarkers can be obtained by measuring 
biological samples (e.g. plasma or other body fluids), by performing a specific test on the 
patients (e.g. hypertension) or through imaging techniques. Biomarkers can be used to 
identify the risk to develop the disease (risk factor or risk marker), to detect the subclinical 
disease (screening biomarkers), to predict the future development of the disease (prognostic 
biomarkers) or can be used for disease staging and diagnosis [113].  
For a biomarker to be successfully applied in the routine clinical practice, five different 
phases of biomarker development have been suggested [114, 115]. In phase I, potential 
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biomarkers are discovered either by hypothesis-driven approaches or hypothesis free 
approaches (-omics technologies). Phase II entails the clinical assay development and 
validation where patients with the disease are compared to controls in a case-control design. A 
retrospective analysis of stored samples is performed in phase III of biomarker development 
while in phase IV, the analysis is done in prospective studies where patients are followed over 
a specific period of time after the biomarker has been assessed at baseline. In the final phase 
V, an interventional trial is performed to evaluate the benefits of measuring the biomarker on 
the patients` outcome [110, 114].  
 
Plasma sphingolipids:  
Plasma sphingolipids constitute about 4% of total plasma lipids but comprise > 200 distinct 
species [50, 116]. This diversity is generated by attaching different sphingoid base backbones 
to different fatty acids in the ceramide moiety combined with different head groups in 
complex sphingolipids. Sphingomyelins are the major sphingolipid species in plasma 
representing ~95% of total plasma sphingolipids. Ceramides and monohexosyl ceramides are 
minor species and represent 3.5 % and < 1% of total plasma sphingolipids, respectively, (Fig. 
3) [50, 116]. Considering the sphingoid base profile, C18SO is the most abundant representing 
~60% of the total sphingoid base backbones. C18SAdiene, C18SA and C16SO represent 18%, 
9% and 10% respectively. Other sphingoid bases are present to a minor extent (< 5%) (Fig. 3) 
[50, 116]. 1-deoxySLs are present in the plasma of healthy individual but reflect less than 1% 
of the total plasma sphingolipids) [9, 117]. Sphingolipids in plasma are primarily transported 
within the different lipoprotein fractions [118]. VLDL and LDL contain higher amount of the 
plasma sphingomyelin and ceramides compared to HDL [118]. S1P was shown to bind 
specifically to ApoM in HDL particles and it was suggested that ApoM is the specific carrier 
for S1P in plasma [119]. Interestingly, plasma 1-deoxySLs are found only in the VLDL and 
LDL but not in the HDL fraction of plasma of healthy subjects [117].  
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Figure 3. Distribution of plasma lipids (A) and sphingolipids (B-C). Plasma sphingolipids 
distribution is shown by the headgroup species for C18 sphingoid base backbone (B). The sphingoid 
base backbone distribution of total plasma sphingoid backbones (C). The figure is reproduced from the 
data published in [50] 
 
1-deoxysphingolipids: from marine chemotherapeutics to targets in a rare hereditary neuropathy  
As mentioned above, serine palmitoyltransferase (SPT) shows promiscuity for its substrates 
under certain conditions. It can use acyl-CoAs other than palmitoy-CoA and amino acids 
other than serine producing atypical sphingolipids. In the case of alanine and palmitoyl CoA, 
SPT produces a special class of 1-deoxysphingolipids (1 deoxySLs) that lack the C1 hydroxyl 
group. Since the C1 hydroxyl group is required for the formation of complex sphingolipids 
and degradation, 1-deoxySLs cannot be metabolized to complex sphingolipids nor degraded  
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through the canonical pathway. Thus, they represent dead-end metabolites. Initially, the 
compound 1-deoxySA was first discovered in the marine clam Spisula polynyma through a 
screen for marine-based cancer chemotherapeutics [120]. It was given the name ES-285 
(according to its MW of 285.3) or spisulosine after the clam in which it was discovered [120]. 
ES-285 was shown to be cytotoxic in mammalian cell culture inducing characteristic loss of 
actin stress fibers  [120]. This cytotoxic effect has been suggested to be mediated through the 
activation of an atypical PKC isoform (PKC ζ) [121, 122]  
We [9] and others [10] have identified 1-deoxySA as a direct product of the SPT reaction 
which is formed by the condensation of alanine and palmitoyl-CoA. It was shown that the 
ceramide synthase inhibitor Fumonisin B1 (FB1) causes an increased formation of 1-
deoxySA in mammalian cell lines [10]. It was also demonstrated that the prolonged culture of 
certain mammalian cell lines leads to accumulation of 1-deoxySLs especially, 1-
deoxydihydroceramides. However, it is not understood why the SPT increases its utilization 
of alanine instead of serine, in these conditions but this remains an area of active 
investigation.  
Several missense mutations in the SPT lead to increased activity with alanine and glycine 
resulting in increased 1-deoxySLs formation in patients with hereditary sensory and 
autonomic neuropathy (HSAN1). HSAN1 is an autosomal dominant disease which affects 
mainly the peripheral sensory nerves and to a variable extent the motor and autonomic nerves. 
Clinical symptoms start typically in the 2nd to 3rd decade of life with the loss of sensations for 
pain, temperature and vibration in the feet and hands. The disease is slowly progressing in a 
stocking-and-glove distribution. Sensory loss leads to ulcers and mutilations which might 
require amputations. Positive sensory symptoms such as parasthesias or lancinating pain, 
motor or autonomic symptoms are also frequently present [123, 124]. It was shown that 1-
deoxySLs are neurotoxic and affects neurite formation, length and branching in cultured 
chicken dorsal root ganglia (DRGs) [70]. There is a surprising similarity in the clinical 
symptoms between HSAN1  and the diabetic sensory polyneuropathy (DSN) - the most 
common form of the diabetic neuropathy [125]. DSN usually starts in the lower extremities 
with either negative (e.g. numbness) or positive symptoms (e.g. neuropathic pain) or a 
combination of both. Symptoms are also symmetrical on both sides with a “stocking and 
gloves” distribution. Sensory loss is frequently associated with bad wound healing at pressure 
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points and ulcers. This in turn frequently requires amputations leading to a significant 
reduction in the quality of life [126].  
We showed previously that an oral serine supplementation results in a significant lowering of 
plasma 1-deoxySL. This was demonstrated in transgenic HSAN1 animal models and in a pilot 
study with HSAN1 patients [127]. An L-serine treatment precluded the development of 
neuropathy in the mouse model whereas a supplementation with alanine significantly 
aggravated the neuropathy in the HSAN1 animals. Thus, lowering 1-deoxySLs with L-serine 
supplementation offers a promising therapeutic target in HSAN1. Therefore, we were also 
interested to investigate this strategy in the diabetic neuropathy context.  
Aim of the study: 
In this work, we aimed to evaluate the potential of atypical sphingolipids as biomarkers for 
cardiometabolic diseases. In addition, we investigated whether a modulation of the plasma 
levels of these sphingolipids could be a therapeutic strategy in the context of diabetes and 
especially, the diabetic neuropathy. 
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Abstract 
Aims/hypothesis Sphingolipid synthesis is typically initiated by the conjugation of L-serine 
and palmitoyl-CoA, a reaction catalysed by the serine-palmitoyltransferase (SPT). SPT can 
also metabolise other acyl-CoAs (C12 to C18) and other amino acids such as L-alanine and 
glycine, giving rise to a spectrum of atypical sphingolipids. Here, we aimed to identify 
changes in plasma levels of these atypical sphingolipids to explore their potential as 
biomarkers in the metabolic syndrome and diabetes. 
Methods We compared the plasma profiles of ten sphingoid bases in healthy individuals with 
those of patients with the metabolic syndrome but not diabetes, and diabetic patients (n=25 
per group). The results were verified in a streptozotocin (STZ) rat model. Univariate and 
multivariate statistical analyses were used.  
Results Deoxysphingolipids (1-deoxySLs) were significantly elevated (p=5×10-6) in patients 
with the metabolic syndrome (0.11±0.04 µmol/l) compared with controls (0.06±0.02 µmol/l) 
but did not differ between the metabolic syndrome and diabetes groups. Levels of C16-
sphingosine-based sphingolipids were significantly lowered in diabetic patients but not in 
patients with the metabolic syndrome but without diabetes (p=0.008). Significantly elevated 
1-deoxySL levels were also found in the plasma and liver of STZ rats. A principal component 
analysis revealed a similar or even closer association of 1-deoxySLs with diabetes and the 
metabolic syndrome in comparison with the established biomarkers. 
Conclusions/interpretation We showed that 1-deoxySLs are significantly elevated in patients 
with type 2 diabetes mellitus and non-diabetic metabolic syndrome compared with healthy 
controls. They may, therefore, be useful novel biomarkers to improve risk prediction and 
therapy monitoring in these patients. 
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Abbreviations:  
ALT  Alanine aminotransferase 
1-deoxySA Deoxysphinganine 
1-deoxySO  Deoxysphingosine 
1-deoxySLs Deoxysphingolipids 
DPN  Diabetic peripheral neuropathy 
HSAN1  Hereditary sensory and autonomic neuropathy type 1 
OPLS-DA Orthogonal partial least square-discriminant analysis 
PCA  Principal component analysis 
ROC  Receiver operating characteristic 
SA  Sphinganine 
SO  Sphingosine 
SPT  Serine palmitoyltransferase 
STZ  Streptozotocin 
VIP  Variable importance for the projection  
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Introduction 
The pathogenesis of diabetes mellitus type 2 is characterised by the development of insulin 
resistance, frequently because of excess body fat, that is initially overcome by increased 
insulin secretion and—after several years—a subsequent decrease in the functional pancreatic 
beta cell mass that can no longer compensate for insulin resistance [2-4]. Insulin resistance or 
the compensating hyperinsulinaemia lead to the manifestation of a cluster of risk factors, 
including hyperglycaemia, hypertriacylglycerolaemia, low plasma levels of HDL-cholesterol 
and arterial hypertension, that has been termed the metabolic syndrome. Although much 
progress [5] has been made in the understanding of the mutual relationships between obesity, 
insulin resistance, type 2 diabetes and atherosclerosis, the complete picture remains elusive. In 
the last years the carbohydrate-centred view of the pathogenesis of diabetes has widened to 
include different classes of lipids [5-7] and inflammatory factors [8]. Mounting evidence 
suggests that sphingolipids play a role in the pathogenesis of insulin resistance and diabetes 
[9-11]. In particular, ceramides have been suggested to be important in the development of 
insulin resistance. For instance, inhibition of ceramide synthesis restored insulin sensitivity in 
palmitate-induced insulin resistance in mice [12]. 
Sphingolipids comprise a heterogeneous class of lipids that are derived from the aliphatic 
amino-alcohol sphingosine, which is commonly formed from the precursors L-serine and 
palmitoyl-CoA (electronic supplementary material [ESM] Fig. 1). This reaction is catalysed 
by the enzyme serine palmitoyltransferase (SPT). In addition to these substrates, SPT 
metabolises other acyl-CoAs with carbon chain lengths in the range C12 to C18 [13]. 
Moreover, SPT also has flexibility in the use of other amino acid substrates such as L-alanine 
and glycine [14, 15], which generate an atypical category of 1-deoxysphingoid bases. 
Whereas the conjugation of alanine forms deoxysphinganine (1-deoxySA), the use of glycine 
results in the formation of deoxymethylsphinganine. These two metabolites can be N-acylated 
to form deoxysphingolipids (1-deoxySLs), but cannot be further metabolised to complex 
sphingolipids because of the missing C1-hydroxyl group [16]. Consequently, these 
metabolites cannot be degraded by the canonical sphingolipid degradation pathway, which 
requires the formation of sphingosine-1-phosphate as a catabolic intermediate. Whereas 1-
deoxySLs occur ubiquitously at low levels in human plasma, levels are greatly increased in 
hereditary sensory and autonomic neuropathy type 1 (HSAN1; OMIM162400), an inherited 
sensory neuropathy caused by missense mutations in SPT [15]. 
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Physiologically, de novo sphingolipid synthesis represents a metabolic cross point that 
interconnects lipid, amino acid and thereby indirectly also carbohydrate metabolism. 
Fluctuations in fatty acid and thereby acyl-CoA concentrations are reflected in altered carbon-
chain compositions of the sphingoid bases [12, 17]. Another node connects serine and alanine 
metabolism to the sphingolipid metabolism. Serine is formed from 3-phosphoglycerate 
whereas alanine can be converted from and to pyruvate through alanine aminotransferase 
(ALT) in a reversible transaminase reaction. Hence, the precursors for both amino acids are 
generated during glycolysis and thereby provide a functional link between sphingolipid and 
carbohydrate metabolism. In this respect, it is noteworthy that alanine is the major 
gluconeogenic amino acid, with important roles in obesity and diabetes [18, 19]. 
In light of these metabolic connections and the increasing evidence that certain sphingolipid 
molecules have roles in the pathogenesis of insulin resistance and diabetes, we compared the 
plasma sphingoid base profiles of healthy humans with those of patients with the metabolic 
syndrome but not diabetes and of patients with type 2 diabetes mellitus. The observed 
differences were further confirmed in an animal model of diabetes.  
Methods 
Patients 
A sex- and age-matched nested cohort of 25 patients with non-diabetic  metabolic syndrome, 
25 patients with the metabolic syndrome and  type 2 diabetes mellitus, and 25 controls 
without diabetes or  the metabolic syndrome was selected from a previously described study 
cohort [20] of the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT; 
Feldkirch, Austria). The samples were derived from a larger cohort of unselected white 
patients undergoing coronary angiography for the evaluation of suspected coronary artery 
disease.  Only patients with negative angiographic results were enrolled in this study. The age 
range was 55 - 69 years. The angiographers were not aware of plasma sphingolipid levels. 
The study was approved by the Ethics Committee of the University of Innsbruck and all 
participants gave written informed consent. 
According to National Cholesterol Education Program-Adult Treatment Panel III criteria, 
non-diabetic metabolic syndrome was diagnosed if three or more of the following criteria 
were fulfilled: waist circumference >102 cm in men or >88 cm in women; triacylglycerols ≥ 
1.7 mmol/l (150 mg/dl); HDL-cholesterol < 1.0 mmol/l (40 mg/dl) in men or <1.3 mmol/l (50 
mg/dl) in women; blood pressure ≥130 / ≥85 mmHg; and fasting glucose ≥6.1 mmol/l (110 
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mg/dl) but <7 mmol/l. Type 2 diabetes mellitus was diagnosed by either fasting glucose levels 
≥ 7 mmol/l (126 mg/dl), or plasma glucose levels ≥ 11.1mmol/l (200 mg/dl) 2 h after an oral 
challenge with 75 g glucose, or previously diagnosed diabetes. Controls were defined by the 
absence of both non-diabetic metabolic syndrome and type 2 diabetes mellitus 
Clinical chemistry 
Venous blood samples were collected after an overnight fast of at least 12 h before 
angiography was performed, and laboratory measurements were performed from fresh serum 
samples. The serum levels of triacylglycerols, total cholesterol and HDL-cholesterol were 
determined by using enzymatic hydrolysis and precipitation techniques (Triglycerides 
glycerol phosphate oxidase-p-aminophenazone (GPO-PAP), cholesterol oxidase phenol 4-
aminoantipyrine peroxidase (CHOD/PAP), QuantolipLDL, QuantolipHDL; Roche, Basel, 
Switzerland) on a Hitachi-Analyzer 717 or 911. Level of HbA1c was determined by high-
performance liquid chromatography (LC) on a Menarini-Arkray KDK HA 8140 (Arkray 
KDK, Kyoto, Japan). Clinical chemistry variables were measured on a Hitachi 717 or 911 
system (Roche). 
Animal model 
Male Sprague Dawley rats (180-200 g, Charles River, Calco, Italy) were housed in pairs. 
Animal room temperature and relative humidity were set at 22±2°C and 55±10%, 
respectively. Artificial lighting provided a 12 h light–dark cycle (07:00–19:00 hours). The 
animals had free access to diet and water. Diabetes was induced in rats fasted overnight by a 
single i.p. injection of 60 mg/kg of streptozotocin (STZ) dissolved in sodium citrate buffer 
(pH 4.5). The control rats were injected with vehicle. Hyperglycaemia was confirmed by 
measuring glycosuria 72 h after STZ injection, using Keto-Diabur test 5000 strips (Roche 
Diagnostics, Spa, Italy). Only animals with glycosuria > 5% were classified as diabetic and 
included in the study. Body weight and blood glucose concentration, determined by tail 
bleeding using strips (Ascensia Elite; Bayer, Basel, Switzerland), were measured weekly. 
Immediately after killing the animals, liver and muscle (gastrocnemius) were carefully 
dissected out and immediately frozen in liquid N2. 
Quantification of sphingoid bases  
The lipids were analysed as described before [15, 21]. Tissue samples were homogenised in 
lysis buffer (25mmol/l HEPES pH 8, 0.2% Triton X-100 (vol/vol)) using a Precellys 24 tissue 
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homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). Briefly, 100µl plasma 
or tissue homogenate containing 80 µg extracted protein was added to 1 ml extraction buffer 
(2:1) methanol–KOH/chloroform and spiked with 200 pmol internal standard C20-sphinganine 
(C20SA; Avanti Polar Lipids, Alabaster, Alabama,USA).   
The extracted dried lipids were acid hydrolysed using methanolic HCl (1 mol/l HCl/10 mol/l 
water in methanol) and heat (65oC, 16 h) to release the sphingoid base backbones. This was 
followed by a second extraction. LC/MS analysis was performed as described earlier [15]. 
Lipids were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, Interchim, 
Montluçon, France) and analysed by an MS detector (LCQ, Thermo, Reinach, BL, 
Switzerland). The samples were measured as singletons for each participant. Inter- and intra-
assay CVs were between 5% and 20% for each sphingoid base.  
The sphingoid bases analysed included C16SO, C16SA, C17SO, C17SA, C18SO, C18SA, C20SO, 
C18SA-diene, 1-deoxySA and 1-deoxySO. 
Statistics 
Mean comparison and receiver operating characteristic curve analyses The original dataset 
was imported into SPSS 16.0 (SPSS Switzerland, Zurich, Switzerland). As some of the 
variables measured did not follow normal distribution, even after transformations, non-
parametric tests were used. The Kruskal–Wallis test was used to compare all three groups. 
The Mann–Whitney U test was used for comparisons between two groups, followed by the 
Bonferroni correction. Spearman correlations were calculated. Receiver operating 
characteristic (ROC) curve analysis was performed and the two-tailed asymptotic p value was 
calculated for the ROC AUCs. 
Orthogonal partial least square-discriminant analysis Orthogonal partial least square-
discriminant analysis (OPLS-DA) [22, 23] was used as a multivariate predictive and 
regression method, based on the concepts of principal component analysis (PCA). In PCA, a 
large number of correlated variables (e.g. clinical, clinical chemistry and sphingolipid 
variables) are summarised into a smaller number of uncorrelated ones called principal 
components. Thus, the correlation structures are preserved while reducing the number of 
variables. In contrast to PCA, which does not consider class membership, in OPLS-DA the 
group information is included (control, the non-diabetic metabolic syndrome and diabetes) as 
a Y variable. OPLS-DA therefore summarises the data into a predictive component, 
maximising the between-group variation and an orthogonal component(s) describing the 
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within-group variation. The predictive component describes the variations in X that correlate 
with Y. The orthogonal component describes the systematic variations within each group that 
do not correlate with Y, thereby removing the noise data from the predictive component. 
For any modelling technique, model evaluation is necessary before any inferences are made. 
R2Y reports the fit of the model to the original dataset and Q2Y reports the predictive ability of 
the model calculated by cross validation. Cross validation is performed by dividing the whole 
dataset into multiple random groups and then predicting the class assignment of members of 
each group at a time. 
The dataset was imported into SIMCA-P+ 12.0.1.0 (Umetrics, Umeå, Sweden) for the 
calculations. The groups (control, non-diabetic metabolic syndrome and diabetes) were 
assigned as classes. Variables that did not follow the normal distribution were log transformed 
before model fitting. As some variables did not follow the normal distribution after log 
transformation, models were fitted twice, once with the log-transformed variables and another 
time without any transformations. The model evaluation parameters and interpretations did 
not differ in both cases. Therefore, the values for all the variables without any transformations 
were used. As the values for the variables had different scales, the dataset was normalised in 
unit variance and centred around the mean. OPLS-DA models were fitted for the classes to 
get the highest R2Y and Q2Y values. Models were used to compare two groups only at a time 
(control vs non-diabetic metabolic syndrome and non-diabetic metabolic syndrome vs 
diabetes). We did not use three groups as a Y variable as this would have made the 
interpretations of the model results more complex.  
As PCA-based methods are sensitive to outliers, Hotelling’s T2 and distance to the model, 
DmodX, were used to detect outliers. Hotelling’s T2 is a generalisation of the t distribution for 
the multivariate case and is usually visualised in score plots. Score plots show on the x-axis 
the scores of the predictive component describing the between-group variation and on the y-
axis the scores of the orthogonal component describing the within-group variation. Tolerance 
ellipse is drawn in score plots outlining the 95% probability of the Hotelling’s T2 distribution. 
Scores for observations situated outside the tolerance ellipse can be considered outliers. 
Moreover, DModX shows the distance to the model in the X space in a way similar to the 
residuals in the linear regression models. A critical value D-Crit of 0.05 was set as a limit for 
outlier detection. After outliers were detected, models were fitted twice, excluding and 
including the outliers. In the current study, no difference was found in the model evaluation 
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parameters or any of the results upon inclusion or exclusion of the outliers. Therefore, models 
without outlier removal were used for the interpretation.  
Cross validation was performed for each model with seven groups. The cross validation 
ANOVA was calculated along with misclassification tables and Fisher’s probabilities.  
Results 
For this study, we analysed plasma samples from patients in three pre-defined subgroups, 
each consisting of 25 sex- and age-matched patients with either manifest type 2 diabetes 
mellitus, the metabolic syndrome but no manifest diabetes mellitus, or without diabetes 
mellitus or the metabolic syndrome (controls). The results are summarised in Table 1.  
Sphingoid bases in plasma are usually N-acylated and conjugated with different headgroups, 
giving rise to a great variety of different sphingolipid species. To analyse the sphingoid base 
composition of these metabolites we subjected the extracted lipids to sequential acid and base 
hydrolysis to remove the N-acyl chain and head group. The resulting free sphingoid bases 
were analysed by LC/MS. 
The most abundant sphingoid base in human plasma was C18-sphingosine (C18SO) followed 
by C18SA-diene, C16-sphingosine (C16SO) and C17-sphingosine (C17SO). Generally, 1-
deoxySLs were recovered as quantitatively minor fractions, representing 0.1-0.3% of the total 
sphingoid bases 
Plasma concentrations of total 1-deoxySLs were significantly higher for the non-diabetic 
metabolic syndrome group (0.11±0.04 µmol/l) compared with controls (0.06±0.02 µmol/l) but 
did not differ between the metabolic syndrome and diabetic groups (Table 1). This elevation 
remained significant after the Bonferroni correction for multiple testing. In contrast, C16SO 
levels were found to be significantly lower (p= 0.008) in diabetic patients (6.37± 2.82 µmol/l) 
in comparison with participants with non-diabetic metabolic syndrome (8.38±2.25 µmol/l). 
However, this decrease missed the significance limit after Bonferroni correction in which a 
significance level of 0.05 corresponds to a p value of 0.002. Concentrations of other 
sphingoid bases were not significantly different between the three groups.  
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Table 1 Baseline characteristics and results. Values are expressed as means±SD or percentages 
for scale or categorical variables, respectively, p values were calculated with Kruskal–Wallis test for 
all three groups, and with the Mann–Whitney U test for two group comparisons; after Bonferroni 
correction a p value of 0.002 corresponded to a significance level of 0.05. For the categorical variable, 
asymptotic two-sided p values for χ2 are shown, AST, aspartate aminotransferase; C, controls; D, 
diabetic patient group; DBP, diastolic BP; MetS, metabolic syndrome group; SBP, systolic BP; TG, 
triacylglycerol; Wcf, waist circumference  
Characteristic Control 
(n=25) 
 
Metabolic syndrome 
(n=25) 
 
Diabetes 
(n=25) 
 
Kruskal–
Wallis 
p value 
Mann–Whitney U  p 
value 
C vs 
MetS 
MetS vs    
D 
Age 61.19±4.28 62.13±5.02 61.56±4.64 0.771 0.50 0.567 
Female (%) 40 40 40 1.000   
Smoking (%) 64 56 60 0.846   
Wcf (cm) 98.24±12.10 105.84±8.23 110.80±11.97 3.70E-04 0.004 0.051 
BMI 28.19±4.49 30.13±3.01 32.21±4.83 0.006 0.05 0.09 
Fasting glucose (mmol/l) 5.26±0.56 5.64±0.57 9.59±4.16 1.94E-09 0.03 4.29×10-7 
HbA1c (%) 5.60±0.33 5.76±0.34 7.79±2.04 4.71E-10 0.17 9.52×10-8 
HbA1c (mmol/l) 37.71 39.45 61.64    
Cholesterol (mmol/l) 5.26±1.24 4.99±1.30 4.98±1.44 0.777 0.49 0.861 
LDL-cholesterol(mmol/l) 3.35±0.96 3.45±1.00 3.16±1.22 0.449 0.52 0.269 
HDL-cholesterol(mmol/l) 1.80±0.69 1.15±0.21 1.31±0.32 1.60E-05 2.37E-06 0.132 
TG (mmol/l) 1.10±0.37 2.51±0.83 2.21±1.47 1.96E-07 1.38E-08 0.067 
SBP (mmHg) 126.80±12.47 133.84±15.23 135.52±15.92 0.081 0.12 0.44 
DBP (mmHg) 78.80±8.50 83.92±9.41 82.24±8.99 0.161 0.06 0.565 
AST 28.56±8.60 30.84±24.10 25.84±8.43 0.388 0.38 0.662 
ALT 29.92±15.71 34.76±24.54 31.68±13.25 0.650 0.35 0.907 
Creatinine 0.84±0.18 0.92±0.21 0.81±0.23 0.144 0.20 0.06 
GFR 100.65±11.53 95.26±15.30 100.77±15.68 0.316 0.22 0.184 
C16SO (µmol/l) 8.31±4.49 8.38±2.25 6.37±2.82 0.041 0.55 0.008 
C16SA (µmol/l) 0.23±0.13 0.23±0.10 0.26±0.14 0.749 0.84 0.491 
C17SO (µmol/l) 4.66±2.42 4.02±1.10 3.71±1.48 0.387 0.64 0.29 
C17SA (µmol/l) 0.15±0.07 0.14±0.05 0.14±0.05 0.960 0.82 0.961 
SO (µmol/l) 88.83±27.23 81.66±21.28 81.54±23.89 0.622 0.34 0.793 
SA (µmol/l) 2.17±0.9 2.20±0.77 2.57±1.14 0.473 0.82 0.299 
C20SO (µmol/l) 0.20±0.08 0.19±0.06 0.19±0.05 0.727 0.46 0.839 
1-deoxySO (µmol/l) 0.15±0.09 0.23±0.09 0.24±0.13 2.14E-04 3E-05 0.839 
1-deoxySA (µmol/l) 0.06±0.02 0.11±0.04 0.12±0.05 3.92E-06 5E-06 0.808 
C18SA-diene (µmol/l) 20.79±8.17 18.27±5.74 16.42±6.80 0.148 0.36 0.273 
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Table 2 Results of STZ rat tissue and plasma analysis, Values are shown as mean ± SD,  p values 
were calculated with Mann–Whitney U test: *p<0.05; ***p<0.001, C, controls; ND, not detected; 
STZ, STZ-treated rats 
Variable 
Liver (pmol/100 µg protein)  Muscle (pmol/100 µg protein)  Plasma (µmol/l) 
C STZ  C STZ  C STZ 
Glucose (mmol/l) - -  - -  8.8 ± 0.4 53.8 ± 3.3*** 
C16SO  3.4 ± 0.8 3.1 ± 0.7  1.5 ± 0.23 1.4 ± 0.24  0.06 ± 0.02 0.09± 0.07 
C17SO  15.7 ± 3.3 13 ± 2.5  4.2 ± 0.44 5.0 ± 1.2  0.3 ± 0.1 0.4 ± 0.1 
C18SA-diene  64.1 ± 10.6 78.1 ± 26.1  11.2 ± 2.3 21.5 ± 10.3*  2.6 ± 0.4 5.0 ± 0.9* 
SO  1130 ± 189 1127 ± 252  180 ± 25.4 262 ± 106*  24.3 ± 7.6 29.1 ± 4.8 
SA  40.3 ± 9.4 66.4 ± 29*  9.1 ± 1.8 8.1 ± 2.6  1.0 ± 0.5 1.6 ± 0.6* 
C20SO  10.8 ± 4.4 11.4 ± 2  6.5 ± 0.6 6.7 ± 1.6  0.1 ± 0.08 0.15 ± 0.9 
1-deoxySA 0.2 ± 0.08 0.4 ± 0.12***  ND ND  0.01 ± 0.003 0.12 ± 0.9*** 
1-deoxySO  ND ND  ND ND  ND ND 
 
A correlation matrix of all variables (clinical data, clinical chemistry measurements along 
with sphingoid base backbone measurements) showed a significant correlation of the serine-
based sphingolipids (C16, C17 or C18SA or SO and C18SA-diene) with LDL-cholesterol and 
total cholesterol but correlated less strongly with HDL-cholesterol. In contrast, the alanine-
based 1-deoxySLs showed a strong correlation with the variables related to the metabolic 
syndrome, such as waist circumference and triacylglycerols (ESM Fig. 2). Therefore, we were 
interested to see whether the increased 1-deoxySL levels are associated with hyperglycaemia 
per se or rather with insulin resistance. To address this issue we analysed plasma, liver and 
muscle tissue samples from STZ-treated rats (Table 2). Although beta cell failure and not 
insulin resistance is the basis of the STZ rat model, we found significantly elevated 1-
deoxySL levels in plasma and liver from STZ rats (Table 2, Fig. 1). No 1-deoxySLs were 
detected in muscle tissue. This suggests that plasma 1-deoxySLs are primarily elevated in 
association with hyperglycaemia and are probably of hepatic origin. 
An OPLS-DA was used to estimate the importance of the individual variables as 
discriminating biomarkers. Both models (control vs non-diabetic metabolic syndrome and 
non-diabetic metabolic syndrome vs diabetes) showed good fit and predictive power. 
Therefore, they are valid for discrimination (ESM Table 1). 
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Fig. 1 1-deoxySA levels are significantly (p<0.001) elevated in liver tissue (a) and plasma (b) of 
STZ rats (STZ) compared with controls (C) 
 
In score plots (Fig. 2a,b), clustering into separate groups was preserved after reducing the 
whole dataset into a single predictive component (shown on the x-axis) and an orthogonal one 
(shown on the y-axis). Loading plots (Fig. 2c,d) show the weights of each of the original 
variables in the model and hence their individual contributions to the disease state.  In the 
control vs metabolic syndrome loading plot (Fig. 2c), triacylglycerols, 1-deoxySA, 1-
deoxySO, and diastolic and systolic blood pressure contributed  to the  metabolic syndrome 
state model (95% CI>0) whereas elevated HDL-cholesterol contributed to the control state 
model (95%CI<0). This confirms the biological and clinical validity of the model, as elevated 
triacylglycerols, low HDL-cholesterol and hypertension are key features of the metabolic 
syndrome. 1-deoxySA and 1-deoxySO were identified as the second and fourth most 
important contributors to the metabolic syndrome model, just after triacylglycerols and HDL-
cholesterol, respectively, but above glucose, waist circumference and systolic blood pressure. 
In the metabolic syndrome vs diabetes model (Fig. 2d), we found elevated fasting glucose and 
HbA1c concentrations, together with low C16SO and creatinine levels, to be the contributors to 
the diabetes state model. 
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Fig. 2 a,b Score plots of OPLS-DA models: (a) control vs non-diabetic metabolic syndrome; (b) 
non-diabetic metabolic syndrome vs type 2 diabetes. Individual observations are shown as: black 
triangles, controls; white triangles, the metabolic syndrome; black rhombus, type 2 diabetes. On the x-
axis, the scores for each individual in the predictive principal component (t[1]) are shown, while the y-
axis shows the scores for each individual in the orthogonal component (to[1]). Thus, variations on the 
x-axis reflect the between-group separation while variations on the y-axis show the within-group 
variations (noise).  The tolerance ellipse corresponds to 95% of the Hotelling’s T2 multivariate 
distribution. c,d Loading column plots of OPLS-DA models control vs the metabolic syndrome (c) and 
the metabolic syndrome vs diabetes (d). The variables are shown on the x-axis, while the loading 
coefficients (weights) are shown on the y-axis.The weights represent the contribution of each variable 
to the model component scores. Variables with larger weights contribute more to the model. Error bars 
represent 95% CIs for calculated weights. e,f VIP plot for OPLS-DA models: control vs the metabolic 
syndrome (e) and the metabolic syndrome vs diabetes (f). The variables are shown on the x-axis, while 
VIP coefficients are shown on the y-axis. The VIP coefficients plot shows the summation of all the 
weights for each X variable to predict Y and hence denoting the importance of each X variable. Chol, 
cholesterol; Crea, creatinine; DBP, diastolic BP; HDL, HDL-cholesterol; LDL, LDL-cholesterol; SBP, 
systolic BP; T2DM, type 2 diabetes mellitus; TG, triacylglycerol; Wcf, waist circumference; 
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Fig. 3 ROC curves. (a) ROC curves for control vs metabolic syndrome showing triacylglycerols and 
HDL-cholesterol as predictors of the metabolic syndrome with AUCs of 0.968 (p<0.001) and 0.111 
(corresponding to 0.889), respectively. The 1-deoxySLs show comparable AUCs, with 0.875 for 1-
deoxySA and 0.842 for 1-deoxySO. Purple, triacylglycerol; dark blue, HDL-cholesterol (reciprocal); 
green, 1-deoxySO; light blue, 1-deoxySA; orange, waist circumference. (b) ROC curves for potential 
biomarkers in metabolic syndrome vs diabetes. HbA1c and glucose show AUCs of 0.939 and 0.917 for 
type 2 diabetes, whereas C16SO shows a significantly lower AUC of 0.282 (corresponding to 0.718), 
denoting its decrement in association with diabetes. Green, glucose; light blue, HbA1c; dark blue, 
C16SO (reciprocal) 
Variable importance for the projection (VIP) plots (Fig. 2e,f) show the contribution of each 
variable to the variation in both the X space and the Y space (and hence their correlations with 
other variables and the control or disease state). A coefficient value >1 signifies that the 
variable is important.  For the control vs metabolic syndrome model (Fig. 2e), the VIP plot 
showed the highest VIP coefficients for triacylglycerols, 1-deoxySA, HDL-cholesterol and 1-
deoxySO. A slight importance (VIP coefficient slightly >1) was noticed for diastolic pressure 
and fasting glucose. For the metabolic syndrome vs type 2 diabetes mellitus model (Fig. 2f) a 
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significant importance of HbA1c, glucose and C16SO was seen. VIP coefficients were also >1 
for BMI, HDL-cholesterol and creatinine. 
In summary, the OPLS-DA analysis revealed that triacylglycerols, 1-deoxySA, 1-deoxySO 
and HDL-cholesterol are the best explanatory variables for the non-diabetic metabolic 
syndrome, while differences in HbA1c, glucose and C16SO were mostly related to the diabetes. 
The diagnostic potential of these markers was analysed in an ROC curve analysis (Fig. 3a,b). 
For the diagnosis of the metabolic syndrome, 1-deoxySA and 1-deoxySO (Fig. 3a) had AUCs 
of 0.875 and 0.842, respectively (p<0.001). Moreover, C16SO (Fig. 3b) showed an AUC of 
0.282 (corresponding to 0.718; p<0.01). 
Discussion 
In this study, we compared the plasma sphingoid base compositions of healthy individuals 
with those of individuals with non-diabetic metabolic syndrome and diabetic patients. We 
found 1-deoxySLs to be significantly elevated in the plasma of patients with either non-
diabetic  metabolic syndrome or type 2 diabetes mellitus compared with controls but not 
different between participants with non-diabetic metabolic syndrome and diabetic patients. In 
contrast, C16SO levels were lower in diabetic patients but did not differ between controls and 
metabolic syndrome patients. Other sphingoid base metabolites were not different between 
the groups (Table 1).  
These results indicate that the metabolic changes in the metabolic syndrome and type 2 
diabetes mellitus are specifically associated with alterations in some, but not all, sphingoid 
base species. Elevated 1-deoxySL levels were also confirmed in the plasma and liver tissue of 
a model of type 1 diabetes (STZ rats), indicating that the observed increase in 1-deoxySLs is 
independent of the type of diabetes. 
Sphingolipid metabolism can be considered as a metabolic cross point that interconnects fatty 
acid (acyl-CoA) and amino acid (serine and alanine) metabolism. Serine and alanine 
formation is thereby linked to glycolysis, which forms their precursors, 3-phosphoglycerate 
and pyruvate, respectively. 
The metabolic syndrome and type 2 diabetes mellitus are associated with the clustering of 
several risk factors. To delineate the relative contribution of each variable we used a 
supervised learning approach (OPLS-DA) [24, 25]. This analysis showed that 1-deoxySL 
levels have, in addition to triacylglycerols and HDL-cholesterol, the highest explanatory 
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power for the metabolic syndrome. In this context it has to be considered that the metabolic 
syndrome and type 2 diabetes mellitus are clinically not two completely separate entities. 
Most diabetic patients also fulfil the criteria for the metabolic syndrome which, by itself, is 
associated with insulin resistance. In fact, most diabetic patients have presented for many 
years with the metabolic syndrome before hyperglycaemia has manifest. The observation that 
1-deoxySL levels are not different between non-diabetic metabolic syndrome patients and 
diabetic patients suggests that the 1-deoxySLs are already formed in the prediabetic state in 
which insulin insensitivity is still compensated by increased insulin production and 
hyperinsulinaemia. 
In contrast, C16SO together with glucose and HbA1c were the strongest contributors in the 
diabetes model. C16SO is generated by the use of myristoyl-CoA instead of palmitoyl CoA—a 
reaction that is primarily catalysed by the SPT long-chain base subunit 3 (SPTLC3) [13]. 
It should be noted at this point that we also found significant levels of C17SO in the plasma 
samples analysed. C17SO is considered to be an ‘unnatural’ sphingoid base and therefore is 
sometimes used as an internal normalisation standard in lipidomics. However, the identity of 
C17SO in human plasma was validated by comparison with a commercial synthetic C17SO 
standard and also reported earlier by Quehenberger et al. [26]. This indicates that C17SO has 
to be used with caution as an internal standard for plasma samples. 
Currently, we do not fully understand why plasma 1-deoxySL levels are increased in the 
metabolic syndrome and diabetes. That 1-deoxySLs are almost exclusively present in VLDL 
and LDL but not HDL indicates that the 1-deoxySLs in plasma are primarily of hepatic origin 
[27]. This view is supported by the observation that 1-deoxySL levels were elevated in liver 
and plasma of STZ rats but were not present in skeletal muscle. A possible explanation for the 
increased 1-deoxySL formation might be an increased hepatic availability of alanine. Recent 
reports show that lifestyle modifications in the metabolic syndrome are associated with 
significant changes in the plasma amino acid profiles [28]. In obese individuals increases in 
skeletal muscle output of alanine and hepatic uptake of alanine were seen while serine levels 
were not changed [18]. Furthermore, hepatic glucose uptake is primarily mediated by GLUT2 
and hence is insulin independent. Hyperglycaemic conditions are therefore associated with 
elevated hepatic glucose levels and an increased glycolytic flux that increases the formation of 
pyruvate and its anaerobic conversion to either lactate or alanine. Elevated glucose levels 
could hence increase hepatic alanine levels and thereby 1-deoxySL generation. This model 
implies that 1-deoxySL levels are elevated independent of the type of diabetes, which is 
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supported by the observation that 1-deoxySL levels were also found to be elevated in the 
plasma and liver of an animal model of type 1 diabetes (STZ rats). In both conditions even 
short-term and transient fluctuations in plasma glucose levels might be integrated over time 
leading to increased formation of 1-deoxySLs that, by themselves, might have a slow turnover 
as they are not degraded by the canonical sphingolipid catabolism. 
Another interesting aspect is whether increased plasma 1-deoxySL levels as well as decreased 
plasma C16SO levels contribute to the pathogenesis of diabetes and its complications. 
Genome-wide association studies have shown a strong association of genetic SPTLC3 
variants with alterations in lipid metabolism [29] and increased risk for myocardial infarction 
[30].  Therefore, lower C16SO levels might be directly or indirectly related to the increased 
risk of diabetic patients for developing cardiovascular complications. 
Previously, we showed that the increased formation of 1-deoxySLs is the pathological cause 
of the inherited neuropathy HSAN1 [15, 31]. Clinically, HSAN1 closely resembles the 
diabetic peripheral neuropathy (DPN) that occurs in about 60% of diabetic patients. Both 
conditions have late onset, slow progression and length-dependent axonopathy. All peripheral 
nerves are affected, including pain fibre, motor neurons and autonomic nerves. The 
degeneration of small sensory fibres results in the loss of pain sensation, which in turn leads 
to painless injuries. Furthermore, HSAN1 and DPN are both associated with skin ulcers, 
which is not a common feature in other peripheral neuropathies. Considering the neurotoxic 
properties of 1-deoxySLs, it might therefore be conceivable that higher levels of 1-deoxySLs 
are not only interesting from the biomarker perspective but also because 1-deoxySLs are 
potential pathogenic agents in the DPN. Interestingly, it has been shown recently that serum 
triacylglycerols correlate with the progression of the diabetic neuropathy [32]. In parallel we 
observed a strong correlation of the 1-deoxySLs and triacylglycerol levels (ESM Fig. 2). 
Taken together our results suggest that 1-deoxySLs are relevant biomarkers for both the 
metabolic syndrome and type 2 diabetes mellitus, whereas C16SO bases seem to be 
specifically lowered in diabetes, possibly reflecting the risk for developing cardiovascular 
complications. Therefore, a combination of these markers might help to improve risk 
prediction and therapy monitoring in diabetic patients. This could be especially relevant in the 
transition from the prediabetic to the diabetic state. A limitation of this study is the rather 
small group size. However, for a pilot biomarker study it is valid to use small numbers as long 
as type I and type II errors are considered carefully. We showed p values in the order of 1×10-
5
 after the most conservative correction for 1-deoxySA and 1-deoxySO, which support 
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rejection of the null hypothesis, that there is no difference in their plasma levels between the 
different groups. However, larger and ideally prospective follow-up studies are needed to 
further validate the potential of these metabolites and to explore their diagnostic and 
prognostic value. Finally, a more detailed knowledge of the physiological and 
pathophysiological properties of these metabolites is important to better understand the 
interplay between sphingolipids, carbohydrate metabolism, insulin resistance and diabetes. 
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Appendix  
Chemical nomenclature 
C16SA   (2S,3R,4E)-2-Aminohexadecan-1,3-diol 
C17SA   (2S,3R,4E)-2-Aminoheptadecan-1,3-diol 
C18SA  (2S,3R,4E)-2-Aminooctadecan-1,3-diol 
C20SA  (2S,3R,4E)-2-Aminoicosan-1,3-diol 
C16SO  (2S,3R,4E)-2-Amino-4-hexadecen-1,3-diol 
C17SO  (2S,3R,4E)-2-Amino-4-heptadecen-1,3-diol 
C18SO   (2S,3R,4E)-2-Amino-4-octadecen-1,3-diol 
C20SO  (2S,3R,4E)-2-Amino-4-icosen-1,3-diol 
 
 
 
 39 
 
Supplementary material 
 
 
 
 
 
 
 40 
 
 41 
 
References 
[1]  (1978) The nomenclature of lipids (Recommendations 1976) IUPAC-IUB Commission on 
Biochemical Nomenclature. Biochem J 171: 21-35 
[2] Donath MY, Halban PA (2004) Decreased beta-cell mass in diabetes: significance, 
mechanisms and therapeutic implications. Diabetologia 47: 581-589 
[3] Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance 
and type 2 diabetes. Nature 444: 840-846 
[4] Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116: 1802-
1812 
[5] DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the 
missing links. The Claude Bernard Lecture 2009. Diabetologia 53: 1270-1287 
[6] McGarry JD (1992) What if Minkowski had been ageusic? An alternative angle on diabetes. 
Science 258: 766-770 
[7] Chavez JA, Summers SA (2010) Lipid oversupply, selective insulin resistance, and 
lipotoxicity: molecular mechanisms. Biochim Biophys Acta 1801: 252-265 
[8] Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev 
Physiol 72: 219-246 
[9] Cowart LA (2009) Sphingolipids: players in the pathology of metabolic disease. Trends 
Endocrinol Metab 20: 34-42 
[10] Summers SA (2006) Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45: 42-
72 
[11] Deevska GM, Nikolova-Karakashian MN (2011) The twists and turns of sphingolipid pathway 
in glucose regulation. Biochimie 2011;93:32-8 
[12] Holland WL, Brozinick JT, Wang LP, et al. (2007) Inhibition of ceramide synthesis 
ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5: 167-
179 
[13] Hornemann T, Penno A, Rutti MF, et al. (2009) The SPTLC3 subunit of serine 
palmitoyltransferase generates short chain sphingoid bases. J Biol Chem 284: 26322-26330 
[14] Zitomer NC, Mitchell T, Voss KA, et al. (2009) Ceramide synthase inhibition by fumonisin 
B1 causes accumulation of 1-deoxy-sphinganine: A novel category of bioactive 1-deoxy-sphingoid 
bases and 1-deoxy-dihydroceramides biosynthesized by mammalian cell lines and animals. J Biol 
Chem 284: 4786-4795 
[15] Penno A, Reilly MM, Houlden H, et al. (2010) Hereditary sensory neuropathy type 1 is caused 
by the accumulation of two neurotoxic sphingolipids. J Biol Chem 285: 11178-11187 
[16] Humpf HU, Schmelz EM, Meredith FI, et al. (1998) Acylation of naturally occurring and 
synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol 
produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase 
inhibitor. J Biol Chem 273: 19060-19064 
[17] Hu W, Bielawski J, Samad F, Merrill AH, Jr., Cowart LA (2009) Palmitate increases 
sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and 
activity. J Lipid Res 50: 1852-1862 
[18] Felig P, Wahren J, Hendler R, Brundin T (1974) Splanchnic glucose and amino acid 
metabolism in obesity. J Clin Invest 53: 582-590 
[19] Wahren J, Felig P, Cerasi E, Luft R (1972) Splanchnic and peripheral glucose and amino acid 
metabolism in diabetes mellitus. J Clin Invest 51: 1870-1878 
[20] Saely CH, Vonbank A, Rein P, et al. (2008) Alanine aminotransferase and gamma-glutamyl 
transferase are associated with the metabolic syndrome but not with angiographically determined 
coronary atherosclerosis. Clin Chim Acta 397: 82-86 
[21] Riley RT, Norred WP, Wang E, Merrill AH (1999) Alteration in sphingolipid metabolism: 
bioassays for fumonisin- and ISP-I-like activity in tissues, cells and other matrices. Nat Toxins 7: 407-
414 
[22] Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS). Journal of 
Chemometrics 16: 119-128 
 42 
 
[23] Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J (2006) OPLS 
discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. Journal of 
Chemometrics 20: 341-351 
[24] Tsutsui H, Maeda T, Toyo'oka T, et al. (2010) Practical Analytical Approach for the 
Identification of Biomarker Candidates in Prediabetic State Based upon Metabonomic Study by 
Ultraperformance Liquid Chromatography Coupled to Electrospray Ionization Time-of-Flight Mass 
Spectrometry. J Proteome Res 9:3912-22 
[25] Qiu Y, Cai G, Su M, et al. (2010) Urinary metabonomic study on colorectal cancer. J 
Proteome Res 9: 1627-1634 
[26] Quehenberger O, Armando AM, Brown AH, et al. (2010) Lipidomics reveals a remarkable 
diversity of lipids in human plasma. J Lipid Res 51:3299-305 
[27] Bertea M, Rutti MF, Othman A, et al. (2010) Deoxysphingoid bases as plasma markers in 
diabetes mellitus. Lipids Health Dis 9: 84 
[28] Kamaura M, Nishijima K, Takahashi M, Ando T, Mizushima S, Tochikubo O (2010) Lifestyle 
modification in metabolic syndrome and associated changes in plasma amino acid profiles. Circ J 74: 
2434-2440 
[29] Illig T, Gieger C, Zhai G, et al. (2010) A genome-wide perspective of genetic variation in 
human metabolism. Nat Genet 42: 137-141 
[30] Hicks AA, Pramstaller PP, Johansson A, et al. (2009) Genetic determinants of circulating 
sphingolipid concentrations in European populations. PLoS Genet 5: e1000672 
[31] Eichler FS, Hornemann T, McCampbell A, et al. (2009) Overexpression of the wild-type 
SPT1 subunit lowers Desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 29: 
14646-14651 
[32] Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL (2009) Elevated 
triglycerides correlate with progression of diabetic neuropathy. Diabetes 58: 1634-1640 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
Chapter	2	
Plasma	Sphingolipid	Profiling	Reveals	Novel	Distinct	
Biomarkers	for	Predicting	Cardiovascular	Disease	
and	Type	2	Diabetes	Mellitus*	
Alaa Othman1,2,3, Christoph H. Saely4,5,6, Heinz Drexel4,5,6,7, Arnold  von Eckardstein1,2,3 and 
Thorsten Hornemann1,2,3 
 
1. Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, 
Switzerland 
2. Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland. 
3. Competence Centre for Systems Physiology and Metabolic Diseases, Zurich, Switzerland 
4. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria 
5. Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, 
Austria 
6. Private University of the Principality of Liechtenstein, Triesen, Liechtenstein 
7. Drexel University College of Medicine, Philadelphia, PA, USA  
 
Contribution statement 
AO did the lipid extraction, mass spectrometric analysis, the statistical analysis and wrote the 
manuscript. CHS and HD were involved in study design, sample collection and patient 
characterization. AvE contributed to study design, data interpretation and critically revised the 
manuscript. TH was involved in study design, data interpretation and supervision and critically revised 
the manuscript.  
 
 
* Manuscript in preparation 
 
 
 
 44 
 
Abstract: 
Background: 
Cardio-metabolic diseases remain to be a major cause of mortality and morbidity, despite the 
progress in risk prediction and stratification. Besides the known risk factors, sphingolipids are 
emerging as novel players in the pathogenesis of atherosclerosis and metabolic diseases. 
Sphingolpid de-novo biosynthesis is typically initiated by the condensation of palmitoyl-CoA 
and serine, a reaction catalyzed by the serine palmitoyltransferase (SPT). Besides these 
canonical substrates, SPT can also metabolize other acyl-CoAs and other amino acids, thereby 
generating a great variety of atypical sphingoid bases. In this study, we investigated the 
predictive potential of these atypical sphingoid bases in cardiovascular disease and type 2 
diabetes mellitus (T2DM). 
Methods: 
Subjects enrolled in this study were selected from patients referred to angiography for the 
evaluation of established or suspected coronary artery disease between September 1999 and 
October 2000 (VIVIT study). They were followed up for cardiovascular events and the 
development of T2DM over a period of 8 years (median 7.7 years, range [16 days- 8.8 
years]). In a cohort (n = 349), the sphingoid base profile of plasma sphingolipids was 
analyzed. Total sphingolipids were extracted, hydrolyzed and the sphingoid base backbones 
determined by LC/MS.  
Results: 
Confirming our earlier results, we observed that plasma 1-deoxysphingolipids (1-deoxySLs) 
were significantly elevated in patients with the metabolic syndrome and T2DM. In contrast, 
plasma C18SO, C18SAdiene and C18SA- based sphingolipids were significantly lowered in 
patients with coronary artery disease. In the prospective analysis, baseline 1-deoxySLs were 
identified as independent predictors for the development of T2DM (OR = 2.05, CI 95% [1.15-
3.64]) even after adjustment for HbA1c and the presence of  metabolic syndrome. ROC curve 
analysis, discriminating the group which developed T2DM, showed a significantly higher 
AUC of the combined variables (1-deoxySO, HbA1c and metabolic syndrome) than for each 
of the covariates alone (AUC = 0.77, p = 0.01). 
Additionally, baseline C20SO sphingoid base backbones were identified as independent 
predictors for the risk to develop cardiovascular events (HR = 1.31, CI 95% [1.1-1.56]) even 
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after the adjustment for traditional risk factors including the degree of coronary artery stenosis 
at baseline. Interestingly, cross sectional plasma C20-based sphingolipids were not 
significantly different between CAD patients and controls. 
Conclusion: 
We show that 1-dexoySLs are promising predictive biomarkers for the development of T2DM 
whereas C20SO are prognostic biomarkers for the prediction of cardiovascular events. They 
might, therefore, provide novel tools for the risk prediction of cardio-metabolic diseases. 
 
 
Abbreviations:  
1-deoxySA  1-deoxysphinganine 
1-deoxySO  1-deoxysphingosine 
1-deoxySLs 1-deoxysphingolipids 
AUC  Area under the curve 
C16-19  Carbon chain length (16 carbons -19 carbons) 
CAD  Coronary artery disease 
HR  Hazards ratio 
HSAN1 Hereditary sensory and autonomic neuropathy type I 
OR  Odds ratio 
ROC  Receiver operating characteristic 
SA  Sphinganine  
SO  Sphingosine  
SPT  Serine palmitoyltransferase 
T2DM  Type 2 diabetes mellitus 
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Introduction: 
Cardiovascular diseases and the related metabolic disorders remain a major cause of mortality 
and morbidity worldwide, despite the advances in risk prediction, diagnosis and management.  
Although traditional risk factors such as smoking, diabetes, dyslipidemia and hypertension 
help to identify patients with increased risk for cardiovascular events [1], a significant group 
of coronary heart disease patients (15-20%) cannot be identified based on these factors [1]. 
Similarly, impaired fasting glucose and impaired glucose tolerance fail to predict almost 50% 
of the patients who will develop T2DM [2, 3]. This fact has fueled an expanding research 
pursuit [4, 5] to identify risk factors and novel biomarkers to reclassify patients into better 
predictive risk categories. However, most of these novel biomarkers fail to improve the 
predictive ability of the current risk algorithms. It was, therefore, suggested that factors which 
are not apparently involved in the disease pathogenesis could serve better as predictive 
biomarkers [6]. With the progress in mass spectrometry and nuclear magnetic resonance, 
many blind spots in the human plasma metabolome and lipidome are becoming visible and 
quantifiable. This might lead to the discovery of novel biomarkers that add further 
information to the current predictive algorithms. Hereby a variety of metabolites such as 
acylcarnitines, amino acids, phospholipids and also sphingolipids have been suggested as 
promising biomarkers for the prediction of T2DM [7-9] and cardiovascular diseases [10]. 
Sphingolipids comprise a heterogeneous class of lipids involving ceramides, sphingomyelins, 
glycosphingolipids and free sphingoid bases. They are typically formed from the precursors 
L-serine and palmitoyl-CoA, in a reaction catalyzed by the enzyme serine 
palmitoyltransferase (SPT). The product of SPT is rapidly reduced to sphinganine, (C18SA) 
which can be further metabolized to form ceramides, sphingomyelin and gylcosphingolipids. 
These metabolites are degraded to form sphingosine (C18SO) which can be phosphorylated to 
form sphingosine 1-phosphate, irreversibly degraded or recycled into ceramides. C18SA and 
C18SO are the typical sphingoid bases or sphingoid base backbones found in sphingolipids. 
SPT is primarily composed of the three subunits SPTLC1, SPTLC2 and SPTLC3 which bind 
further proteins that are involved in regulating substrate specificity and enzyme activity [11-
13]. Besides the canonical substrates L-serine and palmitoyl-CoA, SPT is able to metabolize 
other amino acids such as L-alanine and glycine and other acyl-CoAs with a carbon chain 
length in the range of C12 to C18 as alternative substrates. The reaction with alanine generates 
an atypical category of 1-deoxysphingolipids (1-deoxy-SL) which lack the C1 hydroxyl group 
of the typical sphingolipids. On other hand, the use of stearoly-CoA instead of palmitoyl-CoA 
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results in sphingolipids with a C20 sphingoid base backbone (C20 sphingolipids). The use of 
different acyl-CoAs therefore leads to a considerable diversity in the sphingoid base 
backbones. In this respect, the SPT reaction provides thereby also a metabolic connection 
between amino acid (serine, alanine and glycine) and fatty acid metabolisms. 
Sphingolipids were shown to be involved in the development of atherosclerosis [14]  and  
metabolic diseases [15]. Elevated plasma sphingomyelin levels were found in patients with 
coronary artery disease [16] and have been suggested to be associated with subclinical 
atherosclerosis [17], although this association was not anymore significant after adjustment 
for the traditional risk factors. Moreover, plasma sphingomyelin was reported as an 
independent predictor of myocardial infarction (MI) and cardiovascular death in acute 
coronary syndrome patients [18] but was not associated with future incident MI or 
cardiovascular death in patients with stable angina [18] or in subjects free of clinical 
cardiovascular diseases at baseline [19]. Myriocin, a potent SPT inhibitor, has been suggested 
to help against atherosclerosis by inhibiting sphingolipid biosynthesis in animals [20-22]. The 
oral administration of myriocin to ApoE-KO mice on western diet led to decreased plasma 
sphingomyelin, cholesterol, triglycerides and increased HDL cholesterol which resulted in a 
reduced formation of atherosclerotic lesions [23]. These lipid-lowering effects were shown to 
be associated with a decreased expression of SREBP-1 and an increased LCAT activity [20]. 
In contrast, the intra-peritoneal injection of myriocin, had similar effects on sphingomyelin 
and atherosclerosis in ApoE-KO (on high fat diet), but did not influence total cholesterol or 
triglycerides levels [21, 24]. It has also been suggested that myriocin could even promote the 
regression of atherosclerosis [22]. Moreover, myriocin was shown to improve insulin 
resistance and preclude the development of T2DM in animal models [25]. Ceramides were 
shown to counteract the insulin action on glucose uptake and glycogen synthesis by inhibiting 
protein kinase B/Akt  through different mechanisms [26]. Recently, it has been suggested that 
many of the beneficial effects of adiponectin on insulin sensitivity are linked to its lowering 
effect of intracellular ceramide levels [27].  Plasma ceramides were found elevated in patients 
with T2DM [28] and ceramide levels were shown to correlate with the level of insulin 
resistance in these patients. In the plasma of diabetic monkeys, sphingomyelin and 
gylcosphingolipids were decreased [29]. In our own work, we showed previously that 1-
deoxySLs were significantly elevated in metabolic syndrome [30] and T2DM [31]. 
In light of these findings and the fact that SPT forms a metabolic cross-road between amino 
acid and acyl-CoA metabolism, we aimed to evaluate the predictive role of plasma 
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sphingolipids in cardiovascular disease and T2DM, with a particular focus on the various 
sphingoid base backbones. 
Methods: 
Patients and study design: 
For this study, a cohort of 349 patients were selected from the VIVIT study [32] based on the 
availability of follow-up data for T2DM  and cardiovascular events. The analysed individuals 
were enrolled in the VIVIT study between September 1999 and October 2000. At baseline all 
subjects underwent coronary angiography to evaluate a suspected or established coronary 
artery disease. Anthropometric data were collected, clinical chemistry lab parameters were 
measured and coronary angiography (Judkin`s technique) was performed on all the study 
participants at baseline. 
Metabolic syndrome was defined according to the criteria of the National Cholesterol 
Education Program-Adult Treatment Panel III criteria, if three or more of the following 
criteria were met: waist circumference > 102 cm in men or > 88 cm in women; triglycerides ≥ 
1.7 mmol/l (150 mg/dl); HDL-cholesterol < 1.0 mmol/l (40 mg/dl) in men or < 1.3 mmol/l (50 
mg/dl) in women; blood pressure ≥ 130 / ≥ 85 mmHg; and fasting glucose ≥ 6.1 mmol/l (110 
mg/dl). Patients with fasting glucose ≥ 7 mol/l (126 mg/dl) at baseline were diagnosed with 
T2DM.  Patients with coronary artery stenosis ≥ 50% were diagnosed with significant 
coronary artery disease (CAD). 
Prospective study: 
Patients were followed-up over a period of 8 years (median 7.7 years, range [16 days- 8.8 
years]) for cardiovascular-related events including non-fatal myocardial infarction, non-fatal 
stroke, the need for a coronary artery bypass graft, percutaneous coronary intervention, non-
coronary vascular surgery and mortality due to cardiac or vascular reasons.  
For the diagnosis of incident T2DM, blood samples were collected at the two, four, six and 
eight-year visits. Individuals were considered to be diabetic if one of the three criteria was 
met: fasting glucose levels ≥ 7mmol/l (126 mg/dl), plasma glucose levels ≥ 11.1mmol/l (200 
mg/dl) 2 h after an oral glucose challenge (75 g) or the clinical diagnosis of T2DM by a 
physician during the follow- up period. Subjects were diagnosed to be free from incident 
T2DM if both conditions were met; fasting glucose levels < 7mmol/l (126 mg/dl) and plasma 
glucose levels < 11.1mmol/l (200 mg/dl) 2 h after an oral challenge with 75 g glucose at all 
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the follow-up visits. Subjects with missing values of FPG or 2 h post glucose challenge were 
excluded. Thus, only 105 subjects from the cohort fulfilled the criteria of incident T2DM 
(n=35) or the absence of incident T2DM (n=70) and were included in the prospective analysis 
for T2DM. 
 
Clinical chemistry: 
Venous blood samples were collected after overnight fasting and at least 12 h before 
angiography. Laboratory analysis was performed on fresh serum samples. HbA1c was 
analysed by high-performance liquid chromatography (HPLC) on a Menarini-Arkray KDK 
HA 8140 (Arkray KDK, Kyoto, Japan). Triacylglycerols, total cholesterol, HDL and other 
clinical chemistry variables were measured on a Hitachi 717 or 911 system (Roche). 
 
Sphingolipid analysis: 
The sphingoid base profile was analysed as described before [30] with some modifications. 
Briefly, 0.5 ml methanol including 200 pmol of the internal standards d7-sphingosine and d7-
sphinganine (d7SA, d7SO; Avanti Polar Lipids, Alabaster, Alabama, USA) was added 
to100µl of plasma and extracted for 1h under agitation on a thermo-mixer at 37oC. 
Precipitated proteins were pelleted by centrifugation and the supernatant transferred to a new 
tube. For lipid hydrolysis, 75µl of methanolic HCl (1 N HCl and 10 M H2O in methanol) was 
added to the supernatant and incubated for 16 hours at 65oC. This was followed by the 
addition of 100 µl of 10M KOH to neutralize the HCl and hydrolyze the phospholipids. To 
this mix, 625 µl chloroform was added. Then, 100 µl 2N ammonium hydroxide and 0.5 ml 
alkaline water were added to complete the phase separation. The mix was then vortexed and 
centrifuged at 16000 g for 5 minutes. After centrifugation, the upper phase was discarded and 
the lower organic phase was washed two to three times with alkaline water. Finally, the 
organic phase was dried under N2 and kept at -20 oC freezer until analysis. 
The sphingoid bases were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, 
Interchim, Montluçon, France) and analysed on a TSQ Quantum Ultra mass spec (Thermo, 
Reinach, BL, Switzerland). Each sample was measured as a singleton. Intra- and Inter-assay 
coefficient of variation (CV %) of the method was between 5% and 20%.  
Statistical analysis: 
Continuous variables were log-transformed and the means were compared using the two-sided 
t-test. Categorical variables were compared using the Chi-square test. Prospective analysis of 
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cardiovascular events was done using Kaplan-Meier curves and Cox hazard regression models 
(univariate and multivariate). In some cases, Kaplan Meier curves were done after sorting the 
cohort into two groups above and below the median. The continuous variables were 
standardized in standard deviation units by subtracting each value from the average and then 
dividing it by the standard deviation. Hazard ratios are reported per increase of one standard 
deviation. Univariate Cox regression models were calculated to evaluate the predictive 
potential of each variable. Multivariate cox regression models were performed to evaluate the 
predictive role of individual variables after adjusting for other significant variables from the 
univariate model (with HR lower limit of 95 % CI > 1). Schoenfeld residuals were calculated 
for each of the covariates and plotted against time-to-event to visually check for the 
fulfillment of the proportionality assumption and linear regression models using the 
Schoenfeld residuals as dependent variables were made. None of the covariates showed major 
violation of the proportionality assumption. 
Prospective analysis for the development of T2DM was performed using binary logistic 
regression. Since only the subjects with confirmed new onset of T2DM (n = 35) or confirmed 
absence of incident T2DM (n = 70) were selected for the analysis, binary logistic regression 
was preferred over survival analysis or censored regression methods. Mean comparison was 
done between the group which developed T2DM and the group which did not develop T2DM. 
Two-sided t-test was performed on the log-transformed variables. Univariate binary logistic 
regression models were calculated to evaluate the predictive role of each of the measured 
variables. Multivariate logistic regression models were then performed to adjust for the 
traditional predictors. Log transformed and normalized variables in standard deviation units 
were used for the logistic regression models. The ROC curve analysis was done using the 
predicted probabilities from some of the univariate and multivariate logistic regression models 
and the AUCs were compared using Delong`s test. Statistical analyses were performed in 
SPSS16.0 (IBM, Zurich, Switzerland) and R. 
 
 
 
 
 
 51 
 
Results: 
In a cross-sectional design, we compared sphingoid base plasma profile in individuals with 
and without MetS (Table 1), in subjects with and without T2DM (Table 2) and in subjects 
with coronary artery disease (CAD) to CAD-free subjects at baseline (Table 3).  
Plasma sphingoid bases are usually N-acylated and conjugated to different headgroups, giving 
rise to the various sphingolipid species. In the current study, we were primarily interested in 
analysing the sphingoid base profile. Therefore, the total sphingolipids were extracted and 
acid-hydrolysed to remove the attached N-acyl chains and head groups. It should therefore be 
noted that all reported sphingoid base concentrations are not free sphingoid bases but refer to 
the sphingoid base content in the total extracted sphingolipids e.g. the reported C18SO 
concentration reflects all extracted sphingolipids (ceramides, sphingomyelins, 
glycosphingolipids etc.) which contain a C18SO backbone. 
At baseline, plasma 1-deoxySLs and C20-based sphingolipids were significantly higher in 
patients with MetS (Table 1) (p = 4.35 * 10 e-7 for 1-deoxySO, p = 5.08 * 10e-6 for 1-
deoxySA, p = 0.02 for C20SO and p = 6.047 * 10 e-5 for C20SA), while C17SO, C18 SAdiene 
and C18SO were lower in the plasma of individuals with MetS (p=0.001, p= 0.009, p= 0.007, 
respectively). Sphingoid bases with C16 and C19 backbones were not different between the 
groups.  
A similar picture is seen for individuals with diagnosed T2DM at baseline (Table2). Also in 
this group the 1-deoxySLs and C20-based sphingolipids were significantly elevated compared 
to the non-diabetic subjects (p = 9.68 * 10 e-5 for 1-deoxySO; p = 0.003 for 1-deoxySA; p = 
0.034 for C20SO and p = 5.05 * 10 e-5 for C20SA) whereas C17SO and C18SAdiene sphingoid 
bases were lower in patients with T2DM (p = 0.043 for C17SO and p = 0.013 for C18 
SAdiene). C16-, C19- and C18- sphingoid bases were not significantly different between these 
groups 
In CAD patients (stenosis of the coronary arteries ≥ 50 %), the levels of C17SO (p = 0.04), 
C18SAdiene (p = 8.79 *10 e-4), C18SO (p = 0.001) and C18SA (p = 0.002) were significantly 
lower at baseline whereas C16, C19, C20- sphingoid bases and 1-deoxySLs were not 
significantly different among the groups. 
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Table 1. Baseline characteristics of patients with metabolic syndrome (MetS) and subjects free of 
MetS. Values are shown as mean ±SD for the continuous variables and numbers and percetnage of 
total for the categorical variables. p values were calculated using the unpaired two sided t-test on the 
log transformed continuous variables. For the categorical variables, the p value was calculated using 
the Chi square test. Variables in bold font have p < 0.05. MetS, metabolic syndrome HOMA-IR, 
Homeostatic model assessment-insulin resistance, K, serum potassium, CRP, C-reaction protein, GFR 
(Mayo) Glomerular filtration rate (Mayo equation). 
  
No MetS at baseline 
(n= 195) 
MetS at baseline  
(n= 154) p 
Age (years) 64.14 ± 10.2 61.18 ± 9.78 0.009 
Sex (Female) 66 (33.85%) 46 (29.88%) 0.429 
Hypertension (WHO) 80 (41.03%) 101 (65.59%) 5.13E-06 
T2DM (baseline) 32 (16.42%) 79 (51.3%) 3.68E-12 
History of smoking 108 (55.39%) 103 (66.89%) 0.029 
 Coronary artery stenoses > 50%  113 (57.95%) 102 (66.24%) 0.114 
BMI  26 ± 4.13 28.91 ± 4.14 1.13E-10 
Waist circumference (cm)  91.48 ± 10.71 101.37 ± 11.39 4.51E-14 
Waist-to-Hip Ratio  0.93 ± 0.09 0.99 ± 0.08 3.25E-09 
Cholesterol (mmol/l) 5.64 ± 0.98 5.56 ± 1.25 0.279 
LDL (mmol/l) 3.47 ± 0.81 3.26 ± 0.96 0.012 
HDL (mmol/l) 1.41 ± 0.39 1.05 ± 0.29 5.12E-22 
Triglycerides (mmol/l) 1.38 ± 0.62 2.57 ± 1.59 8.99E-24 
Glucose (mmol/l) 6 ± 1.78 7.8 ± 2.63 2.49E-16 
HbA1c (%) 6.04 ± 0.88 6.77 ± 1.37 1.62E-08 
 Insulin (µU/ml) 9.43 ± 8.27 17.26 ± 15.81 2.29E-14 
HOMA-IR 2.55 ± 2.57 5.78 ± 4.98 9.64E-21 
Systolic BP 131.19 ± 21.53 144.08 ± 20.96 9.55E-09 
Diastolic BP 76.39 ± 12.39 82.19 ± 12.05 5.97E-06 
CRP  0.68 ± 0.98 1.05 ± 1.64 1.18E-04 
K 4.39 ± 0.41 4.41 ± 0.49 0.748 
S.Creatinine (mg/dl)  1.13 ± 0.63 1.2 ± 0.74 0.094 
GFR (Mayo) 86.26 ± 19.34 85.06 ± 21.99 0.414 
T2DM treatment 32 (16.42%) 79 (51.3%) 3.68E-12 
Diuretics 59 (30.26%) 64 (41.56%) 0.028 
Anti-hypertensive drugs 151 (77.44%) 134 (87.02%) 0.022 
Lipid-lowering drugs 93 (47.7%) 82 (53.25%) 0.303 
Plasma Sphingolipids 
      
C16SO (µmol/l) 15.366 ± 5.38 14.275 ± 5.33 0.058 
C16SA (µmol/l) 0.447 ± 0.19 0.501 ± 0.289 0.234 
C17SO (µmol/l) 8.162 ± 2.736 7.273 ± 2.44 0.001 
C18PhytoSO (µmol/l) 0.119 ± 0.042 0.114 ± 0.049 0.103 
C18SAdiene (µmol/l) 28.36 ± 7.81 26.31 ± 7.833 0.009 
C18SO (µmol/l) 95.001 ± 18.615 89.972 ± 22.446 0.007 
C18SA (µmol/l) 3.209 ± 1.047 3.65 ± 1.805 0.075 
C19SO (µmol/l) 2.879 ± 1.2 2.696 ± 1.212 0.094 
C20SO (µmol/l) 0.169 ± 0.05 0.185 ± 0.064 0.020 
C20SA (µmol/l) 0.025 ± 0.014 0.03 ± 0.015 6.47E-05 
1-deoxySO (µmol/l) 0.152 ± 0.086 0.211 ± 0.135 4.35E-07 
1-deoxySA (µmol/l) 0.072 ± 0.035 0.094 ± 0.057 5.08E-06 
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Table 2. Baseline characteristics of patients with T2DM compared to T2DM-free subjects of the 
nested VIVIT cohort. Values are shown as mean ±SD for the continuous variables and numbers and 
percetnage of total for the categorical variables. p values were calculated using the unpaired two sided 
t-test on the log transformed continuous variables. For the categorical variables, the p value was 
calculated using the Chi square test. Variables in bold font have p < 0.05. MetS, metabolic syndrome 
HOMA-IR, Homeostatic model assessment-insulin resistance, K, serum potassium, CRP, C-reaction 
protein, GFR (Mayo) Glomerular filtration rate (Mayo equation). 
  
No T2DM at baseline 
(n= 238) 
T2DM at baseline 
(n= 111) p All (n = 349) 
Age (years) 63.03 ± 10.29 62.43 ± 9.75 0.682 62.84 ± 10.11 
Sex (Female) 79 (33.2%) 33 (29.73%) 0.519 112 (32.1%) 
Hypertension (WHO) 124 (52.11%) 57 (51.36%) 0.896 181 (51.87%) 
History of smoking  136 (57.15%) 75 (67.57%) 0.064 211 (60.46%) 
 Coronary artery stenoses > 50%  139 (58.41%) 76 (68.47%) 0.072 215 (61.61%) 
MetS ATP III  75 (31.52%) 79 (71.18%) 3.68E-12 154 (44.13%) 
BMI  26.85 ± 4.32 28.22 ± 4.36 0.005 27.29 ± 4.37 
Waist circumference (cm)  94.14 ± 11.59 99.46 ± 12.23 2.22E-04 95.89 ± 12.05 
Waist-to-Hip Ratio  0.95 ± 0.09 0.98 ± 0.09 0.002 0.96 ± 0.09 
Cholesterol (mmol/l) 5.67 ± 1.06 5.46 ± 1.18 0.073 5.6 ± 1.11 
LDL (mmol/l) 3.48 ± 0.84 3.14 ± 0.95 7.60E-04 3.37 ± 0.89 
HDL (mmol/l) 1.29 ± 0.39 1.14 ± 0.36 2.26E-04 1.24 ± 0.39 
Triglycerides(mmol/l) 1.71 ± 1.02 2.36 ± 1.69 7.01E-05 1.92 ± 1.3 
Glucose (mmol/l) 5.79 ± 0.92 8.94 ± 3.02 2.78E-23 6.8 ± 2.37 
HbA1c (%) 5.82 ± 0.49 7.52 ± 1.38 5.88E-26 6.36 ± 1.18 
Insulin (µU/ml) 11.42 ± 12.64 16.01 ± 12.59 2.56E-05 12.9 ± 12.78 
HOMA-IR 2.89 ± 2.77 6.24 ± 5.43 9.17E-16 3.97 ± 4.14 
Systolic BP 135.78 ± 22.23 139.36 ± 22.04 0.138 136.93 ± 22.2 
Diastolic BP 78.88 ± 12 79.19 ± 13.72 0.918 78.98 ± 12.56 
CRP  0.79 ± 1.39 0.96 ± 1.19 0.038 0.84 ± 1.33 
K 4.36 ± 0.43 4.48 ± 0.48 0.021 4.4 ± 0.45 
S.Creatinine (mg/dl)  1.15 ± 0.68 1.21 ± 0.68 0.216 1.17 ± 0.68 
GFR (Mayo) 86.38 ± 19.02 84.29 ± 23.56 0.268 85.72 ± 20.55 
Diuretics 71 (29.84%) 52 (46.85%) 0.002 123 (35.25%) 
Anti-hypertensive drugs 186 (78.16%) 99 (89.19%) 0.013 285 (81.67%) 
Lipid-lowering drugs 111 (46.64%) 64 (57.66%) 0.055 175 (50.15%) 
Plasma Sphingolipids       
  
C16SO (µmol/l) 15.031 ± 5.553 14.57 ± 4.991 0.419 14.884 ± 5.378 
C16SA (µmol/l) 0.463 ± 0.244 0.486 ± 0.233 0.538 0.471 ± 0.24 
C17SO (µmol/l) 7.965 ± 2.737 7.351 ± 2.389 0.043 7.77 ± 2.643 
C18PhytoSO (µmol/l) 0.118 ± 0.047 0.115 ± 0.042 0.500 0.117 ± 0.045 
C18SAdiene (µmol/l) 28.114 ± 7.934 26.043 ± 7.591 0.013 27.455 ± 7.875 
C18SO (µmol/l) 93.899 ± 20.869 90.388 ± 19.617 0.105 92.782 ± 20.517 
C18SA (µmol/l) 3.274 ± 1.308 3.681 ± 1.678 0.069 3.403 ± 1.446 
C19SO (µmol/l) 2.879 ± 1.261 2.624 ± 1.066 0.080 2.798 ± 1.207 
C20SO (µmol/l) 0.172 ± 0.058 0.184 ± 0.055 0.034 0.176 ± 0.057 
C20SA (µmol/l) 0.025 ± 0.012 0.032 ± 0.02 5.05E-05 0.027 ± 0.015 
1-deoxySO (µmol/l) 0.159 ± 0.098 0.218 ± 0.135 9.68E-05 0.178 ± 0.114 
1-deoxySA (µmol/l) 0.076 ± 0.043 0.095 ± 0.055 0.003 0.082 ± 0.048 
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Table 3. Baseline characteristics of patients with coronary artery disease (CAD) and subjects 
free of CAD. Values are shown as mean ±SD for the continuous variables and numbers and 
percetnage of total for the categorical variables. p values were calculated using the unpaired two sided 
t-test on the log transformed continuous variables. For the categorical variables, the p value was 
calculated using the Chi square test. Variables in bold font have p < 0.05. CAD, coronary artery 
disease, MetS, metabolic syndrome HOMA-IR, Homeostatic model assessment-insulin resistance, K, 
serum potassium, CRP, C-reaction protein, GFR (Mayo) Glomerular filtration rate (Mayo equation). 
  
No significant CAD at 
baseline (n = 134) 
Significant CAD at 
baseline (n = 215) p 
Age (years) 61.806 ± 9.887 63.47 ± 10.21 0.151 
Sex (Female) 64 (47.77%) 48 (22.33%) 7.4E-07 
Hypertension (WHO) 69 (51.5%) 112 (52.1%) 0.91305 
T2DM 35 (26.12%) 76 (35.35%) 0.071771 
History of smoking  64 (47.77%) 147 (68.38%) 0.000128 
MetS ATP III Definition 52 (38.81%) 102 (47.45%) 0.11406 
BMI  27.989 ± 4.537 26.841 ± 4.21 0.016 
Waist circumference (cm)  96.191 ± 13.768 95.702 ± 10.865 0.935 
Waist-to-Hip Ratio  0.94 ± 0.101 0.961 ± 0.076 0.026 
Cholesterol (mmol/l) 5.701 ± 0.969 5.534 ± 1.177 0.080 
LDL (mmol/l) 3.418 ± 0.757 3.339 ± 0.955 0.178 
HDL (mmol/l) 1.382 ± 0.452 1.148 ± 0.304 1.53E-06 
Triglycerides (mmol/l) 1.763 ± 1.494 2.008 ± 1.151 0.001 
Glucose (mmol/l) 6.472 ± 2.009 6.992 ± 2.55 0.035 
HbA1c (%) 6.157 ± 1.093 6.476 ± 1.212 0.007 
 Insulin (µU/ml) 11.802 ± 8.877 13.574 ± 14.678 0.439 
HOMA-IR 3.348 ± 2.614 4.354 ± 4.818 0.089 
Systolic BP 137.724 ± 24.215 136.42 ± 20.855 0.739 
Diastolic BP 80.366 ± 12.588 78.095 ± 12.483 0.088 
CRP  0.761 ± 1.421 0.891 ± 1.257 0.282 
K 4.344 ± 0.419 4.428 ± 0.456 0.089 
S.Creatinine (mg/dl)  1.083 ± 0.547 1.212 ± 0.748 0.002 
GFR (Mayo) 87.689 ± 19.054 84.462 ± 21.391 0.139 
T2DM treatment 35 (26.12%) 76 (35.35%) 0.071771 
Diuretics 54 (40.3%) 69 (32.1%) 0.118626 
Anti-hypertensive drugs 101 (75.38%) 184 (85.59%) 0.016541 
Lipid lowering drugs 41 (30.6%) 134 (62.33%) 8.14E-09 
Plasma Sphingolipids 
   
C16SO (µmol/l) 15.468 ± 4.825 14.521 ± 5.676 0.050 
C16SA (µmol/l) 0.489 ± 0.219 0.459 ± 0.252 0.080 
C17SO (µmol/l) 8.088 ± 2.5 7.572 ± 2.715 0.040 
C18PhytoSO (µmol/l) 0.119 ± 0.039 0.115 ± 0.049 0.176 
C18SAdiene (µmol/l) 29.234 ± 7.801 26.347 ± 7.734 8.79E-04 
C18SO (µmol/l) 96.435 ± 17.842 90.506 ± 21.751 0.001 
C18SA (µmol/l) 3.643 ± 1.418 3.254 ± 1.447 0.002 
C19SO (µmol/l) 2.796 ± 1.159 2.799 ± 1.239 0.752 
C20SO (µmol/l) 0.176 ± 0.056 0.176 ± 0.058 0.922 
C20SA (µmol/l) 0.028 ± 0.017 0.027 ± 0.013 0.476 
1-deoxySO (µmol/l) 0.179 ± 0.107 0.177 ± 0.118 0.471 
1-deoxySA (µmol/l) 0.084 ± 0.042 0.08 ± 0.051 0.191 
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A correlation analysis (supplementary table 1) between sphingoid bases, laboratory values 
and anthropometric measures at baseline revealed a strong positive correlation between 1-
deoxySLs ( 1-deoxySA and 1-deoxySO) and TG, glucose, HbA1c, insulin and HOMA-IR, 
whereas the other sphingoid bases correlated with LDL and total cholesterol. 
Within the analysed cohort, 126 individuals (36%) developed cardiac and vascular events 
during the follow-up period (Table 4). We therefore evaluated the predictive potential of the 
sphingoid bases for cardiac and vascular events. In the univariate approach, C18SAdiene and 
C20SO showed a significant difference from the zero models in Kaplan Meier plots and 
univariate Cox regression models (Fig. 1 (A, B), supplementary Table 2) while the other 
sphingoid bases did not show any significant difference.  
Table 4: Incident cardiovascular events in the nested VIVIT cohort  
 
N (%)  
total = 349 
Non-fatal myocardial infarction 26 (7.45%) 
Non-fatal stroke 19 (5.45%) 
Coronary artery bypass graft  14 (4.02%) 
Percutaneous coronary 
intervention 48 (13.76%) 
Peripheral vascular surgery(non-
coronary) 24 (6.88%) 
Mortality due to cardiac or 
vascular reasons 69 (19.78%) 
Total (cumulative)cardiac and 
vascular events 126 (36.11%) 
 
Multivariate Cox hazard regression models were used to adjust for known cardiovascular risk 
factors that were significant in the univariate models (i.e. age, sex, smoking, HDL, waist-to-
hip ratio, HbA1c, creatinine, GFR, CRP and the extent of coronary artery stenosis as graded 
by angiography). After adjusting the models to the significant predictors from the univariate 
analysis, C20SO remained predictive for the risk to develop cumulative cardiovascular events 
(Fig 1C, HR = 1.31 [95% CI, 1.09 – 1.56], p = 0.002) whereas C18SAdiene did not (Fig. 1C). 
This result is rather surprising since baseline C20SO levels were not significantly different 
between coronary artery disease patients (as diagnosed by angiography) and controls at 
baseline (Table 3). This indicates that plasma C20SO levels add a predictive value to the 
angiographic diagnosis for the development of cardiovascular- related events.  
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Figure 1. Univariate Kaplan Meier plots (A and B) for plasma C20SO and C18SAdiene. 
The cohort is sorted into two groups higher (red)  and lower (blue) than the median and the p values 
are calculated using log rank test. Forest plot (C) showing the hazard ratio (filled circle) and the 95% 
CI as horizontal error bar for the individual plasma sphingolipids.  Cox hazard regression models were 
built using the log transformed and standardized variables. Each bar represents a different Cox 
regression model for each of the sphingolipids and adjusting for age, sex, smoking, HDL, waist-to-hip 
ratio, HbA1c, creatinine, GFR, CRP and the extent of coronary artery stenosis as graded by 
angiography 
 
Figure 2. Box and whisker plots showing the plasma values of HbA1c (A), triglycerides (B), 1-
deoxySA (C) and 1-deoxySO (D) in the group of patients who developed incident T2DM 
(iT2DM) and those who did not (no iT2DM). p values are calcuated using the t-test  on the log 
transformed values. 
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The role of the plasma sphingolipids as predictive biomarkers for T2DM development, was 
assessed by comparing sphingoid base plasma levels at baseline between individuals who 
developed T2DM during the follow-up period of the study (incident T2DM, n = 35) and those 
who did not (no-incident T2DM, n = 70). Baseline 1-deoxySLs, HbA1c and triglycerides were 
significantly elevated in the incident T2DM group (Fig. 2, supplementary table 3), (p = 9.16 * 
10e-4 for 1-deoxySO, p = 0.003 for 1-deoxySA, p = 0.004 for HbA1c and p = 0.02 for TGs) in 
comparison to the no-incident T2DM group. Univariate binary logistic regression (Table 5) 
revealed that HbA1c, triglycerides, the presence of a metabolic syndrome, potassium, 1-
deoxySO and 1-deoxySA were significant predictors for the development of T2DM. To 
address the predictive role of 1-deoxySLs, we used each of the significant variables in the 
univariate models as covariates in a bivariate binary logistic regression model in combination 
with either 1-deoxySO or 1-deoxySA (Table 5).  
Table 5. Binary logistic regression models results for incident T2DM showing the odds ratios 
for the univariate and multivariate models. Variables are log-transformed and standardized in SD 
units. 
    
Odds ratio per one  SD 
increase  of  the log 
transformed variable    p 
Univariate binary logistic 
regression models       
  1-deoxySO 2.29 (1.35-3.89) 0.002 
  1-deoxySA 1.99 (1.22-3.24) 0.006 
  TG 1.69 (1.07-2.68) 0.025 
  HbA1c 3.94 (1.47-10.55) 0.007 
  MetS 3.47 (1.45-8.31) 0.005 
  K 1.77 (1.05-2.97) 0.033 
Multivariate binary logistic 
regression models       
    
  
  
Model 1 
  
MetS 2.74 (1.1-6.83) 0.031 
1-deoxySO 2.09 (1.21-3.63) 0.009 
Model 2 
  
1-deoxySO 1.92 (1.05-3.53) 0.037 
TG 1.25 (0.73-2.15) 0.426 
Model 3 
  
1-deoxySO 2.25 (1.29-3.91) 0.004 
HbA1c 3.75 (1.34-10.48) 0.012 
Model 4 
  
1-deoxySO 2.04 (1.15-3.65) 0.016 
K 1.58 (0.92-2.7) 0.098 
Model 5 
  
  
HbA1c 3.64 (1.28-10.37) 0.016 
1-deoxySO 2.05 (1.15-3.64) 0.015 
MetS 2.63 (1.02-6.77) 0.047 
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Baseline 1-deoxySO, HbA1c and the presences of a metabolic syndrome remained significant 
after this analysis, while 1-deoxySA turned non-significant after adjusting to triglycerides 
(supplementary table 4). Even after adjusting for HbA1c and MetS status, 1-deoxySO 
remained statistically significant (Table 5) with an odds ratio of 2.05 ([CI 95%, 1.15-3.64], p 
= 0.015). 
  
 
 
A ROC curve analysis, using the predicted probabilities from the univariate logistic 
regression models for 1-deoxySO, HbA1c and metabolic syndrome showed similar areas under 
the curves for the individual variables (AUC = 0.68, 0.64 and 0.64 respectively). However, 
the ROC curve for the multivariate model including all three variables showed a significant 
improvement from the univariate ROC curves (AUC = 0.77, p = 0.011 compared to HbA1c 
only and p =0.013 compared to MetS only). 
Discussion: 
We found in two previous cross sectional studies that 1-deoxySLs are elevated in the plasma 
of patients with metabolic syndrome and T2DM [33, 34]. These previous findings were also 
confirmed in the current study and extended by the observation that plasma 1-deoxySLs are 
predictors for the risk to develop T2DM. The ROC curve analysis showed that 1-deoxySLs, in 
particular 1-deoxySO, has a comparable diagnostic value to some of the traditional risk 
factors such as HbA1c or the presence of a metabolic syndrome. Importantly, we showed that 
the combination of 1-deoxySO with the presence of metabolic syndrome and HbA1c 
Figure 3. Receiver operating 
characteristics (ROC) curves 
showing the area under the curve 
for 1-deoxySO, HbA1c and MetS 
and the combined model based on 
the logistic regression model to 
discriminate the incident T2DM 
group from those who did not 
develop T2DM. Areas under the 
curve (AUCs) and their 95% CIs are 
shown. p values are calculated for 
the difference from the reference 
line (an AUC of 0.5). 
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significantly improved the ability to discriminate the individuals who developed T2DM 
during the follow-up from those who did not. Pathologically elevated plasma 1-deoxySLs 
were originally reported in the context of the rare inherited sensory neuropathy HSAN1 
(hereditary sensory neuropathy type I) which is associated with several missense mutations in 
the SPT genes SPTLC1 and SPTLC2 [35-37]. These mutations induce a shift in the substrate 
specificity of the enzyme that leads to increased 1-deoxySL formation [37]. Further studies 
showed that 1-deoxySLs are neurotoxic and were found to accumulate preferentially in the 
peripheral nerves but not in the brain or other organs of transgenic HSAN1 animals [37, 38]. 
Moreover, it was shown that the formation of 1-deoxySLs can be efficiently suppressed in-
vitro and in-vivo by an oral supplementation with L-serine [38]. HSAN1 mice which received 
an L-serine-enriched diet did not develop neuropathic symptoms whereas a supplementation 
with alanine aggravated the neuropathic symptoms in these animals [38]. In a pilot study with 
HSAN1 patients, we demonstrated that an oral L-serine supplementation was also effective in 
lowering deoxy-SL levels in humans [38]. However, it is not fully understood why 1-
deoxySLs are also elevated in conditions of metabolic disorders such as MetS or T2DM, 
despite the absence of mutations in SPT. Interestingly, Elevated plasma 1-deoxySL levels 
were also found in plasma of pre-diabetic and diabetic monkeys where the animals were fed 
high fat and high fructose diet to induce obesity and T2DM [39]. This corroborates our 
findings that 1-deoxySLs are elevated early in the course of T2DM development. Since 1-
deoxySLs are cytotoxic in culture it cannot be excluded that they are also mechanistically 
involved in the development of insulin resistance, β-cell failure or other hallmarks of T2DM 
pathogenesis. The finding that 1-deoxySLs might be involved in the pathogenesis of HSAN1 
suggests that these lipids might also be involved in the pathogenesis of the diabetic sensory 
neuropathy (DSN) especially since both conditions have a very similar clinical picture. 
In addition, we investigated the associations of the plasma sphingoid base profile with 
atherosclerotic cardiovascular disease. We found that the plasma levels of C18SA, C18SO, and 
C18SAdiene were significantly lower in patients with coronary artery disease whereas plasma 
1-deoxySLs were not altered in these conditions. Interestingly, C20SO-based sphingolipids, 
albeit not significantly different between patients with and without CAD at baseline, emerged 
in multivariate analysis as independent predictors for the risk to develop cardiovascular 
events. This was still true after adjusting for the degree of coronary artery stenosis. The 
decrease in plasma C18SA C18SO, C18SAdiene in CAD patients appears , on the first glance, 
to be in contrast to earlier findings which reported increased plasma sphingomyelin (SM) 
levels in patients with coronary artery disease [16, 17]. However, other studies with the aim to 
 60 
 
evaluate plasma SM as a predictive risk marker for cardiovascular events, either in patients 
with stable angina or in the general adult population, did not show any significant predictive 
role [18, 19]. It is noteworthy that, our study focuses on the analysis of the total sphingoid 
base profile by LC-MS after a complete chemical hydrolysis of the extracted plasma 
sphingolipids. In contrast, sphingomyelin levels were analyzed by an enzymatic method [40] 
which is based on the release of phosphocholine after enzymatic hydrolysis. Since 
sphingomyelins are heterogeneous and not only composed of C18 sphingoid bases, the 
reported sphingomyelin levels represent the total sum of all sphingomyelins whereas our 
analysis reflects the sum of all sphingolipids with a specific sphingoid base composition, 
independently of the N-acyl chains and head groups. Although 
~
95% of the sphingolipids in 
plasma are sphingomyelins [41], only 60% of the total plasma sphingomyelins contain C18 
sphingosine backbone [41]. It is therefore conceivable that the distinct sphingoid base 
composition of sphingomyelin subspecies is not detected by the enzymatic assay.  
To our surprise, we found that C20-sphingosine was predictive for the risk to develop 
cardiovascular events although the cross sectional comparison at baseline showed no 
difference between CAD patients and controls. C20-sphingoid bases are minor constituents of 
plasma of plasma sphingolipids and reflect less than 1% of the total sphingoid bases in 
plasma. The presence of a C20SO backbone was first described in the brain gangliosides of 
rats and humans [42], in gangliosides of human stomach mucosa [43] and in sphingomyelin 
of rat liver [44]. They were shown to increase with aging in human and rat brains [42, 45]. 
Using imaging mass spectrometry, C20-based sphingolipids were shown to exist in distinct 
areas of the rat hippocampus depending on age [46]. It was also demonstrated that the feeding 
of radiolabeled palmitoyl-CoA did not yield any radiolabeled C20-based sphingolipids while 
feeding cells with radiolabeled stearoly-CoA yielded both C18-based and C20-based 
sphingolipids [47]. This indicates that the labeled stearoly-CoA is used directly as a substrate 
for SPT to form C20-based sphingolipids and it can also be metabolized to palmitoyl-CoA 
which acts as a precursor for C18-based sphingolipids. It is not fully understood how the 
substrate shift in SPT is regulated but it has been suggested that certain factors might play a 
role. In particular the SPT small subunit B (ssSPTb) has been shown to increase the 
condensation of stearoly-CoA when over-expressed with SPTLC1 and either the SPTLC2 or 
SPTLC3 subunits [11]. Moreover, It has also been shown that the presence of SPTLC3 
enables the SPT enzyme to metabolize distinct acyl-CoAs Interestingly, in two recent GWAS 
studies variants of the SPTLC3 gene were associated with an increased risk for myocardial 
infarction [49] and with differences in the plasma levels of several sphingomyelin species 
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[50]. This further supports our finding that C20-based sphingolipids are independent 
predictors for cardiovascular events 
With respect to the limitation of the current study, it is important to consider that the analyzed 
cohort might not faithfully represent the situation in the general population. The 
extrapolations of the risk predictions might be done only to clinical settings where the 
prevalence of cardiometabolic disease is high. Moreover, the number of events, especially for 
the development of T2DM, is not sufficient to adjust for all possible confounders without 
over-fitting. Thus, we cannot fully exclude the effect of other confounders. 
In summary, we have demonstrated that sphingolipids with different backbones show 
promising predictive roles in cardiovascular disease or T2DM independent of the traditional 
risk factors. However, ultimately larger and interventional studies are needed to confirm the 
potential of these markers in risk re-classification and the effect on patient management.  
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Supplementary information: 
Table S1. Heat map showing the Spearman correlation coefficients for the analyzed plasma sphingolipids bases and the clinical chemistry and anthropometric 
variables in the nested VIVIT cohort. Bold font signifies p < 0.05. The color code is shown with the lowest value of -1 (blue) and the highest value of 1(red)  
 
C16SO C16SA C17SO C18PhytoSO C18SAdiene C18SO C18SA C19SO C20SO C20SA 1-deoxySO 1-deoxySA 
Age 0.12 -0.03 0.23 0.09 0.11 0.10 -0.06 0.25 -0.05 -0.05 -0.14 -0.18 
BMI 0.06 0.16 -0.08 -0.03 0.02 -0.04 0.20 -0.07 0.09 0.18 0.30 0.26 
waist circum. -0.11 0.04 -0.25 -0.15 -0.12 -0.14 0.10 -0.20 0.03 0.10 0.33 0.26 
WHR -0.25 -0.08 -0.38 -0.20 -0.27 -0.20 -0.02 -0.27 0.00 0.02 0.27 0.16 
Cholesterol 0.42 0.36 0.40 0.42 0.54 0.57 0.38 0.19 0.22 0.20 0.19 0.25 
LDL-C 0.34 0.31 0.37 0.38 0.45 0.51 0.29 0.20 0.18 0.14 0.05 0.12 
HDL-C 0.38 0.06 0.39 0.30 0.44 0.33 0.07 0.16 -0.10 -0.09 -0.09 -0.03 
TG -0.08 0.14 -0.16 -0.02 -0.06 -0.07 0.14 -0.12 0.15 0.22 0.43 0.40 
Glucose -0.04 0.08 -0.15 -0.06 -0.17 -0.10 0.15 -0.08 0.16 0.26 0.34 0.25 
HbA1c 0.02 -0.02 -0.01 0.07 -0.03 0.02 0.09 -0.04 0.04 0.12 0.21 0.22 
Insulin 0.04 0.18 -0.06 -0.04 -0.07 -0.05 0.18 0.02 0.22 0.20 0.23 0.20 
HOMA 0.03 0.20 -0.09 -0.01 -0.10 -0.07 0.19 -0.02 0.23 0.26 0.30 0.26 
Systolic BP 0.05 0.07 0.04 0.07 0.04 0.01 0.07 0.00 0.05 0.13 0.02 0.07 
Diastolic BP 0.02 0.09 -0.03 0.02 -0.01 -0.05 0.06 -0.02 0.05 0.09 0.10 0.13 
CRP  -0.12 -0.04 -0.05 -0.02 -0.01 0.13 0.15 0.01 0.14 0.03 0.05 0.11 
K  -0.04 -0.06 -0.08 -0.01 0.02 0.03 0.01 -0.09 0.00 -0.03 0.16 0.15 
S. Creatinine  -0.11 -0.16 -0.10 -0.08 -0.16 -0.10 -0.19 -0.02 -0.04 -0.13 0.07 0.04 
GFR (Mayo) -0.11 0.09 -0.22 -0.05 -0.11 -0.06 0.12 -0.20 0.07 0.12 0.07 0.07 
             
      
Spearman rho 
     
      
-1 -0.5 
-0.25 0 0.25 0.5 1 
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Table S2. Univariate Cox hazard regression models for the development of total cardiovascular events. 
Continuous variables are log-transformed and standardized into units of standard deviation (SD). Thus hazard 
ratios are expressed for an increase of one unit SD. 
  
HR (95% CI)  
per 1 SD p 
Age  1.18(0.99-1.42) 0.080 
Sex (male) 2.09(1.36-3.19) 7.42E-04 
Hypertension  1.07(0.76-1.52) 0.715 
T2DM  1.29(0.9-1.86) 0.174 
History of smoking  1.58(1.09-2.29) 0.017 
 Coronary artery stenoses > 50%  2.78(1.83-4.23) 1.94E-06 
Extent of stenosis 1.26(1.15-1.38) 6.99E-07 
MetS ATP III Definition 1.29(0.91-1.83) 0.160 
DM drugs 1.29(0.9-1.86) 0.174 
Diuretics 1.16(0.81-1.66) 0.441 
HTN drugs 1.36(0.84-2.21) 0.225 
Lipid lowering drugs 1.33(0.93-1.88) 0.121 
BMI  0.9(0.75-1.08) 0.247 
Hip circumference  0.8(0.66-0.98) 0.027 
Waist circumference (cm)  1.08(0.9-1.29) 0.432 
Waist-to-Hip ratio  1.31(1.09-1.57) 0.005 
Cholesterol  0.8(0.67-0.96) 0.012 
LDL  0.83(0.69-1) 0.042 
HDL  0.75(0.62-0.91) 0.003 
Triglycerides  1.02(0.86-1.21) 0.868 
Glucose  1.17(1-1.37) 0.052 
HbA1c 1.26(1.08-1.47) 0.004 
 Insulin  1.11(0.96-1.28) 0.193 
HOMA-IR 1.1(0.93-1.3) 0.295 
Systolic BP 1.04(0.87-1.24) 0.694 
Diastolic BP 0.99(0.83-1.18) 0.897 
CRP  1.15(1.01-1.31) 0.047 
K 1.19(1-1.43) 0.060 
S.Creatinine 1.32(1.2-1.46) 9.23E-08 
GFR (Mayo) 0.75(0.63-0.89) 8.63E-04 
C16SO 0.9(0.75-1.08) 0.247 
C16SA 0.87(0.72-1.07) 0.168 
C17SO 0.85(0.71-1.02) 0.072 
C18PhytoSO 0.87(0.72-1.06) 0.143 
C18SAdiene 0.79(0.66-0.95) 0.011 
C18SO 0.96(0.81-1.15) 0.642 
C18SA 0.95(0.79-1.15) 0.593 
C19SO 1.02(0.86-1.21) 0.857 
C20SO 1.18(1.02-1.37) 0.028 
C20SA 0.98(0.82-1.18) 0.810 
1-deoxySO 1(0.84-1.18) 0.932 
1-deoxySA 0.95(0.79-1.14) 0.553 
 
 
 
 64 
 
Table S3. Baseline values of clinical, lab and sphingolipid levels in the incident T2DM group and the 
group which did not develop T2DM until the end of the study period (8 years). p values are calculated using 
the t-test on the log transformed variables. Variables in bold have a p <0.05. 
  
no incident T2DM (n= 
70) 
incident T2DM (n= 
35) p 
Age (years) 61.286 ± 9.133 64.486 ± 10.309 0.137 
Sex (Female) 26 (37.15%) 13 (37.15%) 1.000 
Hypertension (WHO) 28 (40%) 21 (60%) 0.053 
History of smoking (baseline) 37 (52.86%) 16 (45.72%) 0.490 
 Coronary artery stenoses > 50%  38 (54.29%) 23 (65.72%) 0.263 
MetS ATP III Definition 15 (21.43%) 17 (48.58%) 0.004 
BMI  26.419 ± 3.325 27.142 ± 5.129 0.642 
Waist circumference (cm)  92.492 ± 10.499 96.157 ± 13.184 0.187 
Waist-to-Hip Ratio  0.928 ± 0.087 0.953 ± 0.103 0.243 
Cholesterol (mmol/l) 5.649 ± 1.05 5.795 ± 1.299 0.677 
LDL (mmol/l) 3.476 ± 0.802 3.437 ± 0.891 0.695 
HDL (mmol/l) 1.305 ± 0.395 1.277 ± 0.4 0.682 
Triglycerides(mmol/l) 1.61 ± 0.93 2.2 ± 1.62 0.020 
Glucose (mmol/l) 5.752 ± 1.062 6.023 ± 1.198 0.241 
HbA1c (%) 5.723 ± 0.391 6.006 ± 0.547 0.004 
Insulin (µU/ml) 8.98 ± 4.605 15.826 ± 26.165 0.324 
HOMA-IR 2.281 ± 1.246 2.895 ± 2.203 0.537 
Systolic BP 131.595 ± 19.088 139.559 ± 20.501 0.053 
Diastolic BP 76.545 ± 10.971 79.853 ± 13.623 0.261 
CRP  0.698 ± 0.96 0.785 ± 1.486 0.792 
K 4.289 ± 0.395 4.462 ± 0.322 0.029 
S.Creatinine (mg/dl)  1.053 ± 0.149 1.231 ± 0.999 0.361 
GFR (Mayo) 89.486 ± 15.349 85.536 ± 22.558 0.257 
Diuretics 20 (28.58%) 14 (40%) 0.238 
Anti-hypertensive drugs 57 (81.43%) 34 (97.15%) 0.026 
Lipid lowering drugs 37 (52.86%) 16 (45.72%) 0.490 
C16SO (µmol/l) 15.272 ± 5.339 16.48 ± 8.635 0.875 
C16SA (µmol/l) 0.46 ± 0.186 0.531 ± 0.409 0.858 
C17SO (µmol/l) 7.96 ± 2.781 8.75 ± 3.753 0.382 
C18PhytoSO (µmol/l) 0.112 ± 0.036 0.134 ± 0.085 0.352 
C18SAdiene (µmol/l) 28.375 ± 7.547 30.828 ± 11.845 0.552 
C18SO (µmol/l) 93.077 ± 19.409 101.702 ± 31.292 0.163 
C18SA (µmol/l) 3.28 ± 1.121 3.682 ± 2.081 0.387 
C19SO (µmol/l) 2.796 ± 1.136 3.228 ± 1.544 0.220 
C20SO (µmol/l) 0.168 ± 0.052 0.192 ± 0.081 0.128 
C20SA (µmol/l) 0.024 ± 0.009 0.028 ± 0.017 0.365 
1-deoxySO (µmol/l) 0.14 ± 0.062 0.213 ± 0.167 9.16E-04 
1-deoxySA (µmol/l) 0.069 ± 0.032 0.098 ± 0.077 0.003 
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Table S4. Binary logistic regression model results for incident T2DM showing the odds ratios for the 
multivariate models including plasma 1-deoxySA as a predictor. 
Multivariate binary 
logistic regression 
models   
OR per 1 SD of log 
transformed variable p 
Model 1 
  
MetS 2.63 (1.05-6.57) 0.039 
1-deoxySA 1.77 (1.06-2.94) 0.029 
Model 2 
  
1-deoxySA 1.68 (0.97-2.88) 0.064 
TG 1.34 (0.8-2.27) 0.279 
Model 3 
  
1-deoxySA 1.87 (1.14-3.09) 0.015 
HbA1c 3.47 (1.26-9.53) 0.016 
Model 4 
  
1-deoxySA 1.74 (1.03-2.95) 0.040 
K 1.67 (0.98-2.84) 0.062 
Model 5 
  
  
1-deoxySA 1.66 (0.99-2.8) 0.058 
HbA1c 3.44 (1.23-9.64) 0.019 
MetS 2.59 (1.01-6.69) 0.050 
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Abstract: 
Background: 
1-Deoxysphingolipds (1-deoxySLs) are neurotoxic sphingolipids which are formed by the 
enzyme serine-palmitoyltransferase (SPT) due to the promiscuous use of L-alanine instead of 
its canonical substrate L-serine. Pathologically elevated 1-deoxySLs are associated with the 
rare hereditary sensory and autonomic neuropathy type 1 (HSANI) , which is caused by 
several missense mutations in the SPT. Plasma 1-deoxySLs are also elevated in patients with 
metabolic syndrome (MetS) or type 2 diabetes mellitus (T2DM). HSAN1 and the diabetic 
sensory neuropathy are clinically very similar and are characterized by a painful, progressive 
and length-dependent axonopathy which typically starts in the distal extremities. We have 
previously shown that the pathological 1-deoxySLs formation in HSAN1 is significantly 
suppressed in response to an oral L-serine supplementation. In this context, we investigated 
whether a serine supplementation is also beneficial for the treatment of the diabetic 
neuropathy in an experimental diabetic rat model. 
Methods: 
A streptozotocin (STZ)-induced diabetic rat model was used to investigate the effects of 
serine on the diabetic neuropathy. STZ was injected intra-peritoneally to induce pancreatic β 
cell failure and type 1 diabetes mellitus. Vehicle-injected rats were used as controls. The 
effect of serine was tested in preventive and therapeutic schemes. In the preventive approach, 
control (n= 8) and STZ rats (n= 10) had immediate access to either a standard or a serine-
enriched diet for 18 weeks after the STZ injection. In the therapeutic schedule, animals were 
fed a standard diet for the first 8 weeks after STZ injection and were then randomized into 
either a control group receiving a standard diet (n= 8) or a treatment group receiving a serine 
enriched diet (n= 10). Plasma and tissue sphingolipids were quantified using LC/MS after 
lipid extraction and acid hydrolysis. Thermal, mechanical nociception and nerve conduction 
velocity (NCV) were measured.  
Results: 
In both treatment schemes (therapeutic and preventive), plasma 1-deoxySLs were 
significantly lowered in the serine-supplemented diabetic animals (p < 0.0001). Serine had no 
significant effect on hyperglycemia, body weight and food intake. Neurologically, the serine 
supplemented animals showed significantly improved mechanical sensitivity in both, the 
preventive (p < 0.01) and therapeutic groups (p < 0.001). NCV was significantly better in the 
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preventive but not in the therapeutic group (30.3 m/sec ± 2.2 (serine diet) vs 23.8 m/sec ± 1.0 
(standard diet), p < 0.05).  NCV showed a highly significant inverse correlation with plasma 
1-deoxySL levels (p = 5.2E-12). 
Conclusion: 
Oral serine supplementation effectively lowered the plasma 1-deoxySLs in diabetic STZ rats 
and significantly improved the mechanical sensitivity and nerve conduction velocity in these 
animals. This suggests that oral serine supplementation could be a potential therapeutic 
strategy in diabetic neuropathy.  
 
Abbreviations:  
1-deoxySA  1-deoxysphinganine 
1-deoxySO  1-deoxysphingosine 
1-deoxySLs 1-deoxysphingolipids 
C16-19  Carbon chain length (16 carbons -19 carbons) 
DRG  Dorsal root ganglia 
HSAN1 Hereditary sensory and autonomic neuropathy type I 
MetS  Metabolic syndrome 
NCV  Nerve conduction velocity 
SA  Sphinganine  
SO            Sphingosine  
SPT  Serine palmitoyltransferase 
STZ   Streptozotocin 
T2DM  Type 2 diabetes mellitus 
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Introduction: 
Diabetic neuropathy is the most common complication of type 1 and type 2 diabetes mellitus 
affecting up to 50 % of these patients [1, 2]. It affects single or multiple nerves 
(mononeuropathy or polyneuropathy) with sensory, motor or autonomic involvement, leading 
to a wide variety of clinical presentations. Distal symmetrical polyneuropathy (DSN) is the 
most common presentation of diabetic neuropathy [3]. It usually starts in the lower 
extremities with either negative (e.g. numbness) or positive symptoms (e.g. neuropathic pain) 
or both at the same time. Symptoms are mainly sensory and symmetrical on both sides with a 
“stocking and gloves” distribution. This is frequently associated with bad wound healing and 
ulcers (diabetic foot), which may require amputations and results in a significant reduction in 
the quality of life [4].  
DSN is caused by an axonopathy of both, myelinated and non-myelinated fibers due to micro-
angiopathy or direct nerve injury. Injuries to the endothelium of the micro-vessels lead to a 
decreased O2 supply to the nerve [5] which is a documented feature of the diabetic 
neuropathy.  However, it is not clear whether the ischemia itself or an associated pathology 
causes the neuropathy since it was shown that the blood flow in sciatic nerves of diabetic rats 
was not altered compared to healthy animals [6]. On the contrary, the number of micro-
vessels in the peripheral nerves of diabetic rats was shown to be increased [7] in the early 
stages of diabetic neuropathy.  
In addition to the micro-angiopathy, direct nerve injury and injury of the nerve supporting 
cells (e.g. Schwan cells in the PNS or satellite cells in the DRGs) are established pathologies 
associated with DSN. In that context, several pathogenic mechanisms for the direct nerve 
injury have been proposed. Hyperglycemia is considered as an essential contributor in the 
pathogenesis of diabetic polyneuropathy (DPN). Excess glucose can be converted to sorbitol 
leading to osmotic and oxidative stress [8]. Glucose can also be shunted to the hexosamine 
pathway leading to modification of transcription factors and an inflammatory response [9]. 
Moreover, the increased flux of glucose through the glycolytic chain and TCA cycle leads to 
oxidative stress by overloading the respiratory capacity of mitochondria [10]. Long term and 
persistent hyperglycemia leads also to non-enzymatic modifications of proteins and the 
formation of the pro-inflammatory advanced glycation end products (AGEs) [11]. All these 
factors are believed to participate in the pathogenesis of DSN to a variable extent.  
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Although hyperglycemia plays a vital role in the pathogenesis of DSN, the tight control of 
plasma glucose levels is not sufficient to prevent or reverse diabetic peripheral neuropathy. 
Intensive glycemic control in T1DM patients delayed the onset and the progression of diabetic 
neuropathy only in 60% of the patients [12].  These findings were replicated in different 
cohorts with different follow-up periods [3]. Thus, a significant proportion of T1DM patients 
still developed neurological symptoms despite intensive glycemic control. Moreover, in 
T2DM, intensive glycemic control failed to show a robust effect in delaying the progression 
of diabetic neuropathy [13, 14]. This suggests that other factors, apart from the 
hyperglycemia, are underlying the pathogenesis of the diabetic neuropathy. Dyslipidemia, in 
particular hypertriglyceridemia, might be one of these additional factors. In the European 
Diabetes Prospective Complications Study (EURODIAB), hypertriglyceridemia was 
identified as an independent predictor for the development of diabetic neuropathy in T1DM 
even after adjusting for the duration of diabetes and HbA1c [15]. Interestingly, in T1DM 
dyslipidemia develops usually after a period of sustained or uncontrolled hyperglycemia [16] 
which coincides with the course of the neuropathy in T1DM patients [17]. In T2DM patients, 
dyslipidemia appears early and might even precede the onset of hyperglycemia. Furthermore, 
hypertriglyceridemia has been shown to correlate with the progression of diabetic neuropathy 
independent of the diabetes control which further supports the view that dyslipidemia plays an 
independent role in diabetic neuropathy [18]. Pre-diabetes and metabolic syndrome, where 
dyslipidemia is more prevalent, might also contribute to the risk and pathogenesis of the 
diabetic neuropathy[19].  
Besides triglyceride, other lipid classes might also be involved in the pathogenesis of diabetes 
and its sequelae. Sphingolipids have been identified over the last years as emerging players in 
insulin resistance and T2DM [20]. Sphingolipids constitute a heterogeneous class of lipids 
and are essential components of the plasma membrane and plasma lipoproteins. Sphingolipid 
de-novo synthesis starts in the ER with the condensation of palmitoyl-CoA and serine – a 
reaction catalyzed by the enzyme serine palmitoyltransferase (SPT). The product 3- 
ketosphinganine is rapidly reduced to sphinganine (C18SA). C18SA can be further metabolized 
to ceramides which are the building blocks for complex sphingolipids such as sphingomyelin 
and glycosphingolipids. Upon degradation, complex sphingolipids are hydrolyzed to 
ceramides which, in turn, are degraded to sphingosine (C18SO). Apart from these two 
canonical substrates, SPT can also utilize other acyl-CoAs in the range of C12-C18 and other 
amino acids such as alanine or glycine thereby generating a diverse class of atypical 
sphingoid bases. SPT is a multimeric enzyme which is composed of three subunits SPTLC1, 
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SPTLC2 and SPTLC3 [21, 22]. Several missense mutations in the SPTLC1 and SPTLC2 
genes [23]  are associated with the rare and inherited sensory neuropathy HSAN1 (hereditary 
sensory and autonomic neuropathy type I) [24-26]. HSAN1 presents as a painful, length-
dependent axonal neuropathy and shows very similar symptoms to the diabetic sensory 
neuropathy. Typical symptoms include loss of sensation, parasthesia, tactile allodynia and 
painless ulcers and starts usually in feet and hands and progresses proximally over time. The 
HSAN1-causing mutations in the SPT lead to increased activity with alanine and glycine 
which results in the formation of an atypical class of 1-deoxySLs that lack the C1 hydroxyl 
group of the serine-based sphingoid bases. Consequently, 1-deoxySLs are not metabolized to 
complex sphingolipids nor degraded by the canonical pathway which requires the formation 
of sphingosine-1-phosphate as a catabolic intermediate. 1-deoxySL levels are significantly 
elevated in the plasma of HSAN1 patients and plasma and nerves of a transgenic HSAN1 
mouse model [25, 27]. 1-deoxySLs were shown to be neurotoxic and to reduce the number 
and length of neurites in vitro [25, 27]. Interestingly, elevated 1-deoxySLs were also found in 
patients with the metabolic syndrome and T2DM, despite the absence of mutations in the SPT 
[28, 29]. Elevated 1-deoxySL levels were also observed in the plasma and liver of STZ rats 
[29]. In analogy to HSAN1, these elevated 1-deoxySL levels in T2DM might also be involved 
in the pathogenesis of the diabetic sensory neuropathy. We previously showed that an oral 
supplementation with L-serine results in a significant reduction of the 1-deoxySLs in HSAN1 
mouse models and HSAN1 patients [27]. Serine-supplemented HSAN1 mice were protected 
and did not develop any neuropathic manifestations [27]. On the basis of these findings, we 
were interested to test whether a serine supplementation is also effective in lowering plasma 
1-deoxySL in the diabetic context in an experimental animal model for diabetic neuropathy 
and whether such a treatment also results in improved neuropathy in these animals. 
Methods: 
Animal experiments: 
Male Sprague-Dawley rats (180-200 g, Charles River, Calco, Italy) were used for the current 
study. The animals had access to food and water ad libitum. Diabetes was induced in 
overnight-fasted rats by a single intra-peritoneal injection of 60 mg/kg streptozotocin (STZ) 
(Sigma, St. Louis, MO) dissolved in sodium citrate buffer (pH 4.5). Control rats were injected 
with sodium citrate buffer (pH 4.5) only. Hyperglycemia was confirmed by measuring 
glycosuria 48 h after STZ injection (Keto-Diabur test, Roche Diagnostics, Spa, Italy). Blood 
glucose was determined after tail bleeding using the Ascensia Elite assay (Bayer, Basel, 
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Switzerland). Food and water intake were assessed at the specified time points by averaging 
over 2-days period. At the end of the study, animals were sacrificed, the tissues were 
dissected and immediately frozen in liquid N2. 
Experimental design: 
In this study, two experimental designs were employed (Fig1.). In the preventive schedule, the 
animals had immediate access to either a serine-enriched diet (containing 10% L- serine for 
the control group and 5% serine for the STZ group) or a standard diet (Mucedola s.r.l, Milan, 
Italy) immediately after the STZ injection. In the therapeutic schedule, animals remained on a 
standard diet for 8 weeks after STZ injection and were then randomized into groups receiving 
either a serine-enriched (10% for the control group or 5% for the STZ group) or a standard 
diet. The serine content in the food for the STZ animals was half since it is known that the 
STZ rats consume double the amount of food compared to the control animals. 
 
 
Figure 1. Schematic diagam showing the flow chart of the exmperiment. Animals were injected 
either STZ 60mg/kg i.p or vehicle at day 0. In the preventive schedule,  at day 0 , a serine-enriched or 
a standard diet was introduced then the animals were followed for 18 weeks post-STZ injection untill 
they were sacrificied. In the therapuetic scheudle, animals were fed a standrad diet for 8 weeks then 
they were randomized into either a serine-enriched diet  or a standard diet groups where they were 
followed until the end of the study period at week 24 post-STZ. 
Behavioural tests and electrophysiology: 
Thermal and mechanical nociception were assessed as behavioral measures for the diabetic 
neuropathy. The nociceptive threshold to radiant heat was quantified using the hot-plate paw 
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withdrawal test [30]. In brief, a 40-cm-high Plexiglas cylinder was suspended over the hot 
plate, and the temperature was maintained at 50°C to give a latency period of approximately 
10 s for control rats. Withdrawal latency was defined as the time between placing the rat on 
the hot plate and the time of withdrawal and licking the hind paw (or manifesting discomfort). 
Mechanical allodynia on the plantar surface of the rat was assessed by a dynamic paw 
withdrawal test with a Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, Italy), which 
generates a linearly increasing mechanical force. The paw withdrawal reflex was recorded 
automatically by measuring the latency until withdrawal in response to the applied force.  
Nerve Conduction Velocity, NCV, was measured as described previously [30]. In brief, the 
anti-dromic sensory NCV in the tail nerve was assessed by placing recording ring electrodes 
distally in the tail. Stimulating ring electrodes were placed 5 and 10 cm proximally from the 
recording point. The latencies of the potentials, recorded at the two sites after nerve 
stimulation, were determined (peak to peak), and NCV was calculated. All of the 
neurophysiological determinations were performed under standard conditions and at a 
controlled temperature (room and animals). Core temperature was maintained at 37°C by 
using heating pads and lamps. 
Sphingolipid analysis:  
The lipids were analysed as described before [29] with some modifications. Briefly, 100µ l 
plasma or 80 ug proteins from the tissue homogenate was added to 0.5 ml of methanol and 
spiked with 200 pmol of the internal standards d7-sphingosine and d7-sphinganine (d7SA, 
d7SO; Avanti Polar Lipids, Alabaster, Alabama, USA). Tissues were homogenized in 
Precellys® homogenization tubes in (PBS pH =7.4 with 0.2% Triton X-100 (vol/vol)) using a 
Precellys 24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). The 
mix was then incubated in thermo-mixer at 37oC for one hour. Precipitated proteins were 
pelleted by centrifugation and the supernatant transferred to a new tube. For lipid hydrolysis, 
75µl of methanolic HCl (1 N HCl and 10 M H2O in methanol) was added to the supernatant 
and incubated for 16 hours at 65oC. This was followed by the addition of 100 µl of 10M KOH 
to neutralize the HCl and hydrolyze the phospholipids. To this mix, 625µl chloroform was 
added. Then, 100 µl 2N ammonium hydroxide and 0.5 ml alkaline water were added to 
complete the phase separation. The mix was then vortexed and centrifuged at 16000g for 5 
minutes. After centrifugation, the upper phase was discarded and the lower organic phase was 
washed two to three times with alkaline water. Finally, the organic phase was dried under N2 
and kept at -20 oC freezer until analysis. 
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The sphingoid bases were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, 
Interchim, Montluçon, France) and analysed on a TSQ Quantum Ultra mass spec (Thermo, 
Reinach, BL, Switzerland). Each sample was measured as a singleton. Intra- and Inter-assay 
coefficient of variation (CV %) of the method was between 5% and 20%.  
In this study 9 different sphingoid base backbones were analysed. The plasma and tissue 
levels of C16SO, C17SO, C18SO, C18SA, C18SAdiene, C18PhytoSO, C20SO, C20SA, and 1-
deoxySA sphingoid bases were quantified. 
 
Statistical analysis: 
Data are shown as mean ± SEM. For normally distributed variables, one way ANOVA is 
performed followed by the Bonferroni correction for the multiple comparisons. In the 
Bonferroni correction, only four comparisons were considered, control on standard diet vs. 
control on serine diet; control on standard diet vs. streptozotocin on standard diet, control on 
serine diet vs. streptozotocin on serine diet and streptozotocin on standard diet vs. 
streptozotocin on serine diet. Variables which were not normally distributed were log-
transformed. The statistical analysis was done in SPSS 16.0 (IBM, Zurich, Switzerland) and 
GraphPad Prism 5.04 (GraphPad Software, Inc., San Diego, CA). 
 
Results: 
Serine-enriched diet does not affect the body weight, hyperglycemia or food intake in STZ rats. 
STZ-treated animals developed hyperglycemia (Fig. 2C-D, 3B) within 48 hours post-
injection. Hyperglycemia (400 mg/dl - 800 mg/dl or 22.2 mmol/l - 44.4 mmol/l) persisted in 
the STZ group until the end of the study (preventive 18 weeks; therapeutic 24 weeks). Serine 
supplementation did not affect the hyperglycemia. In contrast to controls and despite of an 
increased food and water intake, the STZ group failed to gain body weight (Fig. 2A-B, 3A). 
Serine supplementation had no influence on body weight, food or water consumption in the 
STZ and control groups (Fig. 2 E-H, 3C-D). 
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Figure 2. Time course of general phenotype characteristics. Line plots showing the body weight 
(A-B), blood glucose (C-D), food (E-F) and water intake (G-H) of the animal used in the study. The 
plots show the values over the entire period of the preventive (Left) and therapeutic (right) schedules 
for the different groups. The values are expressed as mean ± SEM.  CTRL_Std, control on standard 
diet, CTRL_Ser, control on serine diet, STZ _Std STZ on standard diet, STZ_Ser STZ on serine diet.   
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Fig 3. Phenotype characteristics at the last time point before sacrifice.. Scatter plots show the 
values of the body weight (A), blood glucose (B), food (C) and water intake (D) at week 16 post-STZ 
injection for the preventive group and week 24 post-STZ injection for the therapeutic group. The 
values are expressed as mean ± SEM.  p values are calculated using ANOVA followed by the 
Bonferroni correction comparing CTRL_Std to CTRL_Ser, CTRL_Std to STZ_Std, CTRL_Ser to 
STZ _Ser and STZ_Std to STZ_Ser.  CTRL_Std, control on standard diet, CTRL_Ser, control on 
serine diet, STZ _Std STZ on standard diet, STZ_Ser STZ on serine diet. 
 
Serine enriched diet lowers 1-deoxysphingolipids in the plasma of STZ rats without 
affecting the other typical and atypical sphingolipids 
Sphingoid bases in plasma are usually conjugated to a variety of fatty acids and different head 
groups. In the current analysis, we were primarily interested in the sphingoid base profile as a 
measure of the heterogeneous SPT activities. Therefore, the N-acyl chains and the head 
groups of the extracted plasma sphingolipids were removed by acid hydrolysis and the free 
sphingoid bases were analysed by LC-MS. The herein reported sphingoid base concentrations 
are therefore a measure for the total concentrations of sphingolipids which are formed on this 
specific sphingoid base backbone. 
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Figure 4. Time course of plasma levels of typical sphingolipids. Line plots show the plasma levels 
of C18SO (A-B), C18SA (C-D), C18PhytoSO-based sphingolipids (E-F) and C18SAdiene (G-H) over the 
entire period of the preventive (Left) and therapeutic (right) schedules for the different groups. The 
values are expressed as mean ± SEM. CTRL_Std, control on standard diet, CTRL_Ser, control on 
serine diet, STZ _Std STZ on standard diet, STZ_Ser STZ on serine diet 
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Figure 5. Plasma levels of typical sphingolipids at the last time point before sacrifice. Scatter plots 
show the values for C18SO (A), C18SA (B), C18PhytoSO (C) and C18SAdiene (D) at week 17 post-STZ 
for the preventive group and week 24 post-STZ for the therapeutic groups. The values are expressed as 
mean ± SEM. p values are calculated using ANOVA followed by the Bonferroni correction comparing 
CTRL_Std to CTRL_Ser, CTRL_Std to STZ_Std, CTRL_Ser to STZ _Ser and STZ_Std to STZ_Ser. 
CTRL_Std, control on standard diet, CTRL_Ser, control on serine diet, STZ _Std STZ on standard 
diet, STZ_Ser STZ on serine diet 
Sphingolipids containing a C18SO backbone were the dominant forms in plasma but were not 
significantly different among the groups (Fig. 4A-B, 5A). C18SA increased initially in the 
serine-supplemented STZ animals, reaching a maximum after 3-4 weeks and then decreased 
again, although the levels remained slightly elevated until the end of the study (Fig.4 C-D, 
5B). C18-SAdiene and C18PhytoSO (Fig. 4E-H, 5C-D) were significantly elevated in all 
diabetic groups but did not change upon serine supplementation. 
Plasma 1-deoxySA was significantly elevated in the STZ rats on standard diet but remained 
low in the serine supplemented STZ rats. In the preventive schedule, the plasma 1-deoxySA 
was significantly higher in the STZ animals on standard diet (p < 0.0001) compared to the 
other groups (Fig. 6A-B, 7E). 1-deoxySA increased from 0.03 µmol/l ± 0.003 at the beginning 
of the study to reach 0.05 µmol/l ± 0.007 before sacrifice in the STZ rats on standard diet (Fig 
6A, 7E) whereas the levels remained low in the serine-fed STZ rats until the end of the 
preventive scheme (0.016 µmol/l ± 0.001 at week 17 post-STZ injection).  
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Figure 6. Time course plasma levels of atypical sphingolipids. Line plots show plasma levels of 1-
deoxySA (A-B).C16SO (C-D), C17SO (E-F), C20SO (G-H), C20SA-based sphingolipids (I-J) over the 
entire period of the preventive (Left) and therapeutic (right) schedules for the different groups. The 
values are expressed as mean ± SEM. CTRL_Std, control on standard diet, CTRL_Ser, control on 
serine diet, STZ _Std STZ on standard diet, STZ_Ser STZ on serine diet 
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For the therapeutic scheme, we observed a rapid decrease of 1-deoxySA to the control levels 
after switching to the serine-enriched diet in week 8 whereas 1-deoxSA levels remained high 
in the diabetic rats on standard diet (Fig. 6B). This effect remained significant until the end of 
the therapeutic protocol (Fig. 6E). No significant difference was observed between the control 
rats with and without serine supplementation.  
C16SO (Fig. 6 C-D, 7A) was not significantly different among the groups at the beginning but 
was significantly lower in the STZ groups compared to vehicle controls in both schemes at the 
end of the study. C17SO, C20SO and C20SA did not change among all groups (Fig .6C-J, 7B-
D).  
Figure 7. Plasma levels of atypical 
sphingolipids at the last time point before 
sacrifice. Scatter plots show the values for 1-
deoxySA (E), C16SO (A), C17SO (B), C20SO 
(C), C20SA (D) at week 17 post-STZ for the 
preventive group and week 24 post STZ for the 
therapeutic groups. The values are expressed as 
mean ± SEM.  p values are calculated using 
ANOVA followed by the Bonferroni correction 
comparing the groups as before. CTRL_Std, 
control on standard diet, CTRL_Ser, control on 
serine diet, STZ _Std STZ on standard diet, 
STZ_Ser STZ on serine diet 
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In contrast to the plasma, 1-deoxySLs were not detected in the nervous tissues including 
sciatic nerve, spinal cord, dorsal root ganglia, neither of control nor of diabetic animals (Fig. 
8). Comparing the sphingoid bases distribution within these tissues revealed that the sciatic 
nerve and dorsal root ganglia had a similar sphingoid base distribution. In contrast, the 
proportion of C18SA and C17SO was higher while the proportion of C18SAdiene was lower in 
the neuronal tissue compared to the plasma  
 
Figure 8. Sphingolipid distribution by backbone in the plasma, sciatic nerve, dorsal root ganglia 
(DRGs) and spinal cord. The total sphingolipid content is set to 100% and the relative ratio of each 
sphingoid base backbone is shown. . CTRL, control animals, STZ, streptozotocin animals, Std 
standard diet, Ser, serine diet, Prev, preventive scheme, Ther, therapeutic scheme.  
 
Serine-enriched diet improves the diabetic neuropathy phenotype in STZ rats 
Although the STZ groups showed by trend an increased thermal response latency (Fig. 9A-B), 
the average thermal sensitivity at the end of the study was not significantly different between 
the STZ and vehicle treated animals on standard diet (Fig .10A) Therefore, the effect of serine 
supplementation on thermal sensitivity could not be assessed. 
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Figure 9. Time course of thermal and mechanical nociception. Thermal response latency (A-B) and 
force withdrawal threshold (C-D) were assessed for the preventive and the therapeutic groups at the 
beginning of the study and over time till the end the study.  The values are expressed as mean ± SEM. 
Black arrows refer to the time of introduction of the serine-enriched diet to the respective groups in the 
therapeutic schedule. CTRL_Std, control on standard diet, CTRL_Ser, control on serine diet, STZ 
_Std STZ on standard diet, STZ_Ser STZ on serine diet 
 
In contrast, mechanical nociception was significantly impaired in the STZ groups (Fig. 9C-D, 
10B). STZ rats on standard diet showed a significantly decreased withdrawal threshold (Fig 9 
C-D) whereas serine-supplementation resulted in a significantly improved mechanical 
sensitivity in both, the preventive and the therapeutic schemes. In the preventive scheme, the 
force withdrawal threshold did not decrease in the serine treated STZ animals (103.2 g ±11.6 
at week 14) while the STZ rats on standard diet showed a continuous decrease until the end of 
the study ( 54.6 g ± 5.0 at week 14). At the end of the preventive protocol, a significantly 
improved mechanical sensitivity was observed for the serine-treated STZ rats versus those on 
standard diet (p < 0.01). No difference was seen in the control animals. Similar results were 
obtained in the therapeutic scheme, mechanical sensitivity was not significantly different 
between the STZ groups before starting the serine supplementation in week 8 (74.5 g ± 6.6 in 
the STZ group on a standard diet and 73.4 g ± 8.4 in the STZ group on a serine-enriched diet). 
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Serine supplementation led to an improved mechanical sensitivity and the differences became 
significant at week 23 prior to sacrifice (52.0 g ± 5.4 on standard diet and 101.8g ± 13.0 on 
serine-enriched diet, p < 0.001) (Fig. 10B). 
 
 
 
 
 
 
Figure 10. Neurobehavioral tests 
and nerve conduction velocity at 
the last time point before sacrifice. 
Thermal response latency (A) force 
withdrawal threshold (B) and sensory 
nerve conduction velocity (C) are 
shown for the preventive and the 
therapeutic groups at week 14 post-
STZ injection for the preventive 
group and week 23 post-STZ 
injection for the therapeutic groups. 
The values are expressed as mean ± 
SEM. p values are calculated using 
ANOVA followed by the Bonferroni 
correction as mentioned earlier. For 
the force withdrawal threshold, the 
values were log-transformed before 
the calculation of the p values. 
CTRL_Std, control on standard diet, 
CTRL_Ser, control on serine diet, 
STZ _Std STZ on standard diet, 
STZ_Ser STZ on serine diet  
 
 87 
 
Nerve conduction velocity (NCV) decreased significantly in the STZ groups on a standard 
diet compared to the controls (Fig. 10C) ( p < 0.0001 comparing the STZ on standard diet to 
the control  in the preventive schedule  and p < 0.001  comparing the same groups in the 
therapeutic schedule).  
 
 
Figure 11.  Scatter plot showing the correlation between the nerve conduction velocity (NCV) 
and plasma 1-deoxySA levels. The values from the different animal groups are used to investigate the 
correlation between plasma 1-deoxySA levels. The variables were log transformed since the control 
groups were skewing the normal distribution to the right. Pearson correlation coefficient and the 
asymptomatic p value are shown 
 
STZ rats on the serine-enriched diet showed a significant improvement in the NCV for the 
preventive scheme (30.3 m/sec ± 2.2 in the STZ on a serine-enriched diet vs.23.8 m/sec ± 1.0 
for the STZ on a standard diet, p < 0.05). No significant improvement in the NCV was 
observed in the serine-treated animals in the therapeutic schedule (Fig. 10C). Interestingly, 
plasma 1-deoxySA levels correlated inversely with the NCV values (r = 0.62, p = 5.23 *10-12) 
(Fig. 11). 
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Discussion: 
The inherited neuropathy HSAN1 is associated with several mutations in SPT [23, 25] which 
lead to increased 1-deoxySL formation in the plasma and tissues of the affected carriers [27]. 
Elevated plasma 1-deoxySLs were also found in individuals with metabolic syndrome [31] 
and T2DM [28] despite the absence of mutations in the SPT. We demonstrated earlier that an 
oral L-serine supplementation effectively lowers 1-deoxySL levels in HSAN1 animal models 
and human patients. Serine-supplemented HSAN1 mice were protected and did not develop 
any neuropathic symptoms [27]. 
Here, we report that a serine supplementation is also effective in reducing the plasma 1-
deoxySL levels and improves the neuropathy in diabetic STZ rats independent of changes in 
the plasma glucose levels. This was tested in preventive and therapeutic schemes. 1-deoxySLs 
were shown to be neurotoxic in vitro, impairing the length, number and branching of neurites 
in cultured dorsal root ganglia (DRGs) without directly affecting the viability of the neurons 
[25]. In addition, 1-deoxySLs inhibited neurite growth and induced cytotoxicity in primary 
dopaminergic neurons from rat ventral mesencephalon [32]. In both , the preventive and 
therapeutic schemes, we observed a significant reduction of the 1-deoxySL plasma levels 
upon serine supplementation which was associated with improved mechanical sensitivity, 
better NCV and increased neuronal Na/K activity (data no shown).. This suggests that the 
serine-mediated lowering of plasma deoxySLs might be connected to the improved nerve 
function in the serine-treated animals. Serine supplementation was reported earlier to improve 
neuronal differentiation and survival of embryonic chicken DRGs in-vitro [33] although the 
underlying mechanism was not clear. It was demonstrated that this effect was due to the 
serine itself and not mediated by a serine-to-glycine conversion and the activation of the 
glycine receptor [33] while other amino acids did not show this effect. It is noteworthy that 
neurons cannot synthesize L-serine due to the lack of 3-phosphgylcerate dehydrogenase 
(PHGDH), the rate limiting enzyme for serine biosynthesis. Neuronal cells depend, therefore, 
on the supply of serine from the supporting cells (e.g. glia and satellite cells). Astrocytes were 
shown to release L-serine which acts as a neurotrophic factor for fetal rat hippocampal 
neurons [34] and cerebellar Purkinje neurons [35], thereby promoting survival and phenotypic 
maturation.  Interestingly, intra-peritoneal administration of L-serine was also shown to 
improve the paclitaxel induced peripheral neuropathy in a rat model [36].  
Although 1-deoxSLs were elevated in the plasma of the diabetic rats, we did not detect 1-
deoxySLs in the DRGs, sciatic nerve or spinal cord of the rats. This is in contrast to the results 
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from HSAN1 mice where 1-deoxySL showed a significant accumulation within the sciatic 
nerves [27, 37]. Although it is feasible that the total concentration of the 1-deoxySLs in the 
neuronal tissues of the STZ rats is below the detection limit of our method, it indicates that 
the neurotoxic effects are probably not caused by a toxic accumulation of these lipids within 
the nerve. A potential alternative explanation could be that 1-deoxySLs exert their neurotoxic 
effect by interfering with cellular signaling events. It has been reported that 1-deoxySA could 
bind and activate endothelial differentiation gene (EDG) receptors in cell culture [38, 39]. The 
EDG receptor family consists of several G protein coupled receptors that regulate various 
neuronal functions [40]. Another possible mechanism might be a 1-deoxySL- mediated 
modulation of protein kinase C (PKC) activity, since free sphingoid bases were shown to 
affect the PKC activity in vitro [41-43]. Interestingly, PKC is shown to be involved in the 
pathogenesis of diabetic microvascular complications including diabetic neuropathy [44] 
There is also increasing evidence from gene expression arrays and cell culture studies 
suggesting that 1-deoxySL interfere with the Rho-Rac signaling cascade which might impair 
neuronal cytoskeleton dynamics and growth cone formation [45] (data not shown). 
For the moment, we cannot exclude that the observed beneficial effects of serine are mediated 
by other neurotropic mechanisms. Moreover, it is not clear yet whether the elevated plasma 1-
deoxySLs in T2DM are causally involved in the pathogenesis of the diabetic neuropathy or 
simply indicators of the metabolic derailments in diabetes. Further mechanistic studies are, 
therefore, necessary to dissect the interplay between 1-deoxySLs formation and the protective 
effect of serine in the context of the diabetic neuropathy.  
However, independent of the underlying mechanism we demonstrated that an oral serine 
supplementation could be an effective novel therapeutic approach in the treatment of diabetic 
neuropathy.  
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Abstract: 
Background: 
Sphingolipid de-novo synthesis is typically initiated by the enzymatic condensation of 
palmitoyl-CoA and serine in a reaction catalyzed by the serine palmitoyltransferase (SPT). 
SPT can metabolize, in addition to these canonical substrates, other acyl-CoAs (C12- C18) and 
other amino acids such as alanine and glycine. This gives rise to a great variety of atypical 
sphingoid bases. In particular, the conjugation of alanine with palmitoyl CoA generates a 
novel class of 1-deoxyphingolipids (1-deoxySL) which lack the C1 hydroxyl group. 
Pathologically elevated 1-dexySLs are associated with HSAN1 – a rare inherited neuropathy 
caused by several missense mutations in SPT. We demonstrated previously that the 1-
deoxySLs are also significantly elevated in individuals with metabolic syndrome and type 2 
diabetes mellitus As 1-deoxySLs show a strong correlation with plasma triglycerides (TG), 
we were interested to investigate the effect of the two triglyceride-lowering drugs, fenofibrate 
and niacin, on the sphingoid base profile in dyslipidemic patients. 
Methods: 
56 patients with primary hypercholesterolemia or mixed dyslipidemia were enrolled in a 
multi-center, open label, cross-over study to compare the effects of niacin and fenofibrate on 
the plasma sphingolipid profile.  After an initial 2-to-6-week wash-out period, patients were 
randomized to either fenofibrate 160 mg/d for 6 weeks or niacin 0.5 g/d for 3 weeks followed 
by 1 g/d for 3 weeks. This treatment period was followed by a 4-week wash-out period and 
the same treatment scheme was repeated with crossed over groups. Plasma samples were 
taken before and at the end of each treatment/washout period and sphingoid base profile was 
quantified using LC/MS. 
Results: 
Fenofibrate and niacin had similar effects on lipoproteins and apolipoproteins apart from 
ApoAII.  Both treatments increased HDL-C (+14.25 % and +10.92%, respectively) and apoAI 
(+7.7% and +5.82 %, respectively). The effect on increasing ApoAII was significantly higher 
for fenofibrate than for niacin (+ 27.95% for fenofibrate vs. 0.5% for niacin, p < 0.001). 
Fenofibrate lowered LDL-C (-15.99% vs. -6.9%), total cholesterol (-13.7% vs. -3.98%), 
ApoB (-18.4% vs, -7.11%) and triglycerides (-33.4% vs. -11.98%) compared to niacin. 
Besides these effects on the lipoprotein profile we observed a significant lowering of all 
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atypical sphingoid base species (p < 0.001). Fenofibrate treatment lowered 1-deoxySLs (-39.6 
% for 1-deoxySO and -26.4% for 1-deoxySA), C20-based sphingolipids (-28.0% for C20SO 
and -24.6% for C20SA), C19SO (-24.4%), and the shorter chain backbone sphingolipids (-12.4 
% for C17SO, -11.6% for C16SO). This effect was not observed with niacin. Interestingly, 
neither fenofibrate nor niacin showed any significant effect on the typical sphingolipids (C18-
based sphingolipids) 
Conclusions: 
Both, fenofibrate and niacin were effective in improving the lipoprotein profile in plasma of 
dyslipidemic patients. However, only fenofibrate but not niacin was also effective in lowering 
atypical plasma sphingolipids in dyslipidemic patients. None of the compounds did affect the 
typical C18-based sphingolipids. 
 
Abbreviations:  
1-deoxySA  1-deoxysphinganine 
1-deoxySO  1-deoxysphingosine 
1-deoxySLs 1-deoxysphingolipids 
C16-19  Carbon chain length (16 carbons -19 carbons) 
HSAN1 Hereditary sensory and autonomic neuropathy type I 
PPAR   peroxisome proliferator-activated receptors 
SPT  Serine palmitoyltransferase 
SA  Sphinganine  
SO  Sphingosine  
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Introduction: 
Pathologically altered plasma lipids are one of the major causes for cardiometabolic diseases 
and dyslipidemia remains one of the main therapeutic targets for the treatment of 
cardiovascular diseases and metabolic syndrome (MetS) [1, 2].  The best characterized lipid- 
modifying drugs include HMG-CoA reductase inhibitors, (statins), fibric acid derivatives 
(fibrates) and nicotinic acid derivatives (niacin) [3]. Fibrates have been identified as agonists 
for the peroxisome proliferator-activated receptors α (PPARα) [4], a member of  the nuclear 
hormone receptor superfamily [5]. Three different subclasses of PPARs have been identified - 
PPARα, β / δ and γ [4, 6-8]. The activation of PPARα by fenofibrate has been shown to 
increase the expression of lipoprotein lipase which increases the release of fatty acids from 
the triglyceride-rich lipoproteins. Activation of PPARα stimulates also fatty acid uptake, 
activation and β-oxidation while it decreases fatty acid synthesis by down regulating acetyl-
CoA carboxylase and fatty acid synthase. In addition, fenofibrate increases the expression of 
the apolipoproteins ApoAI and ApoAII, the two major lipoproteins of HDL, and down 
regulates ApoB and ApoCIII. Fibrates, therefore, improve the plasma lipid profile by 
decreasing plasma triglycerides and increasing HDL [9]. Niacin, on the other hand, exerts its 
functions through both receptor and non-receptor mediated routes. It binds to the membrane 
receptor GPR109A [10, 11] in adipocytes. This leads to the inhibition of lipolysis in adipose 
tissue by decreasing c-AMP concentration. Low c-AMP levels in adipocytes  lead to 
decreased protein kinase A(PKA) activity which decreases the activity of the hormone 
sensitive lipase (HSL) [12]. This, in turn, decreases plasma free fatty acids and reduces 
triglyceride synthesis in the liver [12]. Niacin was also shown to lower the activity of 
cholesterol ester transfer protein (CETP) in ApoE*3 Leiden mice which were transgenic for 
the human CETP gene [13]. Moreover, non-receptor mediated effects of niacin have been 
reported [14] but the exact mechanisms leading to the improvements in the lipoprotein profile 
are not fully elucidated. 
Plasma lipids are very heterogeneous in nature with > 600 distinct species. The most abundant 
classes of plasma lipids are sterols and glycerophospholipids reflecting approx. 50% and 30% 
of the total plasma lipids, respectively [15, 16]. Sphingolipids are present in plasma to a minor 
extent and represent about 4% of the total plasma lipids [15, 16]. However, more than 200 
different sphingolipid species have been identified in plasma [15]. This diversity is due to the 
combination of different sphingoid base backbones with different N-linked fatty acid chains in 
combination with different headgroups [15, 17-19]. Sphingolipid biosynthesis is typically 
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initiated by the condensation of serine and palmitoy-CoA by the enzyme serine 
palmitoyltransferase (SPT). The product 3-ketosphinganine is rapidly reduced to sphinganine 
(C18SA). C18SA is subsequently N-acylated to dihydroceramides and finally converted to 
ceramides by the introduction of a C4-C5 double bond into the sphinganine backbone. 
Ceramides are building blocks for complex sphingolipids which are formed by attaching 
different headgroups to the C1 hydroxyl group. In the degradation pathway, ceramides are 
hydrolyzed to sphingosine (C18SO). C18SA and C18SO are usually referred to as sphingoid 
bases or sphingoid base backbones. Apart from the canonical substrates (serine and palmitoyl-
CoA), SPT can also utilize other acyl-CoAs and other amino acids which results in the 
formation of a diverse class of atypical sphingoid bases. In particular, the use of alanine, 
instead of serine, forms the group of 1-deoxysphingolipds (1-deoxySL) which lack the C1 
hydroxyl group of the serine-based sphingolipids. Due to the missing C1 -OH group, 1-
deoxySLs can neither be converted to complex sphingolipids nor degraded by the canonical 
sphingolipid catabolism. 
We showed previously that 1-deoxySLs are significantly elevated in patients with the 
metabolic syndrome [17] and T2DM [19]. A principal-component-analysis revealed that 1-
deoxySLs are one of the most significant contributors to differentiate between MetS and 
healthy controls. Discriminant analysis revealed that 1-deoxySA and 1-deoxySO together 
with triglycerides and HDL-cholesterol are the best explanatory variables for non-diabetic 
metabolic syndrome [17]. In the previous studies, we also observed a strong positive 
correlation between 1-deoxySL plasma levels and triglycerides[17] which was not observed 
for the serine-based sphingolipids. This correlation is not obvious on a direct metabolic basis 
since 1-deoxySLs are not defined by their carbon chain but rather by their alanine moiety. 
This indicates a metabolic connection between TG, alanine and 1-deoxySL formation. In the 
current study, we investigated this relationship in more detail by testing whether the lowering 
of TGs by fenofibrate and niacin in dyslipidemic patients also affects the plasma 
sphingolipids and in particular the 1-deoxySL levels. 
 
 
 
 
 98 
 
Methods: 
Patients and study design:  
56 patients with primary hypercholesterolemia or mixed dyslipidemia were enrolled into a 
multi-center, open label, cross-over study to compare the effects of niacin and fenofibrate on 
the plasma lipid profile (Fig. 1). Patients with a history of coronary heart disease were 
excluded. After an initial 2-to 6-week wash-out period, patients were randomized to either 
fenofibrate 160 mg/d for 6 weeks or niacin 0.5 g/d for 3 weeks followed by 1 g/d for 3 weeks. 
This treatment period was followed by a 4-week wash-out period and the same treatment 
scheme repeated with the crossed over groups.  
 
Figure 1. HiFUN study design. This was an open label randomized trial where patients with 
primary hypercholesterolemia and mixed dyslipidemia were enrolled. The initial wash-out period was 
applied to eliminate the effect of patients’ past medication. Blood samples were collected at baseline, 
week 6, 10 and 16. The patients were treated for 6 weeks using either fenofibrate or niacin and then 
crossed over, with a wash-out period of 4 weeks in between. Green color represents the fenofibrate 
treatment while red represents the niacin treatment. 
Fasting plasma samples were collected at baseline (week 0), after the end of the first treatment 
period (week 6), at the end of the wash-out period (week 10) and after the second treatment 
period following the cross over (week 16). The study was conducted by F. Hoffmann-La 
Roche Ltd. Basel, Switzerland. Plasma HDL-C, LDL-C, triglycerides, total cholesterol, 
ApoAI, ApoAII and ApoB were analyzed by Roche and collaborators. Clinical data were also 
provided by F. Hoffmann-La Roche Ltd. Basel 
Sphingolipid analysis:  
The sphingoid base profile was analysed as described before [17] with some modifications. 
Briefly, 0.5 ml methanol including 200 pmol of the internal standards d7-sphingosine and d7-
sphinganine (d7SA, d7SO; Avanti Polar Lipids, Alabaster, Alabama, USA) was added 
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to100µl of plasma and extracted for 1h under agitation on a thermo-mixer at 37oC. 
Precipitated proteins were pelleted by centrifugation and the supernatant transferred to a new 
tube. For lipid hydrolysis, 75µl of methanolic HCl (1 N HCl and 10 M H2O in methanol) was 
added to the supernatant and incubated for 16 hours at 65oC. This was followed by the 
addition of 100 µl of 10M KOH to neutralize the HCl and hydrolyze the phospholipids. To 
this mix, 625 µl chloroform was added. Then, 100 µl 2N ammonium hydroxide and 0.5 ml 
alkaline water were added to complete the phase separation. The mix was then vortexed and 
centrifuged at 16000 g for 5 minutes. After centrifugation, the upper phase was discarded and 
the lower organic phase was washed two to three times with alkaline water. Finally, the 
organic phase was dried under N2 and kept at -20 oC freezer until analysis. 
The sphingoid bases were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, 
Interchim, Montluçon, France) and analysed on a TSQ Quantum Ultra mass spec (Thermo, 
Reinach, BL, Switzerland). Each sample was measured as a singleton. Intra- and Inter-assay 
coefficient of variation (CV %) of the method was between 5% and 20%.  
In this study 10 different sphingoid base backbones were analysed. The plasma levels of 
C16SO, C17SO, C18SO, C18SA, C18SAdiene, C19SO, C20SO, C20SA, 1-deoxySO and 1-
deoxySA sphingoid bases were quantified. 
 
Statistical analysis:  
Data are expressed as mean ± SD or SEM as mentioned. Since the values for most of the 
measured variables did not follow a normal distribution even after log-transformation, non-
parametric statistical methods were employed in the current study. Baseline and wash-out 
mean comparisons were performed and the p values were calculated using the Mann-Whitney 
U test followed by the Bonferroni correction (p value less than 0.001 was considered 
significant).  To test the treatment effect, the mean comparison before and after each 
treatment was performed and Wilcoxon signed-rank test was used followed by the Bonferroni 
correction to calculate the p values. Statistical analysis was performed in SPSS 16.0 (IBM, 
Zurich, Switzerland)   
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Results: 
Baseline characteristics of the study population are summarized in Table 1. The study subjects 
had normal levels for HDL-C (1.1 mol/l), and borderline-high LDL-C (4.03 mmol/l) levels 
according to the NCEP-ATPIII criteria [3] which resulted from the selection criteria that 
excluded patients with a history of coronary heart disease or its risk equivalents. In contrast, 
the average plasma triglycerides (2.49 mmol/l) and total cholesterol (6.26 mmol/l) were high 
according to the NCEP-ATPIII criteria [3]. No significant difference in the values for 
lipoproteins, apolipoproteins and sphingolipids was observed between baseline and after 
wash-out which excludes a carry-over effect of the two treatments.  
Table 1. Baseline patient characteristics and clinical chemistry levels and after wash-out. 
Values are expressed as mean ± SD. p values are calculated using the Mann-Whitney U test to 
compare the baseline values to the values after the wash-out period. After the wash-out, none 
of the measured variables was significantly different from the baseline. 
  Baseline       
(week 0) 
After wash-out         
(week 10) 
p 
Age (years) 54.98 ± 9.75     
Weight (kg) 81.41 ± 11.65     
BMI 26.49 ± 2.24     
ApoAI  (mg/dl) 136.43 ± 18.56 138.82 ± 16.54 0.57 
ApoAII  (mg/dl) 32.07 ± 4.26 33.57 ± 4.96 0.20 
ApoB  (mg/dl) 136.02 ± 18.18 139.55 ± 20.2 0.36 
HDL-C  (mmol/l) 1.1 ± 0.22 1.13 ± 0.22 0.50 
LDL-C (mmol/l) 4.03 ± 0.57 4.22 ± 0.73 0.23 
Total Cholesterol (mmol/l) 6.26 ± 0.65 6.45 ± 0.73 0.18 
Triglycerides (mmol/l) 2.49 ± 0.99 2.67 ± 1.27 0.62 
        
C16SO (µmol/l) 24.61 ± 6.27 24.64 ± 6.83 0.76 
C17SO (µmol/l) 10.9 ± 2.51 10.94 ± 2.64 0.85 
C18SAdiene (µmol/l) 44.64 ± 8.37 45.86 ± 9.54 0.63 
C18SO (µmol/l) 136.94 ± 19.1 144.14 ± 29.75 0.33 
C18SA (µmol/l) 4.82 ± 1.3 5.55 ± 2.77 0.57 
C19SO (µmol/l) 3.65 ± 1.19 3.86 ± 1.57 0.87 
C20SO (µmol/l) 0.31 ± 0.09 0.35 ± 0.11 0.12 
C20SA (µmol/l) 0.04 ± 0.02 0.04 ± 0.02 0.88 
1-deoxySO (µmol/l) 0.21 ± 0.1 0.23 ± 0.16 0.88 
1-deoxySA (µmol/l) 0.12 ± 0.04 0.14 ± 0.07 0.56 
 
Fenofibrate significantly increased ApoAI and ApoAII (Fig. 2A, B) and significantly lowered 
ApoB (Fig. 2C) whereas niacin had similar effects on ApoB and ApoAI but did not change 
ApoAII levels (Fig 2.A-C). In both groups plasma triglycerides, total cholesterol and LDL-C 
were significantly lowered whereas HDL-C was significantly increased (Fig. 2D-G). 
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Figure 2. Fenofibrate and  niacin treatment effect on the major apolipoproteins; ApoAI 
(A), ApoAII (B) and ApoB (C)  and lipoproteins HDL-C (D), LDL-C (E), triglycerides 
(F) and total cholesterol (G).  Box and whisker plots show the median and interquartile range of 
plasma lipoproteins and apolipoproteins in the patients before and after each treatment. p values were 
calculated using the Wilcoxon signed-rank test followed by the Bonferroni correction comparing the 
before and after treatment values. FF = fenofibrate, ***
 
p < 0.001, **
 
p < 0.01, ns , non-significant,. 
Green color represents the fenofibrate treatment while red represents the niacin treatment. 
Plasma sphingoid bases are usually N-acylated and conjugated to different headgroups, giving 
rise to the variety in sphingolipid species. In the current study, we focused our analysis on the 
sphingoid base backbone. To analyse the total sphingoid base profile of plasma sphingolipids, 
the lipids were extracted and hydrolysed to remove the N-acyl chain and head group. The here 
reported sphingoid bases concentrations therefore reflect the total concentration of 
sphingolipid species which are composed on this specific sphingoid base backbone. 
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In accordance with our earlier observations [17, 19] the correlation analysis (Table 2) showed 
a significant positive correlation of 1-deoxySL with triglycerides while the serine-based 
sphingoid bases correlated positively with LDL-C and total cholesterol (Table 2).  
Table2 . Heat map of Spearman correlation coefficients for the analyzed plasma sphingolipids bases 
and the clinical chemistry and anthropometric variables in the current study. Bold font signifies a p < 
0.05. The color code is showing the Spearman rho coefficient with the lowest value of -1 and the 
highest value of 1, Wcf, waist circumference, TC total cholesterol, TG triglycerides. 
 
C16SO C17SO C18SAdiene C18SO C18SA C19SO C20SO C20SA 1-deoxySO 1-deoxySA 
AGE -0.05 -0.03 0.12 0.07 0.03 -0.07 0.12 0.07 0.07 0.05 
Weight 0.30 0.14 -0.10 -0.05 0.17 0.17 0.06 0.20 0.45 0.36 
Wcf 0.18 -0.01 -0.04 -0.09 0.19 0.06 0.05 0.19 0.45 0.39 
BMI 0.20 0.12 0.03 -0.02 0.14 0.03 -0.02 0.14 0.31 0.30 
ApoAI 0.16 0.02 0.08 0.00 0.01 -0.04 -0.05 0.01 0.14 0.13 
ApoAII   -0.05 -0.19 -0.07 -0.06 -0.03 -0.29 -0.33 -0.24 -0.10 -0.03 
ApoB   0.37 0.41 0.44 0.41 0.18 0.37 0.46 0.43 0.34 0.29 
TC 0.43 0.43 0.45 0.41 0.18 0.39 0.44 0.36 0.36 0.34 
LDL-C 0.36 0.45 0.37 0.44 0.17 0.41 0.42 0.27 0.13 0.15 
HDL-C  0.05 0.00 0.10 0.05 -0.01 -0.05 -0.09 -0.11 -0.08 -0.05 
TG 0.19 0.12 0.17 0.08 0.08 0.18 0.27 0.34 0.53 0.44 
           
    
Spearman Rho 
     
    
-1 -0.5 -0.25 0 0.25 0.5 1 
 
The plasma sphingoid base profile was analyzed before and after each treatment period (Fig. 
3, 4). After fenofibrate treatment, we observed a lowering of all atypical sphingoid bases 
(C16SO, C17SO, C19SO, C20SO, C20SA 1-deoxySO and 1-deoxySA) which was not seen after 
niacin treatment (Fig. 3). 
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Neither fenofibrate nor niacin had any significant effect on the typical sphingoid bases 
(C18SO, C18SA and C18SAdiene) (Fig. 4), which represent together more than 84 % of the 
total sphingolipids in plasma. The effect of fenofibrate on the atypical sphingolipids was 
significantly different from that of niacin (Fig. 5A). Fenofibrate lowered 1-deoxySLs (-39.6 % 
for 1-deoxySO and -26.4% for 1-deoxySA), C20-sphingoid bases (-28.0% for C20SO and -
24.6% for C20SA), C19SO (-24.4%) and also the shorter chain sphingoid bases (-12.4 % for 
C17SO, -11.6% for C16SO).
Figure 3. Fenofibrate and 
niacin treatment effect on 
plasma atypical 
sphingolipids. Box and 
whisker plots show the median 
and interquartile range of 
plasma atypical sphingolipids; 
C16SO (A), C17SO (B), C19SO 
(C), C20SA(D), C20SO (E), 1-
deoxySO (F) and 1-deoxySA 
(G) in the patients before and 
after each treatment. p values 
were calculated using the 
Wilcoxon signed-rank test 
followed by the Bonferroni 
correction comparing the 
before and after treatment 
values. FF = fenofibrate, ***
 
p 
< 0.001. Green color 
represents the fenofibrate 
treatment while red represents 
the niacin treatment. 
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The effect of fenofibrate and niacin on the lipoprotein and apolipoprotein profile (Fig. 5 B) 
was comparable. Fenofibrate and niacin had similar effects on HDL-C (+14.25 % and 
+10.92%, respectively) and apoAI (+7.7% and +5.82 % for fenofibrate and niacin, 
respectively). The effect of fenofibrate on ApoAII was significantly different from that of 
niacin (+27.95 for fenofibrate vs. +0.5% for -niacin, p < 0.001). In general, fenofibrate was 
more effective in lowering LDL-C (-15.99% vs. -6.90%), total cholesterol (-13.7% vs. -
3.98%), ApoB (-18.4% vs. -7.11%) and triglycerides (-33.4% vs. 11.42%) in comparison to 
niacin. 
Figure 4. Fenofibrate and niacin 
treatment effect on plasma typical 
sphingolipids. Box and whisker plots 
show the median and interquartile range of 
plasma typical sphingolipids (C18SO, C18SA 
and C18SAdiene) in the patients before and 
after each treatment. p values were 
calculated using the Wilcoxon signed-rank 
test followed by the Bonferroni correction 
comparing the before and after treatment 
values. FF = fenofibrate, ***
 
p < 0.001. 
Green color represents the fenofibrate 
treatment while red represents the niacin 
treatment. 
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Figure 5. Difference from baseline due to fenofibrate or niacin treatment. Column plots 
show the mean difference from baseline in percent of the plasma sphingolipids (A) and lipoproteins 
and apolipoproteins (B) after each treatment. The data is shown as mean ± SEM. p values are 
calculated using Mann-Whitney U test followed by the Bonferroni correction comparing the 
fenofibrate to niacin effect. ***
 
p <0.001, **
 
p <0.01 
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Discussion: 
Atypical sphingolipids are formed by SPT through the incorporation of acyl-CoAs other than 
palmitoyl-CoA, or amino acids other than serine. In particular, the alternative use of alanine 
instead of serine results in the formation of a novel class of 1-deoxySLs. We have shown 
previously that pathologically elevated 1-deoxySLs are associated with the inherited 
neuropathy HSAN1 (hereditary sensory neuropathy type I) [20] which is caused by several 
missense mutations in SPT [21, 22]. Theses mutations lead to a shift in the substrate 
preference from serine to alanine and increase the 1-deoxySLs formation. 1-dexoxySLs are 
neurotoxic and were suggested to play a role in the pathogenesis of HSAN1 [20]. 
Interestingly, it was shown that an oral serine treatment suppresses the formation of 1-
deoxySLs in HSAN1 animal models and humans [23]. Elevated plasma1-deoxySLs were also 
found in plasma of patients with metabolic diseases such as the metabolic syndrome and 
T2DM. This increased 1-deoxySL formation in metabolic diseases is not caused by mutations 
in SPT but is probably associated with a derailed carbohydrate and fatty acid metabolism. In 
two previous studies, we observed a strong correlation between plasma deoxySLs and 
triglyceride levels [17, 19]. In this study, we demonstrated that fenofibrate but not niacin is 
able to specifically lower atypical sphingoid bases in the plasma of patients with 
dyslipidemia. On the other hand, neither fenofibrate nor niacin showed any significant effect 
on the levels of typical sphingolipids. This effect on the atypical sphingoid bases is 
independent of the changes in the lipoprotein profile since both niacin and fenofibrate had 
comparable effects on triglycerides, LDL-C and total cholesterol (although with  different 
efficacies). It is not clear at this point if this effect is due to PPARα activation or a non-
PPARα mediated effect of fenofibrate although preliminary results from PPARα knock-out 
mice point to the involvement of PPARα (data not shown). In accordance with our earlier 
observations [17, 19], we showed in the current study a significant correlation between 
plasma triglycerides and 1-deoxySL levels However, this relationship is probably indirect 
since it is not the fatty acid but rather the conjugation of alanine, instead of serine, which 
defines the formation of 1-deoxySLs. This indicates that fenofibrate directly or indirectly 
might influence the use of the amino acid substrate by SPT. In contrast, neither fenofibrate 
nor niacin showed any significant effect on the plasma levels of the typical, serine based 
sphingoid bases (C18SO, C18SA and C18SAdiene).  
The observation that 1-deoxySLs are neurotoxic and being elevated in HSAN1 [20] and 
T2DM, suggests a potential involvement of these lipids in the pathogenesis of the diabetic 
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sensory neuropathy. In post-hoc analyses from randomized clinical trials and longitudinal 
cohorts, fenofibrate has been associated with improvements in the diabetic neuropathy and 
other microvascular complications [24, 25]. Thus, it would be intriguing to investigate 
whether the lowering effect of fenofibrate on plasma 1-deoxySLs is associated with the 
observed improvement in neuropathy.  
In this study, we have also shown that fenofibrate lowers other atypical sphingolipids (C16, 
C17, C19 and C20-sphingoid bases). Primarily the SPTLC3 subunit [26, 27] , probably in 
conjunction with other subunits [28], might be responsible for the incorporation of different 
acyl CoAs, other than palmitoyl-CoA leading to the formation of these atypical sphingoid 
bases. It is not clear yet whether fenofibrate directly affects the expression or the function of 
these subunits or whether the observed effects are due to alterations in the substrate 
availability for SPT. Several lines of evidence suggest a connection between PPARs and 
sphingolipid metabolism. For example, in a rat partial hepatectomy model, activation of 
PPARα by bezafibrate decreased de novo sphingolipid synthesis [29]. In that model, it was 
suggested that the bezafibrate effect on SPT is mainly due to decreased substrate availability 
(palmitoyl-CoA) because of a decrease in plasma saturated fatty acids [29]. It was also shown 
that bezafibrate increases the activity of acid sphingomylinase, an enzyme hydrolyzing 
sphingomyelin into ceramide thereby increasing ceramide levels through the degradation 
pathway [30]. On the other hand, it was shown that pioglitazone, a PPARγ agonist, increased 
de novo sphingolipid activity in the rat hearts [31]. This effect was partly mediated through 
increased protein expression of SPTLC2 [31]. These observations point to a connection 
between PPARs and the expression of sphingolipid metabolizing enzymes. Interestingly, 
phytoceramide, phytosphingosine (PhytoSO) and C18SA have been shown to be direct 
activators for PPARs, although to different extents. Several phytoSO analogues have been 
shown to activate PPARs without being selective to a specific subtype [33] and it was shown 
by affinity binding assay, that sphingosine and sphinganine were able to physically interact 
with PPARα which supports the notion that also free sphingoid bases can act as endogenous 
ligands for PPARs [34]. In contrast, ceramides and dihydroceramides failed to activate 
PPARs in vitro [32]. This indicates that the relationship between sphingolipids and PPAR 
activation could be bidirectional since some of the sphingolipid metabolites can bind and 
activate PPARs and PPAR activation might in return affect sphingolipid formation. 
In summary, we have shown that fenofibrate but not niacin specifically lowers the atypical 
sphingolipids in the plasma of dyslipidemic patients without affecting the typical 
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sphingolipids. Further studies are needed to investigate this relationship in more detail and to 
explore the potential therapeutic use of PPARα activators for the treatment of the diabetic 
neuropathy. 
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General	conclusions	and	outlook	
In this work, we evaluated the potential of plasma atypical sphingolipids to act as biomarkers 
in cardio-metabolic disease. We also evaluated some therapeutic strategies to modulate the 
levels of these atypical sphingolipids in plasma in the context of dyslipidemia and diabetic 
neuropathy. 
We showed that 1-deoxysphingolipids (1-deoxySLs) were significantly elevated in the plasma 
of patients with metabolic syndrome and T2DM [1].  This was confirmed in three independent 
cohorts (total n = 524) [1, 2]. Multivariate analysis and receiver operating characteristic 
(ROC) curves revealed that 1-deoxySA and 1-deoxySO can discriminate between patients 
with metabolic syndrome and healthy controls better than other traditional biomarkers such as 
glucose, hypertension and HDL-C. Furthermore, we showed that 1-deoxySLs are independent 
predictors for the development of T2DM (Chapter 2). In particular, plasma 1-deoxySO had an 
adjusted odds ratio similar to HbA1c and the presence of metabolic syndrome. The regression 
model containing 1-deoxySO, HbA1c and the presence of metabolic syndrome showed a 
significantly higher ability (AUC of the ROC curve) to discriminate the incident T2DM group 
than each of the covariates alone. These findings establish the association between plasma 1-
deoxySLs, T2DM and the metabolic syndrome. A limitation of the prospective T2DM study 
is the small number of events (incident T2DM =30). Thus, adjustment for all the potential 
confounders was not possible. Consequently, it would be important to reproduce the 
prospective potential of 1-deoxySLs in a larger prospective cohort. Eventually, an 
interventional randomized controlled trial has to be performed. In such a trial, patients with 
high and low plasma 1-deoxySLs should be compared in their response to different 
therapeutic options in T2DM [3, 4]. For example, in studies aiming at the prevention of 
T2DM (e.g. by life style intervention such as diet and exercise [5, 6] or by the use of 
therapeutic drugs like metformin[7]), the incidence of T2DM can be compared in patients 
with high and low plasma levels of 1-deoxySLs in different preventive schemes. This would 
show whether the clinical adoption of 1-deoxySA as a risk marker for T2DM development 
has a measurable beneficial effect on the patients’ outcome.  
Moreover, it would be interesting to explore the ability of plasma 1-deoxySLs as diagnostic or 
prognostic biomarkers for the microvascular and neurological complications of T2DM. This 
is of particular interest in the context of the diabetic neuropathy.  This line of investigation is 
supported by our findings that plasma 1-deoxySLs are associated with both T2DM (Chapter1, 
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2) and the rare hereditary sensory neuropathy type I (HSAN1) [8]. Furthermore, in-vitro 
studies have shown that 1-deoxySLs are neurotoxic, affecting neurite length and the number 
of branching points [8] which suggests a potential role for 1-deoxySLs in the development of 
diabetic neuropathy. 
Although we showed a robust association between 1-deoxySLs plasma levels, MetS and 
T2DM, a causal role in the pathogenesis of these diseases was not addressed. Further studies 
are necessary to investigate whether 1-deoxySLs are causally involved in the pathogenesis of 
T2DM or not. For example, it would be interesting to investigate whether 1-deoxySLs are 
involved in insulin resistance or in β-cell failure. Preliminary experiments showed that 1-
deoxySA is toxic to pancreatic β cell lines and primary pancreatic islets (data not shown). The 
previous results should also be validated in T2DM animal models, e.g.in high-fat fed mice 
model. In these studies, the plasma 1-deoxySLs can be lowered by one of the strategies shown 
in the current work (fenofibrate or serine supplementation) and the development of pre-
diabetes and impaired glucose tolerance can be monitored. This would show whether the 
lowering of 1-deoxySLs in plasma in these animal models would delay or prevent the 
progression to T2DM.  
The mechanism through which plasma 1-deoxySLs are elevated in T2DM and MetS remains 
largely not understood. One possible mechanism could be an increase in intracellular alanine 
levels, which is the substrate for SPT to form 1-deoxySLs. Indeed, an increase in alanine flux 
into the liver in case of obesity and diabetes has been reported in early physiological human 
studies [9, 10]. Moreover, a high glycolytic flux in the liver of hyperglycemic patients is 
conceivable since the liver expresses mostly the insulin-independent glucose transporter 2 
(GLUT2). This increased glycolytic flux might result in an increase in alanine as a side 
product of pyruvate accumulation when the TCA cycle capacity is exceeded. However the 
increased availability of alanine alone is not sufficient to increase 1-deoxySL formation in 
cultured cells (data not shown). This indicates that additional factors are required for the 
elevated 1-deoxySL formation in T2DM and MetS and warrants further investigation. 
To our surprise, C20SO, another atypical sphingoid base which is formed by the use of 
stearoly-CoA instead of palmitoyl-CoA, evolved as an independent risk predictor for 
cardiovascular events (Chapter 2). The predictive ability of this marker was significant even 
after the adjustment for other cardiovascular risk factors including the degree of coronary 
artery stenosis as graded by angiography. This implies that the C20SO plasma levels add 
predictive power to angiography - the current gold standard for evaluating atherosclerosis. 
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These findings have also to be confirmed in another independent prospective cohort ideally 
with a larger number of follow-up events to validate the predictive ability of the marker.  
We have previously shown that serine is effective in lowering plasma 1-deoxySLs in animal 
models and humans with hereditary sensory neuropathy type I (HSAN1) [14].  HSAN1 is 
associated with several missense mutations in SPT which were shown to increase the activity 
of SPT with alanine, thereby increasing 1-deoxySLs formation [8, 15, 16]. Given the 
similarity between diabetic neuropathy and HSAN1, and the finding that plasma 1-deoxySLs 
are elevated in both conditions, we investigated the effect of an oral L-serine supplementation 
on plasma 1-deoxSLs and the diabetic neuropathy in a streptozotocin-induced type 1 diabetes 
in rats. We showed that a serine-enriched diet significantly lowered the plasma 1-deoxySLs in 
STZ rats and improved the mechanical sensitivity and nerve conduction velocity. These 
findings showed that L-serine treatment might be a novel therapeutic option for the treatment 
of the diabetic neuropathy. 
Interestingly, in contrast to the HSAN1 mice where 1-deoxySL accumulates in the sciatic 
nerves [8, 14], 1-deoxySLs were not detected in the sciatic nerves, DRGs, or spinal cords of 
the STZ rats (Chapter 3). This discrepancy argues against the concept that a toxic 
accumulation of 1-deoxySLs in the peripheral nerves contributes to the pathogenesis of 
diabetic neuropathy. Moreover, 1-deoxySLs could also not be detected in nerve biopsies from 
human patients with diabetic neuropathy (data not shown). On the other hand, there are 
several lines of evidence which support a potential role for 1-deoxySLs in the pathogenesis of 
neuropathy. In HSAN1, several single point mutations in the SPT lead to a neuropathy 
phenotype in humans and animal models that is mainly associated with increased 1-deoxySLs 
generation. Moreover, 1-deoxySA is shown to affect the neurite length and branching in 
chicken DRGs in vitro, which shows their neurotoxic properties. Furthermore, serine 
supplementation significantly lowered the plasma 1-deoxySLs in STZ and HSAN1 mice, 
improved the neuropathy in the STZ rats and precluded the development of the neuropathy in 
the HSAN1 mice whereas alanine supplementation increased the plasma 1-deoxySL in 
HSAN1 mice and exacerbated the neuropathy [14].  
To resolve this discrepancy, it is important to address two major questions: First, whether 
elevated plasma 1-deoxySLs are sufficient to induce a neuropathy in vivo, and second, 
whether the above-mentioned beneficial effects of serine in neuropathy are mediated solely 
through the lowering of plasma 1-deoxySL. To address these points, several strategies could 
be employed. For example, a specific transient elevation of plasma 1-deoxySLs by the 
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injection of a specific 1-deoxySL formulation (e.g. single or multiple injections by 
intravenous, intra-peritoneal or intra-thecal route) in animals would allow the evaluation of 
the short-term effects of 1-deoxySL elevation in plasma or cerebrospinal fluid (CSF). 
Moreover, a viral-mediated delivery of a 1-deoxySL-producing mutant of SPT (e.g. an 
HSAN1 associated mutation) to the liver of WT animals could help to address the systemic 
effects of elevated plasma1-deoxySLs. Another approach would be to inject the serine-
supplemented STZ rats with a specific 1-deoxySL formulation to re-induce the neuropathy, to 
exclude that the protective effect of serine is mediated by a general neurotrophic action 
independent if its ability to lower the plasma1-deoxySLs.  
In the clinical studies, we observed a consistent positive correlation between plasma 1-
deoxySLs and triglycerides (TG). 1-deoxySLs are transported mainly in VLDL and LDL[2], 
and correlate positively and strongly with TGs which are also enriched in VLDL and LDL. 
Therefore, we hypothesized that the increase of plasma 1-deoxySL in MetS and T2DM might 
be due to the increase in its lipoprotein containing particles. This hypothesis was evaluated in 
an interventional clinical trial in which the effects of fenofibrate and niacin, two triglyceride-
lowering drugs, on plasma sphingolipids were tested in dyslipidemic patients.  We showed 
that fenofibrate but not niacin significantly lowered the atypical sphingolipids (C16SO, C17SO, 
C19SO, C20SO, C20SA 1-deoxySO and 1-deoxySA) in the plasma without any significant 
effect on the typical sphingolipids (C18SO, C18SA and C18SAdiene). Interestingly, both 
fenofibrate and niacin lowered plasma triglycerides as expected. This demonstrates that the 
atypical sphingolipids (including 1-deoxySLs) in the plasma can be lowered by fenofibrate 
but not by niacin, although both drugs showed comparable effects on TG levels and the 
lipoprotein profile. This refutes our initial hypothesis and instead indicates that the increase in 
plasma 1-deoxySL in T2DM and MetS is probably due to other reasons and not merely a 
bystander of the increase in the production or excretion of the 1-deoxySL-containing 
lipoproteins. This also shows that the 1-deoxySL-lowering-effect of fenofibrate might be 
related to its major mode of action, i.e. PPARα activation. This aspect could be addressed in 
more detail using PPARα knock-out (KO) animal model. In these experiments, the effect of 
fenofibrate on plasma 1-deoxySLs could be tested by feeding KO and WT animals a high-fat 
diet, which increases the plasma 1-deoxySLs, together with fenofibrate. If fenofibrate lowers 
plasma 1-deoxySLs only by a PPARα-dependent mechanism, then this effect should not be 
observed in the PPARα KO model. This would elucidate whether the effect of fenofibrate on 
plasma 1-deoxySLs is mediated by PPARα or by other off-target effects. In a similar 
approach, potent specific agonists and antagonists of PPARα can be added to cell culture 
 115 
 
models of increased 1-deoxySA generation (e.g. cell lines incubated with high palmitate or 
high glucose or both). This would also help dissect out the role of PPARα, if any, in 
regulation of 1-deoxySL formation.  
Interestingly, fenofibrate lowered also the other atypical sphingolipids which are usually 
generated by the use of different acyl-CoAs.  Little is known about the regulation of SPT 
acyl-Co substrate specificity. Our lab has recently identified a new subunit of SPT, SPTLC3, 
which shifts the substrate specificity to different acyl-CoAs other than palmitoyl-CoA [11, 
12]. Other subunits associated with the SPT enzyme have also been suggested to regulate the 
acyl-CoA substrate specificity of SPT [13].  In this context, it will be interesting to investigate 
whether fenofibrate affects the expression or the activity of these subunits e.g. by adding 
fenofibrate or other specific PPARα agonist to cell lines that naturally express high levels of 
these subunits or by similar strategies.   
In summary, we have identified some of the promising potentials of atypical sphingolipids as 
novel biomarkers and therapeutic targets in T2DM, MetS and cardiovascular disease. 
Although most of these atypical sphingolipids are usually present in minor concentrations in 
plasma, they might not be minor regarding their clinical significance. Thus, this work, 
hopefully, paves the way for further studies, both clinical and mechanistic, to further explore 
their full potential.  
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